# Imai_2016_Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults.

Cochrane
Library

Cochrane Database of Systematic Reviews

Psychological therapies versus pharmacological interventions for
panic disorder with or without agoraphobia in adults (Review)

Imai H, Tajika A, Chen P, Pompoli A, Furukawa TA

Imai H, Tajika A, Chen P, Pompoli A, Furukawa TA. 
Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. 
Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD011170. 
DOI: 10.1002/14651858.CD011170.pub2.

www.cochranelibrary.com

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in
adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
Figure 5..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis 1.1. Comparison 1 All psychological therapies versus SSRI, Outcome 1 Short-term remission.........................................
Analysis 1.2. Comparison 1 All psychological therapies versus SSRI, Outcome 2 Short-term response..........................................
Analysis 1.3. Comparison 1 All psychological therapies versus SSRI, Outcome 3 Dropouts for any reason....................................
Analysis 1.4. Comparison 1 All psychological therapies versus SSRI, Outcome 4 Short-term improvement...................................
Analysis 2.1. Comparison 2 All psychological therapies versus tricyclic antidepressants, Outcome 1 Short-term remission........
Analysis 2.2. Comparison 2 All psychological therapies versus tricyclic antidepressants, Outcome 2 Short-term response.........
Analysis 2.3. Comparison 2 All psychological therapies versus tricyclic antidepressants, Outcome 3 Dropouts for any reason......
Analysis 2.4. Comparison 2 All psychological therapies versus tricyclic antidepressants, Outcome 4 Short-term improvement.....
Analysis 3.1. Comparison 3 All psychological therapies versus other antidepressants, Outcome 1 Short-term remission............
Analysis 3.2. Comparison 3 All psychological therapies versus other antidepressants, Outcome 2 Short-term response.............
Analysis 3.3. Comparison 3 All psychological therapies versus other antidepressants, Outcome 3 Dropouts for any reason........
Analysis 3.4. Comparison 3 All psychological therapies versus other antidepressants, Outcome 4 Short-term improvement.......
Analysis 4.1. Comparison 4 All psychological therapies versus benzodiazepines, Outcome 1 Short-term remission.....................
Analysis 4.2. Comparison 4 All psychological therapies versus benzodiazepines, Outcome 2 Short-term response......................
Analysis 4.3. Comparison 4 All psychological therapies versus benzodiazepines, Outcome 3 Dropouts for any reason................
Analysis 4.4. Comparison 4 All psychological therapies versus benzodiazepines, Outcome 4 Short-term improvement..............
Analysis  5.1.  Comparison  5  All  psychological  therapies  versus  either  antidepressants  alone  or  antidepressants  and
benzodiazepines, Outcome 1 Short-term remission..........................................................................................................................
Analysis  5.2.  Comparison  5  All  psychological  therapies  versus  either  antidepressants  alone  or  antidepressants  and
benzodiazepines, Outcome 2 Short-term response...........................................................................................................................
Analysis  5.3.  Comparison  5  All  psychological  therapies  versus  either  antidepressants  alone  or  antidepressants  and
benzodiazepines, Outcome 3 Dropouts for any reason.....................................................................................................................
Analysis  5.4.  Comparison  5  All  psychological  therapies  versus  either  antidepressants  alone  or  antidepressants  and
benzodiazepines, Outcome 4 Short-term improvement....................................................................................................................
Analysis  6.1.  Comparison  6  Subgroup  analysis:  All  psychological  therapies  versus  either  antidepressants  alone  or
antidepressants and benzodiazepines (participants without depressive disorder), Outcome 1 Short-term remission.................
Analysis  6.2.  Comparison  6  Subgroup  analysis:  All  psychological  therapies  versus  either  antidepressants  alone  or
antidepressants and benzodiazepines (participants without depressive disorder), Outcome 2 Dropouts for any reason.............
Analysis  7.1.  Comparison  7  Subgroup  analysis  (investigation  of  heterogeneity):  All  psychological  therapies  versus  SSRI,
Outcome 1 Short-term remission........................................................................................................................................................
Analysis  7.2.  Comparison  7  Subgroup  analysis  (investigation  of  heterogeneity):  All  psychological  therapies  versus  SSRI,
Outcome 2 Short-term response.........................................................................................................................................................
Analysis  7.3.  Comparison  7  Subgroup  analysis  (investigation  of  heterogeneity):  All  psychological  therapies  versus  SSRI,
Outcome 3 Short-term improvement..................................................................................................................................................

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
4
11
12
12
17
19
21
22
26
27
31
33
34
35
41
69
69
70
70
71
72
73
74
75
76
77
78
78
79
80
80
81
83

84

85

86

87

87

88

89

89

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  8.1.  Comparison  8  Subgroup  analysis  (investigation  of  heterogeneity):  All  psychological  therapies  versus  other
antidepressants, Outcome 1 Short-term remission............................................................................................................................
Analysis  9.1.  Comparison  9  Subgroup  analysis  (investigation  of  heterogeneity):  All  psychological  therapies  versus  either
antidepressants alone or antidepressants and benzodiazepines, Outcome 1 Short-term remission.............................................
Analysis  9.2.  Comparison  9  Subgroup  analysis  (investigation  of  heterogeneity):  All  psychological  therapies  versus  either
antidepressants alone or antidepressants and benzodiazepines, Outcome 2 Short-term improvement.......................................
Analysis 10.1. Comparison 10 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus SSRI, Outcome 1 Short-term remission...................................................................................................................................
Analysis 10.2. Comparison 10 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus SSRI, Outcome 2 Short-term response....................................................................................................................................
Analysis 10.3. Comparison 10 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus SSRI, Outcome 3 Dropouts for any reason..............................................................................................................................
Analysis 10.4. Comparison 10 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus SSRI, Outcome 4 Short-term improvement.............................................................................................................................
Analysis 11.1. Comparison 11 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus other antidepressants, Outcome 1 Short-term remission......................................................................................................
Analysis 11.2. Comparison 11 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus other antidepressants, Outcome 2 Short-term response.......................................................................................................
Analysis 11.3. Comparison 11 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus other antidepressants, Outcome 3 Dropouts for any reason.................................................................................................
Analysis 12.1. Comparison 12 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus benzodiazepines, Outcome 1 Short-term response................................................................................................................
Analysis 12.2. Comparison 12 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus benzodiazepines, Outcome 2 Dropouts for any reason..........................................................................................................
Analysis 12.3. Comparison 12 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus benzodiazepines, Outcome 3 Short-term improvement........................................................................................................
Analysis 13.1. Comparison 13 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus either antidepressants alone or antidepressants and benzodiazepines, Outcome 1 Short-term remission.......................
Analysis 13.2. Comparison 13 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus either antidepressants alone or antidepressants and benzodiazepines, Outcome 2 Short-term response........................
Analysis 13.3. Comparison 13 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus either antidepressants alone or antidepressants and benzodiazepines, Outcome 3 Dropouts for any reason...................
Analysis 13.4. Comparison 13 Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus either antidepressants alone or antidepressants and benzodiazepines, Outcome 4 Short-term improvement.................
Analysis 14.1. Comparison 14 Sensitivity analysis (best case): All psychological therapies versus SSRI, Outcome 1 Short-term
remission...............................................................................................................................................................................................
Analysis 14.2. Comparison 14 Sensitivity analysis (best case): All psychological therapies versus SSRI, Outcome 2 Short-term
response.................................................................................................................................................................................................
Analysis 15.1. Comparison 15 Sensitivity analysis (worst case): All psychological therapies versus SSRI, Outcome 1 Short-term
remission...............................................................................................................................................................................................
Analysis 15.2. Comparison 15 Sensitivity analysis (worst case): All psychological therapies versus SSRI, Outcome 2 Short-term
response.................................................................................................................................................................................................
Analysis  16.1.  Comparison  16  Sensitivity  analysis  (best  case):  All  psychological  therapies  versus  tricyclic  antidepressants,
Outcome 1 Short-term remission........................................................................................................................................................
Analysis  16.2.  Comparison  16  Sensitivity  analysis  (best  case):  All  psychological  therapies  versus  tricyclic  antidepressants,
Outcome 2 Short-term response.........................................................................................................................................................
Analysis  17.1.  Comparison  17  Sensitivity  analysis  (worst  case):  All  psychological  therapies  versus  tricyclic  antidepressants,
Outcome 1 Short-term remission........................................................................................................................................................
Analysis  17.2.  Comparison  17  Sensitivity  analysis  (worst  case):  All  psychological  therapies  versus  tricyclic  antidepressants,
Outcome 2 Short-term response.........................................................................................................................................................
Analysis  18.1.  Comparison  18  Sensitivity  analysis  (best  case):  All  psychological  therapies  versus  other  antidepressants,
Outcome 1 Short-term remission........................................................................................................................................................
Analysis  18.2.  Comparison  18  Sensitivity  analysis  (best  case):  All  psychological  therapies  versus  other  antidepressants,
Outcome 2 Short-term response.........................................................................................................................................................
Analysis  19.1.  Comparison  19  Sensitivity  analysis  (worst  case):  All  psychological  therapies  versus  other  antidepressants,
Outcome 1 Short-term remission........................................................................................................................................................

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

91

92

94

94

95

95

96

97

97

98

99

99

101

102

103

104

105

106

106

107

107

108

109

109

110

110

110

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  19.2.  Comparison  19  Sensitivity  analysis  (worst  case):  All  psychological  therapies  versus  other  antidepressants,
Outcome 2 Short-term response.........................................................................................................................................................
Analysis 20.1. Comparison 20 Sensitivity analysis (best case): All psychological therapies versus benzodiazepines, Outcome 1
Short-term remission............................................................................................................................................................................
Analysis 21.1. Comparison 21 Sensitivity analysis (worst case): All psychological therapies versus benzodiazepines, Outcome
1 Short-term remission.........................................................................................................................................................................
Analysis 22.1. Comparison 22 Sensitivity analysis (best case): All psychological therapies versus either antidepressants alone
or antidepressants and benzodiazepines, Outcome 1 Short-term remission...................................................................................
Analysis 22.2. Comparison 22 Sensitivity analysis (best case): All psychological therapies versus either antidepressants alone
or antidepressants and benzodiazepines, Outcome 2 Short-term response....................................................................................
Analysis 23.1. Comparison 23 Sensitivity analysis (worst case): All psychological therapies versus either antidepressants alone
or antidepressants and benzodiazepines, Outcome 1 Short-term remission...................................................................................
Analysis 23.2. Comparison 23 Sensitivity analysis (worst case): All psychological therapies versus either antidepressants alone
or antidepressants and benzodiazepines, Outcome 2 Short-term response....................................................................................
Analysis 24.1. Comparison 24 Sensitivity analysis (without imputation): All psychological therapies versus SSRI, Outcome 1
Short-term remission............................................................................................................................................................................
Analysis  25.1.  Comparison  25  Sensitivity  analysis  (without  imputation):  All  psychological  therapies  versus  other
antidepressants, Outcome 1 Short-term remission............................................................................................................................
Analysis 26.1. Comparison 26 Sensitivity analysis (without imputation): All psychological therapies versus benzodiazepines,
Outcome 1 Short-term remission........................................................................................................................................................
Analysis  27.1.  Comparison  27  Sensitivity  analysis  (without  imputation):  All  psychological  therapies  versus  either
antidepressants alone or antidepressants and benzodiazepines, Outcome 1 Short-term remission.............................................
Analysis  27.2.  Comparison  27  Sensitivity  analysis  (without  imputation):  All  psychological  therapies  versus  either
antidepressants alone or antidepressants and benzodiazepines, Outcome 2 Short-term response..............................................
APPENDICES.................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

111

111

112

113

113

114

114

115

116

116

117

117

118
119
119
119
119

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

iii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Psychological therapies versus pharmacological interventions for panic
disorder with or without agoraphobia in adults

Hissei Imai1, Aran Tajika1, Peiyao Chen2, Alessandro Pompoli3, Toshi A Furukawa1

1Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto,
Japan. 2Henan Cancer Hospital, Henan, China. 3Private practice, no academic affiliations, Malcesine, Italy

Contact: Hissei Imai, Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of
Public Health, Kyoto, Japan. ihits@hotmail.com.

Editorial group: Cochrane Common Mental Disorders Group.
Publication status and date: New, published in Issue 10, 2016.

Citation:  Imai H, Tajika A, Chen P, Pompoli A, Furukawa TA. Psychological therapies versus pharmacological interventions for panic
disorder with or without agoraphobia in adults. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD011170. DOI:
10.1002/14651858.CD011170.pub2.

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Panic disorder is common and deleterious to mental well-being. Psychological therapies and pharmacological interventions are both used
as treatments for panic disorder with and without agoraphobia. However, there are no up-to-date reviews on the comparative efficacy and
acceptability of the two treatment modalities, and such a review is necessary for improved treatment planning for this disorder.

Objectives

To assess the efficacy and acceptability of psychological therapies versus pharmacological interventions for panic disorder, with or without
agoraphobia, in adults.

Search methods

We searched the Cochrane Common Mental Disorders Group Specialised Register on 11 September 2015. This register contains reports
of relevant randomised controlled trials from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1950 to present),
Embase (1974 to present), and PsycINFO (1967 to present). We cross-checked reference lists of relevant papers and systematic reviews. We
did not apply any restrictions on date, language, or publication status.

Selection criteria

We included all randomised controlled trials comparing psychological therapies with pharmacological interventions for panic disorder
with or without agoraphobia as diagnosed by operationalised criteria in adults.

Data collection and analysis

Two  review  authors  independently  extracted  data  and  resolved  any  disagreements  in  consultation  with  a  third  review  author.  For
dichotomous data, we calculated risk ratios (RR) with 95% confidence intervals (CI). We analysed continuous data using standardised mean
differences (with 95% CI). We used the random-effects model throughout.

Main results

We included 16 studies with a total of 966 participants in the present review. Eight of the studies were conducted in Europe, four in the
USA, two in the Middle East, and one in Southeast Asia.

None of the studies reported long-term remission/response (long term being six months or longer from treatment commencement).

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

There was no evidence of a difference between psychological therapies and selective serotonin reuptake inhibitors (SSRIs) in terms of short-
term remission (RR 0.85, 95% CI 0.62 to 1.17; 6 studies; 334 participants) or short-term response (RR 0.97, 95% CI 0.51 to 1.86; 5 studies;
277 participants) (very low-quality evidence), and no evidence of a difference between psychological therapies and SSRIs in treatment
acceptability as measured using dropouts for any reason (RR 1.33, 95% CI 0.80 to 2.22; 6 studies; 334 participants; low-quality evidence).

There was no evidence of a difference between psychological therapies and tricyclic antidepressants in terms of short-term remission (RR
0.82, 95% CI 0.62 to 1.09; 3 studies; 229 participants), short-term response (RR 0.75, 95% CI 0.51 to 1.10; 4 studies; 270 participants), or
dropouts for any reason (RR 0.83, 95% CI 0.53 to 1.30; 5 studies; 430 participants) (low-quality evidence).

There  was  no  evidence  of  a  difference  between  psychological  therapies  and  other  antidepressants  in  terms  of  short-term  remission
(RR  0.90,  95%  CI  0.48  to  1.67;  3  studies;  135  participants;  very  low-quality  evidence)  and  evidence  that  psychological  therapies  did
not significantly increase or decrease the short-term response over other antidepressants (RR 0.96, 95% CI 0.67 to 1.37; 3 studies; 128
participants) or dropouts for any reason (RR 1.55, 95% CI 0.91 to 2.65; 3 studies; 180 participants) (low-quality evidence).

There was no evidence of a difference between psychological therapies and benzodiazepines in terms of short-term remission (RR 1.08,
95% CI 0.70 to 1.65; 3 studies; 95 participants), short-term response (RR 1.58, 95% CI 0.70 to 3.58; 2 studies; 69 participants), or dropouts
for any reason (RR 1.12, 95% CI 0.54 to 2.36; 3 studies; 116 participants) (very low-quality evidence).

There  was  no  evidence  of  a  difference  between  psychological  therapies  and  either  antidepressant  alone  or  antidepressants  plus
benzodiazepines in terms of short-term remission (RR 0.86, 95% CI 0.71 to 1.05; 11 studies; 663 participants) and short-term response
(RR 0.95, 95% CI 0.76 to 1.18; 12 studies; 800 participants) (low-quality evidence), and there was no evidence of a difference between
psychological therapies and either antidepressants alone or antidepressants plus benzodiazepines in terms of treatment acceptability
as  measured  by  dropouts  for  any  reason  (RR  1.08,  95%  CI  0.77  to  1.51;  13  studies;  909  participants;  very  low-quality  evidence).  The
risk of selection bias and reporting bias was largely unclear. Preplanned subgroup and sensitivity analyses limited to trials with longer-
term, quality-controlled, or individual psychological therapies suggested that antidepressants might be more effective than psychological
therapies for some outcomes.

There were no data to contribute to a comparison between psychological therapies and serotonin–norepinephrine reuptake inhibitors
(SNRIs) and subsequent adverse effects.

Authors' conclusions

The evidence in this review was often imprecise. The superiority of either therapy over the other is uncertain due to the low and very low
quality of the evidence with regard to short-term efficacy and treatment acceptability, and no data were available regarding adverse effects.

The sensitivity analysis and investigation of the sources of heterogeneity indicated three possible influential factors: quality control of
psychological therapies, the length of intervention, and the individual modality of psychological therapies.

Future studies should examine the long-term effects after intervention or treatment continuation and should provide information on risk
of bias, especially with regard to selection and reporting biases.

P L A I N   L A N G U A G E   S U M M A R Y

Psychological therapies versus medication for panic disorder with or without agoraphobia in adults

Why is this review important?

Panic  disorder  is  common  and  harmful  to  mental  well-being.  Psychological  therapies  and  medication  (usually  antidepressants  or
benzodiazepines) are effective against panic disorder. However, there are no up-to-date reviews on the superiority and acceptability of
these two forms of treatment, and such a review is necessary to improve treatment planning for this disorder.

Who will be interested in this review?

Adult patients, professionals working in mental health services, and general practitioners.

What questions does this review aim to answer?

The present review aims to answer the following questions:

• Are psychological therapies more effective than antidepressants or benzodiazepines?

• Are psychological therapies more acceptable than antidepressants or benzodiazepines?

Which studies were included in the review?

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

We  searched  databases  to  find  all  trials  published  between  1950  and  September  2015  comparing  psychological  therapies  with
antidepressants or benzodiazepines for the treatment of panic disorder with or without agoraphobia in adults. To be included in the review,
the studies had to be randomised controlled trials and had to include people with a clear diagnosis of panic disorder with or without
agoraphobia.

We included 16 studies with a total of 966 participants in the review. We rated the overall quality of the evidence from these studies as
very low to moderate.

What does the evidence from the review tell us?

The  superiority  or  inferiority  of  psychological  therapies  over  drugs  remains  unclear  with  regard  to  treatment  effectiveness  and
acceptability.

None of the studies reported information regarding long-term effectiveness and quality of life.

What should happen next?

The review authors recommend that future research should use less biased psychological therapies, evaluate long-term outcomes, and
report information related to the risk of study bias.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
S U M M A R Y   O F   F I N D I N G S

Summary of findings for the main comparison.   All psychological therapies compared to SSRI for panic disorder with or without agoraphobia in
adults

All psychological therapies compared to SSRI for panic disorder with or without agoraphobia in adults

Patient or population: adults with panic disorder with or without agoraphobia
Settings: outpatient
Intervention: all psychological therapies
Comparison: SSRI

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

SSRI

All psychological therapies

Short-term remission

618 per 1000

Short-term response

447 per 1000

Dropouts for any reason

176 per 1000

525 per 1000 
(383 to 723)

434 per 1000 
(228 to 831)

234 per 1000 
(141 to 390)

Long-term remission/response

Study population

See comment**

See comment**

Moderate

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

RR 0.85 
(0.62 to 1.17)

334
(6 studies)

RR 0.97 
(0.51 to 1.86)

277
(5 studies)

⊕⊝⊝⊝
very low 1,2,3

⊕⊝⊝⊝
very low 1,2,3

RR 1.33 
(0.8 to 2.22)

334
(6 studies)

⊕⊕⊝⊝
low 1,3

Not estimable

0
(0)

See comment**

Short-term improvement 
Scale used (range; lower is better):

-

• panic frequency
• Clinical Global Impression (1 to 7)
• Agoraphobic  Cognitive  Question-

naire (1 to 70)

The mean short-term improvement
in the intervention groups was
0.20 standard deviations lower 
(1.09 lower to 0.69 higher)

-

242
(5 studies)

⊕⊕⊕⊝
moderate 1

Scores estimat-
ed using a stan-
dardised mean
difference

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
v
e
r
s
u
s
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l

i

n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
(
R
e
v
i
e
w

)

4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
v
e
r
s
u
s
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l

i

n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
(
R
e
v
i
e
w

)

5

• Fear  Questionnaire  Agoraphobia

Subscale (0 to 14)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; SSRI: selective serotonin reuptake inhibitor

** No study reported long-term remission/response

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Downgraded one point for risk of bias due to a high risk of bias for blinding and an unclear risk of bias for several domains in many studies.
2Downgraded one point for inconsistency due to substantial heterogeneity.
3Downgraded one point for imprecision based on the fact that the 95% confidence interval around the pooled estimate of the effect included both no effect and an appreciable
benefit.

Summary of findings 2.   All psychological therapies compared to tricyclic antidepressants for panic disorder with or without agoraphobia in adults

All psychological therapies compared to tricyclic antidepressants for panic disorder with or without agoraphobia in adults

Patient or population: adults with panic disorder with or without agoraphobia
Settings: outpatient
Intervention: all psychological therapies
Comparison: tricyclic antidepressants

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Tricyclic anti-
depressants

All psychological therapies

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

Short-term remission

525 per 1000

Short-term response

322 per 1000

430 per 1000 
(326 to 572)

241 per 1000 
(164 to 354)

RR 0.82 
(0.62 to 1.09)

229
(3 studies)

RR 0.75 
(0.51 to 1.10)

270
(4 studies)

Dropouts for any reason

271 per 1000

225 per 1000 

RR 0.83 

430

⊕⊕⊝⊝
low 1,2

⊕⊕⊝⊝
low 1,2

⊕⊕⊝⊝

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
v
e
r
s
u
s
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l

i

n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
(
R
e
v
i
e
w

)

6

Long-term remission/response

Study population

Not estimable

0
(0)

See comment**

(143 to 352)

(0.53 to 1.3)

(5 studies)

low 1,2

See comment**

See comment**

Moderate

Short-term improvement

-

Scale used (range; lower is better):

• Clinical Global Impression (1 to 7)
• Agoraphobic Cognitions Question-

naire (1 to 70)

• Panic Disorder Severity Scale (0 to

28)

• Brief Scale for Anxiety (0 to 60)

The mean short-term improvement
in the intervention groups was
0.20 standard deviations higher 
(0.03 lower to 0.43 higher)

-

414
(5 studies)

⊕⊕⊕⊝
moderate 1

Scores estimat-
ed using a stan-
dardised mean
difference

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio

** No study reported long-term remission/response

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Downgraded one point for risk of bias due to a high risk of bias for blinding and an unclear risk of bias for several domains in many studies.
2Downgraded one point for imprecision based on the fact that the 95% confidence interval around the pooled estimate of effect included both no effect and appreciable benefit.

Summary of findings 3.   All psychological therapies compared to other antidepressants for panic disorder with or without agoraphobia in adults

All psychological therapies compared to other antidepressants for panic disorder with or without agoraphobia in adults

Patient or population: adults with panic disorder with or without agoraphobia
Settings: outpatient
Intervention: all psychological therapies

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
v
e
r
s
u
s
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l

i

n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
(
R
e
v
i
e
w

)

7

Comparison: other antidepressants

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Other antide-
pressants

All psychological therapies

Short-term remission

576 per 1000

Short-term response

705 per 1000

Dropouts for any reason

191 per 1000

518 per 1000 
(276 to 962)

677 per 1000 
(472 to 966)

296 per 1000 
(174 to 506)

Long-term remission/response

Study population

See comment**

See comment**

Moderate

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

RR 0.90 
(0.48 to 1.67)

135
(3 studies)

⊕⊝⊝⊝
very low 1,2,3

RR 0.96 
(0.67 to 1.37)

128
(3 studies)

RR 1.55 
(0.91 to 2.65)

180
(3 studies)

⊕⊕⊝⊝
low 2,3

⊕⊕⊝⊝
low 2,3

Not estimable

0
(0)

See comment**

Short-term improvement 
Scale used (range; lower is bet-
ter):

-

• Panic  Disorder  Severity  Scale

(0 to 28)
• Symptom 

Checklist-90-Re-

vised Global Severity

The mean short-term improvement in
the intervention groups was
0.43 standard deviations lower 
(1.36 lower to 0.51 higher)

-

27
(2 studies)

⊕⊕⊕⊝
moderate 2

Scores estimat-
ed using a stan-
dardised mean
difference

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio

** No study reported long-term remission/response

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
v
e
r
s
u
s
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l

i

n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
(
R
e
v
i
e
w

)

8

Very low quality: We are very uncertain about the estimate.

1Downgraded one point for inconsistency due to the existence of substantial heterogeneity.
2Downgraded one point for imprecision based on the fact that the 95% confidence interval around the pooled estimate of effect included both no effect and appreciable benefit.
3Downgraded one point for risk of bias due to a high risk of bias for blinding and an unclear risk of bias for several domains in many studies.

Summary of findings 4.   All psychological therapies compared to benzodiazepines for panic disorder with or without agoraphobia in adults

All psychological therapies compared to benzodiazepines for panic disorder with or without agoraphobia in adults

Patient or population: adults with panic disorder with or without agoraphobia
Settings: outpatient
Intervention: all psychological therapies
Comparison: benzodiazepines

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Benzodi-
azepines

All psychological therapies

Short-term remission

404 per 1000

Short-term response

261 per 1000

Dropouts for any reason

227 per 1000

437 per 1000 
(283 to 667)

412 per 1000 
(183 to 934)

255 per 1000 
(123 to 536)

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

RR 1.08 
(0.70 to 1.65)

95
(3 studies)

RR 1.58 
(0.7 to 3.58)

69
(2 studies)

RR 1.12 
(0.54 to 2.36)

116
(3 studies)

⊕⊝⊝⊝
very low 1,2

⊕⊕⊝⊝
very low 1,2

⊕⊝⊝⊝
very low 1,2

Long-term remission/re-
sponse

Study population

Not estimable

0
(0)

See comment**

See comment**

See comment**

Moderate

Short-term improvement

-

Scale used (range; lower is
better):

The mean short-term improvement in the
intervention groups was
0.23 standard deviations lower 

-

89
(3 studies)

⊕⊝⊝⊝
very low 1,2

Scores estimat-
ed using a stan-

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
v
e
r
s
u
s
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l

i

n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
(
R
e
v
i
e
w

)

9

• Brief Scale for Anxiety (0 to

(0.69 lower to 0.23 higher)

60)

• STAI state anxiety (20 to 80)

dardised mean
difference

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; STAI: State-Trait Anxiety Inventory

** No study reported long-term remission/response

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Downgraded one point for risk of bias due to a high risk of bias for blinding and an unclear risk of bias for several domains in many studies.
2Downgraded two points for very serious imprecision due to the very small sample size and small number of studies.

Summary of findings 5.   All psychological therapies compared to antidepressants alone or antidepressants and benzodiazepines for panic disorder
with or without agoraphobia in adults

All psychological therapies compared to antidepressants alone or antidepressants and benzodiazepines for panic disorder with or without agoraphobia in adults

Patient or population: adults with panic disorder with or without agoraphobia
Settings: outpatient
Intervention: all psychological therapies
Comparison: antidepressants alone or antidepressants and benzodiazepines

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

All psychological therapies

Antidepressants
alone or antide-
pressants and
benzodiazepines

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

Short-term remission

585 per 1000

Short-term response

474 per 1000

503 per 1000 
(415 to 614)

460 per 1000 
(365 to 578)

RR 0.86 
(0.71 to 1.05)

663
(11 studies)

RR 0.95 
(0.76 to 1.18)

800
(12 studies)

⊕⊕⊝⊝
low 1,2

⊕⊕⊝⊝
low 1,2

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Dropouts for any reason

217 per 1000

234 per 1000 
(167 to 328)

RR 1.08 
(0.77 to 1.51)

909
(13 studies)

⊕⊝⊝⊝
very low 1,2,3

Long-term remission/response

Study population

Not estimable

0
(0)

See comment**

See comment**

See comment**

Moderate

Short-term improvement

-

Scale used (range; lower is better):

• panic frequency
• Clinical Global Impression (1 to 7)
• Agoraphobic  Cognitive  Question-

naire (1 to 70)

• Fear  Questionnaire  Agoraphobia

Subscale (0 to 14)

• Brief Scale for Anxiety (0 to 60)
• STAI state anxiety (20 to 80)

-

The mean short-term improve-
ment in the intervention groups
was
0.01 standard deviations
higher 
(0.34 lower to 0.35 higher)

638
(11 studies)

⊕⊕⊝⊝
low 1,3

Scores estimat-
ed using a stan-
dardised mean
difference

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; STAI: State-Trait Anxiety Inventory

** No study reported long-term remission/response

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Downgraded one point for risk of bias due to a high risk of bias for blinding and an unclear risk of bias for several domains in many studies.
2Downgraded one point for imprecision based on the fact that the 95% confidence interval around the pooled estimate of effect included both no effect and appreciable benefit.
3Downgraded one point for publication bias judged by the funnel plot asymmetry.

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
v
e
r
s
u
s
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l

i

n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
(
R
e
v
i
e
w

)

1
0

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

A  panic  attack  is  a  discrete  period  of  fear  or  anxiety  that  has  a
rapid  onset  and  reaches  a  peak  within  10  minutes.  According  to
the Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition,  Text  Revision  (DSM-IV-TR)  (APA  2000),  it  includes  at  least
four out of 13 characteristic symptoms. These are bodily symptoms,
such  as  a  racing  heart,  chest  pain,  sweating,  shaking,  dizziness,
flushing,  stomach-churning,  faintness,  and  breathlessness,  and
fearful  cognitions,  such  as  the  fear  of  collapse,  going  mad  or
dying,  and  derealisation  (unreal  perception).  Panic  disorder  is
characterised  by  recurrent,  spontaneous,  and  unexpected  panic
attacks, at least one of which has been followed by one month (or
more) of persistent concern about having additional attacks, worry
about  the  implications  of  the  attack  (or  its  consequences),  or  a
significant change in behaviour related to the attacks (APA 2000).
In  around  a  quarter  of  patients,  panic  disorder  is  accompanied
by  agoraphobia  (avoidance  of  situations  where  escape  would  be
difficult  when  panic  attacks  occur)  (Kessler  2006).  The  presence
of  agoraphobia  is  associated  with  increased  severity  and  worse
outcome (Kessler 2006).

Panic disorder is a very common disorder that presents across the
spectrum of severity, with very large numbers of people suffering
considerable  handicaps  as  a  result.  Panic  disorder  is  common  in
the general population, with a lifetime prevalence of 1% to 4% (Bijl
1998;  Eaton  1994).  In  primary  care  settings,  the  prevalence  rises
to  around  10%  (King  2008).  It  is  also  highly  comorbid  with  other
psychiatric disorders, such as drug dependence, major depression,
bipolar I disorder, social phobia, specific phobia, and generalised
anxiety  disorder  (Grant  2006).  It  is  estimated  that  generalised
anxiety  disorder  co-occurs  in  68%  of  people  with  panic  disorder
(Starcevic 2009), and only 38.6% of people with major depression
(Wittchen  2002).  People  suffering  from  panic  disorder  exhibit
considerably  poorer  overall  mental  well-being  than  individuals
with  cancer,  diabetes,  heart  disease,  arthritis,  hypertension,  and
a host of other chronic physical conditions (Comer 2011). Having
panic disorder is also related to poorer quality of life and physical
function (Sherbourne 2010); the risk of attempting suicide is also
higher  (Sareen  2005).  These  effects  are  similar  to  or  greater  than
those associated with major depression (Markowitz 1989). A study
has reported that nearly one-third of these patients in primary care
had seen three or more healthcare professionals, and almost one-
fifth had visited general hospital emergency departments (Swinson
1992).

Description of the intervention

Psychological therapies

There are various psychological therapies for panic disorder. Whilst
they may all be variously used in the treatment of panic disorder
in  everyday  clinical  practice,  only  approaches  informed  by  the
principles  of  cognitive  behavioural  therapy  are  recommended  in
clinical guidelines for panic disorder (NICE 2011).

Psychoeducation  consists  of  providing  information  to  patients
on  things  such  as  symptoms  and  theories  of  psychological
therapy  (Schotte  2006).  Supportive  psychotherapy  is  the  non-
specific  component  of  psychological  therapies  and  involves
warm,  empathic,  and  non-directive  emotional  support  (Winston
2004).  Physiological  therapy  uses  physical  techniques  such  as

Cochrane Database of Systematic Reviews

breathing  retraining,  relaxation,  and  biofeedback  with  the  goal
of  helping  patients  to  control  the  physiological  symptoms  of
panic  disorder  (Mauret  2010).  Behaviour  therapy  is  characterised
by  exposure  aimed  at  habituation;  patients  are  gradually
exposed  to  their  phobic  situations  (in  vivo  exposure,  virtual
reality  exposure)  or  bodily  sensations  (interoceptive  exposure)
in  order  to  reduce  their  anxiety  in  such  environments  through
habituation  (Marks  1981).  Cognitive  therapy  is  composed  of
cognitive  restructuring, 
in  which  the  patient  and  therapist
co-operate  to  find  and  reconstruct  irrational  or  maladaptive
thoughts  (Barlow  1988).  Cognitive  behavioural  therapy  (CBT)  is
the  combination  of  behaviour  and  cognitive  therapy,  and  often
includes  psychoeducation  and  physiological  therapy  elements,
such  as  breathing  retraining  and  progressive  muscle  relaxation.
The  third-wave  therapies  are  a  group  of  treatments  that
share  some  features  of  CBT,  but  focus  more  on  mindfulness,
acceptance,  the  patient's  values  in  life,  and  relationships  (Ost
2008).  Examples  are  acceptance  and  commitment  treatment,
cognitive behavioural analysis, dialectical behavioural therapy, and
mindfulness-based cognitive therapy (Kahl 2012). Psychodynamic
therapy is represented by psychoanalysis and its derivatives, which
deal with the unconscious anger that patients with panic disorder
are hypothesised to have, and the defence mechanisms of reaction
formation, undoing and denial, which are frequently employed by
people  with  panic  disorder,  compromising  the  formations  which
panic  attacks  represent,  the  pleasure  principle,  and  transference
(Busch 1999).

Pharmacological interventions

Different  types  of  antidepressants  augment  the  function  of
chemicals  in  the  brain,  in  particular  serotonin,  noradrenaline,
or  both.  Tricyclic  antidepressants  and  serotonin-noradrenaline
reuptake  inhibitors  inhibit  both  serotonin  and  noradrenaline
reuptake.  Selective  serotonin  reuptake  inhibitors  (SSRIs)  inhibit
the  reuptake  of  serotonin  into  nerve  terminals  by  inhibiting
serotonin transporters. Selective noradrenaline reuptake inhibitors
inhibit  noradrenaline  transporter.  Monoamine  oxidase  inhibitors
inhibit  enzymes  that  oxidise  monoamines  such  as  serotonin,
noradrenaline,  and  dopamine.  Other  types  of  antidepressants
include  bupropion,  which  is  a  weak  inhibitor  of  the  neuronal
uptake  of  norepinephrine  and  dopamine  but  has  no  effect  on
serotonin;  trazodone  and  nefazodone,  which  block  serotonin
receptors; and mirtazapine, which increases central noradrenergic
and  serotonergic  neurotransmission  (by  inhibiting  the  negative
feedback from serotonin and noradrenaline that has already been
released  by  the  neuron),  but  also  has  antagonist  and  partial
agonist  actions  on  certain  serotonin  receptors  (Baudry  2011).
Benzodiazepines  have  been  used  for  panic  disorder  (Ravindran
2010).  However,  recent  guidelines  recommend  SSRIs  as  the  first-
line  medication  (APA  2009;  BAP  2014),  as  benzodiazepines  may
lead to dependence, and tricyclic antidepressants and monoamine
oxidase  inhibitors  have  more  unfavourable  adverse  effects  than
SSRIs (Freire 2011).

How the intervention might work

Psychological  therapy  can  be  broadly  conceived  and  defined
as  therapeutic  interaction  aimed  at  the  alleviation  of  mental
suffering through verbal and non-verbal communication between
a  professional  and  a  client,  based  on  a  certain  theoretical
model  of  how  that  mental  suffering  occurs  and  is  maintained.
Psychoeducation  aims  to  help  people  acquire  the  competence

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

to  manage  their  symptoms  and  preserve  their  mental  health
(Daele  2012).  Supportive  psychological  therapy  helps  patients
see things more clearly by supporting reality testing, challenging
unrealistic  ideas,  and  demonstrating  more  effective,  less  costly
ways  of  defending  while  supporting  adaptive  defences  (Douglas
2008).  Physiological  therapy  is  based  on  the  suffocation  alarm
theory,  which  postulates  that  a  monitor  in  the  human  central
nervous system sets off the alarm for imminent suffocation when
its  regulatory  threshold  is  exceeded  (Klein  1993).  Physiological
therapy, such as respiratory training, tries to treat panic disorder
by controlling pCO2 (partial pressure of carbon dioxide), which is
the key to the suffocation alarm. Applied relaxation, one element
of  physiological  therapy,  is  to  teach  the  patient  to  observe  the
very first signs of a panic attack and to apply a rapid and effective
relaxation  technique  to  cope  with,  and  eventually  abort,  these
symptoms  before  they  develop  into  a  panic  attack.  Behavioural
therapy focuses on the maintenance of fear through avoidance and
treats agoraphobia by exposure to feared stimuli and habituation
of fear responses (Marks 1981). Cognitive therapy postulates that
panic disorder occurs through a catastrophising misinterpretation
of bodily sensations, which should therefore be corrected through
cognitive  restructuring  with  or  without  behavioural  experiments
(Barlow 1988). The third-wave therapies focus more on contact with
internal events, acceptance, and mindfulness; emphasis is given to
contacting  the  present  moment  (Hayes  2004).  Mindfulness  alters
the function of thoughts without first altering their form (Teasdale
2002). Psychodynamic therapy assumes that a panic attack occurs
when the defence mechanism against anxiety is broken. According
to  this  theory,  the  loss  of  parents  or  experience  of  separation
anxiety  in  childhood  is  regarded  as  the  cause  of  agoraphobia
(Sadock 2003).

A  range  of  psychotropic  agents  have  been  shown  to  be  effective
against panic disorder. Medications affecting the serotonin system,
such as tricyclic antidepressants and SSRIs, have anxiolytic effects
(Michelson  1998);  some  studies  also  suggest  that  they  have  a
regulatory effect on respiration (Eldridge 1981). The frontal cortex is
the most consistently reported site that responds to antidepressant
treatment,  which  induces  normalisation  of  its  overactivity  and
underactivity  (Goldapple  2004).  Other  supposed  regions  affected
by  antidepressant  treatment  include  specific  subcortical  (brain
stem,  hypothalamus),  limbic-paralimbic  (hippocampus,  posterior
cingulate), and striatal (caudate, globus pallidus) nodes (Mayberg
2000).  The  site  and  direction  of  regional  changes  also  suggest
mechanisms  for  changes  in  mood  and  motor,  cognitive,  and
somatic symptoms of depression (Mayberg 1999). Benzodiazepines
enhance gamma-aminobutyric acid (GABA) transmission by acting
as  agonists  at  a  specific  site  on  the  GABA-A  receptor,  resulting  in
anxiolytic, hypnotic, and anticonvulsant effects. They are effective
for  rapid  relief  of  symptoms,  but  have  disadvantages,  such  as
sedation  and  the  potential  for  abuse  and  formation  of  tolerance
(Zohar  2000).  Decreased  benzodiazepine  receptor  binding  in
people with panic disorder has been suggested in one study (Malizia
1998),  which  is  consistent  with  the  idea  that  panic  disorder  may
be  due  to  defective  brain  inhibition  that  leads  to  paroxysmal
elevations in anxiety during panic attacks.

Some authors have suggested that the biological mechanisms of
action of psychological therapies and antidepressants may not be
entirely mutually exclusive (Goldapple 2004).

Cochrane Database of Systematic Reviews

Why it is important to do this review

Various  randomised  controlled  trials  (RCTs)  and  meta-analyses
have  demonstrated  the  efficacy  of  psychological  therapies
in  comparison  with  waiting 
list,  psychological  placebo,  or
pharmacological  placebo  controls  (Sanchez-Meca  2010),  and
the  efficacy  of  pharmacotherapy  in  comparison  with  placebo
(Bradwejn  2005).  Several  meta-analyses  have  also  examined  the
relative efficacy of psychological therapies and pharmacotherapy.

to  either 

therapy  and
A  meta-analysis  of  combined  psychological 
antidepressant  medication,  compared 
treatment
administered as monotherapy, concluded that combined therapy
is  better  than  antidepressants  and  that  psychological  therapy  is
as  effective  as  combined  therapy  (Furukawa  2007).  Considering
this  evidence,  it  may  be  the  case  that  psychological  therapy  is
better than antidepressants. However, to draw any firm and direct
conclusions we would need to analyse head-to-head comparisons
of psychological therapy alone and antidepressants alone.

Three  previous  meta-analyses  have  included  studies  directly
comparing psychological therapy with pharmacotherapy, but they
have some critical limitations (Clum 1993; Gould 1995; Mitte 2005).
Two  of  these  reviews  used  data  from  1964  to  1990  and  from
1974  to  1994,  and  are  therefore  out  of  date.  Moreover,  only
one  out  of  the  29  included  studies  in  Clum  1993,  and  three
out  of  the  43  included  studies  in  Gould  1995,  directly  compared
pharmacotherapy  with  psychological  therapies,  and  their  only
pharmacological intervention was imipramine. Given that between
30 to 40 antidepressants are now available, with different modes
of  action  (such  as  selective  serotonin  uptake  inhibitors  and
noradrenergic  and  specific  serotonergic  antidepressants),  meta-
analyses including a wide range of medications should be carried
out.

recent  meta-analysis  analysed  different 

therapy
A  more 
approaches 
including  pharmacotherapy  and  psychological
therapies,  but  only  cognitive  behavioural  therapy  or  behaviour
therapy  were  included  within  the  latter  category  (Mitte  2005).
Other psychotherapies have been shown to be effective for panic
disorder, such as psychoanalytic therapy (Milrod 2007).

is  therefore  a  need 

There 
for  an  up-to-date  and  more
comprehensive  review  that  directly  compares  different  types  of
psychological  therapy  and  pharmacotherapy  to  better  inform
treatment choices.

O B J E C T I V E S

the  effects  of  psychological 

To  assess 
therapies  versus
pharmacological interventions for panic disorder, with or without
agoraphobia, in adults.

M E T H O D S

Criteria for considering studies for this review

Types of studies

We included all relevant RCTs in the review. We planned to include
cluster-randomised studies in which the effects of clustering have
been taken into account, as well as trials using a cross-over design,
however  we  found  no  cluster-randomised  or  cross-over  trials.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

We  excluded  quasi-randomised  trials,  such  as  those  allocating
participants using alternate days of the week.

Types of participants

Age

The  participants  had  to  be  18  years  of  age  or  older.  We  did  not
include studies focusing on adolescents. There is a Cochrane review
on cognitive behavioural therapy for anxiety disorders in children
and adolescents (James 2013). However, we included studies with
participants younger that 18 in the sample as long as at least 80%
of participants were aged 18 or older.

Diagnosis

We included studies that have enlisted participants with a primary
diagnosis of panic disorder, with or without agoraphobia, according
to any of the following criteria: Feighner (Feighner 1972), Research
Diagnostic Criteria (Spitzer 1978), Diagnostic and Statistical Manual
of Mental Disorders (DSM)-III (APA 1980), DSM-III-R (APA 1987), DSM-
IV  (APA  2000),  or  International  Classification  of  Diseases,  Tenth
Edition (ICD-10) (WHO 1992). We anticipated there would be few,
if  any,  studies  that  use  DSM-5  diagnostic  criteria,  owing  to  its
relatively  recent  publication.  As  such,  we  planned  not  to  include
DSM-5 criteria in this version of the review. DSM-5 considers panic
disorder  and  agoraphobia  as  independent  conditions;  in  future
revisions of the review, we will include studies based on DSM-5 if
they focus on panic disorder, with or without agoraphobia.

If  studies  focused  on  agoraphobia,  rather  than  panic  disorder,
we  included  them  if  participants  were  operationally  diagnosed
according to the above criteria and when it could be safely assumed
that some of the participants were suffering from panic disorder as
defined by the above criteria. In other words, we planned to exclude
studies  that  focused  on  agoraphobia  without  panic  disorder.
There  is  evidence  that  over  95%  of  people  with  agoraphobia
seen clinically also suffer from panic disorder (Goisman 1995). We
planned to examine the effect of the inclusion of these studies (i.e.
studies in which some, but possibly not all, of the participants had
panic disorder) in a sensitivity analysis. However, we found no such
studies.

We excluded studies where panic was induced.

Setting

Participants must have been outpatients at the time of enrolment.

Previous treatment

We included both treatment-naive patients and patients who had
already undergone some previous treatment (either psychological
or pharmacological), as long as they satisfied the above inclusion
criteria.

Comorbidities

We  included  studies  in  which  participants  may  have  other
anxiety  disorders  (e.g.  generalised  anxiety  disorder,  specific
phobias)  or  with  subthreshold  panic  disorder  if:  1)  separate
results for participants with panic disorder were available; and 2)
randomisation was stratified by specific diagnosis. Stratification by
diagnosis  was  not  required  if  the  total  sample  included  at  least
40 participants with panic disorder.

Cochrane Database of Systematic Reviews

We  excluded  studies  in  which  all  participants  had  a  concurrent
primary diagnosis of Axis I or II disorders other than panic disorder
or agoraphobia.

We included studies in which the participants may have physical
comorbidities.  However,  we  excluded  studies  that  explicitly
focused  on  panic  disorder  or  agoraphobia  among  people  with  a
specific physical comorbidity, which can be a confounding factor.

Types of interventions

For  this  review,  we  chose  to  focus  on  the  most  representative
psychological  therapy  schools  (i.e.  CBT  and  its  components
or  developments,  psychodynamic  psychological  therapy,  and
supportive psychological therapy) and their control conditions.

We included trials if they compared a psychological therapy with a
pharmacological intervention.

Psychological therapies

• Psychoeducation,  defined  as  sessions  in  which  patients  are
provided with information about their disease (Daele 2012).
• Supportive psychological therapy, defined as sessions in which
patients  are  administered  an  active,  although  non-specific,
psychological treatment (Douglas 2008).

• Physiological therapies that use some kind of physical training
(e.g.  breathing  retraining,  progressive  muscle  relaxation,
applied  relaxation) 
in  order  to  reduce  the  physiological
manifestations of anxiety (Klein 1993).

• Behaviour therapy, with or without physiological components,
aiming at patients' habituation to anxiety-provoking situations
and  sensations 
(e.g.
interoceptive, in vivo) (Marks 1981).

through  some  kind  of  exposure 

• Cognitive  therapy,  with  or  without  physiological  components
and  behavioural  experiments,  aiming  at  the  modification
of  maladaptive  thoughts  through  some  kind  of  cognitive
restructuring (Barlow 1988).

• Cognitive  behavioural 

(CBT),  with  or  without
physiological  components,  comprising  both  cognitive  and
behavioural therapy elements.

therapy 

• Third-wave  therapies,  including  acceptance  and  commitment
therapy, mindfulness-based therapy, and other so-called third-
wave  therapies  administered  with  or  without  other  CBT
components  (e.g.  exposure,  cognitive  restructuring,  breathing
retraining, muscle relaxation) (Hayes 2004).

• Psychodynamic  therapy,  focused  on  revealing  and  resolving

intrapsychic or unconscious conflicts (Sadock 2003).

As therapies could be of any length, we accepted those given in a
single session.

We included both individual and group therapies.

Therapies  must  be  administered  face-to-face.  We  excluded
therapies  administered  in  their  self  help  (e.g.  book,  computer,
internet)  or  remote  (e.g.  telephone,  video  conference)  versions.
In  the  case  of  psychoeducation,  we  did  not  consider  the  simple
provision  of  informational  material  without  any  face-to-face
session  to  be  an  active  intervention,  but  rather  a  comparator
intervention (such as no psychological treatment or waiting list).

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

family 

therapy,  and  other
therapy,  couple 
We  excluded 
psychosocial  interventions  whose  intervention  focus  is  not  the
individual but rather the family system or couple as a whole.

We 
included  so-called  component  studies  (e.g.  dismantling
studies) as long as each arm could be regarded as any of the above-
defined  experimental  interventions  compared  against  another
experimental  or  comparator  treatment.  We  ultimately  regarded
study  arms  as  giving  information  about  the  same  experimental
intervention and thus combined them.

(such  as
We  excluded  any  other  psychological  therapies 
interpersonal 
therapy,  eye  movement  desensitisation  and
reprocessing  (EMDR),  and  Morita  therapy)  on  the  grounds  that
they  did  not  meet  the  criteria  described  above  for  a  CBT  (and
its components and developments), psychodynamic psychological
therapy, or supportive psychological therapy approach.

When  psychoeducation  or  psychological  support  (or  both)
were  accompanied  by  any  other  psychological  intervention,
we  classified  study  arms  according  to  the  latter  and  regarded
psychoeducation and psychological support as components of that
intervention.

Pharmacotherapy

• Tricyclic  and  heterocyclic  antidepressants: 

imipramine,
clomipramine,  desipramine,  nortriptyline,
lofepramine,

trimipramine, 

amitriptyline, 
doxepin,  dosulepin/dothiepin, 
protriptyline, amineptine.

• Selective  serotonin  reuptake  inhibitors  (SSRIs):  citalopram,
escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline.

• Monoamine 

oxidase 

inhibitors 

(MAOIs): 

phenelzine,

isocarboxazid, tranylcypromine, moclobemide, brofaromine.

• Serotonin-noradrenaline 

reuptake 

inhibitors 

(SNRIs):

desvenlafaxine, duloxetine, milnacipran, venlafaxine.

• Noradrenergic  and  specific  serotonergic  antidepressants:

mirtazapine.

• Selective noradrenergic reuptake inhibitors: reboxetine.
• Other  antidepressants:  agomelatine,  bupropion,  trazodone,
nefazodone,  mianserin,  maprotilin,  vortioxetine,  vilazodone,
viloxazine.

• Benzodiazepines:  adinazolam,  alprazolam,  bentazepam,
bromazepam,  brotizolam,  camazepam,  chlordiazepoxide,
clobazam,  clonazepam,  clorazepate,  clotiazepam,  cloxazolam,
diazepam,  etizolam,  flutoprazepam,  halazepam,  ketazolam,
lormetazepam,  medazepam,
loflazepate, 
metaclazepam,  mexazolam,  midazolam, 
nordazepam,
oxazepam,  prazepam,  propazepam,  quazepam,  ripazepam,
tofisopam.

lorazepam, 

Combination pharmacotherapy

We  included  studies  in  which  regular  use  of  antidepressants  and
irregular use of benzodiazepines took place and regarded them as
antidepressant  monotherapy.  We  also  included  studies  in  which
regular  use  of  antidepressants  and  benzodiazepines  took  place
but  regarded  them  as  combination  therapy  of  antidepressants
plus  regular  benzodiazepines.  We  excluded  other  combination
pharmacotherapy.

Cochrane Database of Systematic Reviews

Types of outcome measures

Primary outcomes

1. Efficacy

a. Short-term* 'remission', i.e. satisfactory end-state as defined
by  the  global  judgement  of  the  original  investigators,  such
as 'panic free' or 'no or minimal symptoms' according to the
Clinical  Global  Impression  (CGI)  Severity  Scale  (Guy  1976),
or a Panic Disorder Severity Scale (PDSS) score of seven or
below  (Shear  1997),  or  a  Fear  Questionnaire  Agoraphobia
Subscale score of nine or below (Marks 1979).

b. Short-term* 

'response' 

(a  dichotomised  outcome).
'Response'  is  intended  to  be  a  substantial  improvement
from  baseline  as  defined  by  the  global  judgement  of  the
original authors, such as 'very much' or 'much' improvement
according  to  the  CGI  Change  Scale,  a  more  than  40%
reduction in the PDSS, or a more than 50% reduction in the
Fear Questionnaire Agoraphobia Subscale.

2. Adverse effects

a. Total number of dropouts for any reason, as a proxy measure

of treatment acceptability.

(*)  within  six  months  from  treatment  commencement.  When
multiple time point measures were available, we gave preference
to  measures  at  approximately  three  months  after  treatment
commencement.

Secondary outcomes

1. Efficacy

a. Long-term  remission/response  of  panic  disorder,  with  or
without agoraphobia, either after treatment discontinuation
or  on  continued  treatment.  We  defined  long  term  as  six
months  or  longer  after  treatment  commencement.  When
multiple  time  point  measures  were  available,  we  gave
preference  to  measures  at  approximately  12  to  15  months
after treatment commencement.

b. Short-term improvement of panic disorder, with or without
agoraphobia, as measured on a continuous scale. Examples
of continuous scales are the PDSS (total score 0 to 28), Panic
and  Agoraphobia  Scale  (total  score  0  to  45),  CGI  Severity
Scale (1 to 7), CGI Change Scale (1 to 7), etc. When multiple
measures  were  used,  we  gave  preference  in  the  following
order:
i. PDSS > Panic and Agoraphobia Scale (Bandelow 1995) >
Anxiety Sensitivity Index-Revised (Deacon 2003) > Anxiety
Sensitivity  Index  (Reiss  1986)  >  Agoraphobic  Cognition
Questionnaire  (Chambless  1984)  >  Body  Sensation
Questionnaire (Chambless 1984) > other scales specific to
panic disorder.

ii. CGI  Severity  Scale  >  CGI  Improvement  Scale  >  Global
Assessment Scale (Endicott 1976) > Global Assessment of
Functioning (APA 2000) > other global scales.

iii. Fear  Questionnaire  Agoraphobia  Subscale  >  Fear
Questionnaire  Global  Phobia  Rating>  Mobility  Inventory
for Agoraphobia (Chambless 1985) > other scales specific
to agoraphobia only.

iv. Panic frequency > panic severity > other scales specific to

panic attacks only.

v. Beck  Anxiety  Inventory  (Beck  1988)  >  Hamilton  Anxiety
Rating  Scale  (Hamilton  1959)  >  State-Trait  Anxiety

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Inventory  (Spielberger  1989)  >  other  general  anxiety
scales.

vi. When  both  self  and  observer-rated  assessments  were
available, we gave preference to the latter. We indicated
the actual measure entered into the meta-analysis at the
top of the listings in the Characteristics of included studies
table.

c. Short-term  improvement  of  quality  of  life  as  measured  on
a  continuous  scale.  Examples  are  the  36-Item  Short  Form
Health Survey (SF-36), in Ware 1992, or EuroQoL (Kind 1996).

2. Adverse effects

a. Suicide and suicide attempts.
b. Number of dropouts due to adverse effects.
c. Number  of  participants  experiencing  at  least  one  adverse

effect.

Timing of outcome assessment

Short-term timing of outcome assessment was within six months
from  treatment  commencement,  and  long-term  assessment  was
six months or longer.

Search methods for identification of studies

Specialised Register of the Cochrane Common Mental
Disorders Group (CCMDCTR)

The  Cochrane  Common  Mental  Disorders  Group  maintains  a
specialised  register  of  RCTs,  the  CCMDCTR.  This  register  contains
over  40,000  reference  records  (reports  of  RCTs)  for  anxiety
disorders, depression, bipolar disorder, eating disorders, self harm,
and  other  mental  disorders  within  the  scope  of  this  Group.  The
CCMDCTR  is  a  partially  studies-based  register  with  more  than
50%  of  reference  records  tagged  to  c12,500  individually  PICO
coded study records. Reports of trials for inclusion in the register
are  collated  from  (weekly)  generic  searches  of  MEDLINE  (1950-),
Embase  (1974-),  and  PsycINFO  (1967-),  quarterly  searches  of  the
Cochrane  Central  Register  of  Controlled  Trials  (CENTRAL),  and
review-specific searches of additional databases. Reports of trials
are also sourced from international trial registries, drug companies,
the  handsearching  of  key  journals,  conference  proceedings,  and
other  (non-Cochrane)  systematic  reviews  and  meta-analyses.
Details of CCMD's core search strategies (used to identify RCTs) can
be found on the Group's website; an example of the core MEDLINE
search is displayed in Appendix 1.

Electronic searches

CCMDCTR-Studies Register

The  Cochrane  Common  Mental  Disorders  Group's  Information
Specialist  searched 
(to  11
September 2015) using the following terms:

the  CCMDCTR-Studies  Register 

Condition/Co-morbidity = panic AND
Intervention  =  (attention*  or  behav*  or  biblio*  or  biofeedback  or
cognitive  or  collaborative  or  contact  or  counsel*  or  desensiti*  or
educat* or expos* or feedback or 'group” or imag* or interpersonal
or  intervention  or  management  or  panic  or  prevention  or  psycho*
or relaxation or self* or stress* or support* or *therap* or *train* or
treatment or unclear or 'not stated')

Studies comparing a psychological therapy with a pharmacological
intervention were manually selected for the authors to screen.

Cochrane Database of Systematic Reviews

The CCMDCTR-References Register

The CCMDCTR-References Register was searched (to 11 September
2015)  using  a  more  sensitive  set  of  terms  to  identify  additional
untagged/uncoded reports of RCTs (Appendix 2).

Anxiety Disorders Not Otherwise Specified (ADNOS)

A  further  search  of  the  CCMDCTR  was  conducted  at  this  time
to  identify  ADNOS  studies.  The  CCMDCTR-Studies  Register  and
References Register were cross-searched using the following terms:

("anxiety disorder*" not (agoraphobi* or panic or (social and (anxi*
or phobi*)) or generalised or generalized or obsessive or compulsive
or OCD or PTSD or post-trauma* or "post trauma*” or posttrauma* or
"specific phobia*" or "spider phobi*")) + ('psychotherapies' as listed
in Appendix 2).

Supplementary searches

We  conducted  a  complementary  search  in  PubMed  (Appendix
3),  as  well  as  in  trials  registries  such  as  the  World  Health
Organization 
International  Clinical  Trials  Registry  Platform
(WHO  ICTRP)  (apps.who.int/trialsearch/)  and  ClinicalTrials.gov
(clinicaltrials.gov/).

We applied no restrictions on date, language, or publication status
to the searches.

Searching other resources

Reference search

We checked the reference lists of all included studies and relevant
systematic reviews to identify additional studies missed from the
original electronic searches.

Citation search

We  conducted  a  citation  search  on  Web  of  Science  to  identify
articles citing any of the included studies.

Personal communication

We  contacted  trialists  and  subject  experts  for  information  on
unpublished or ongoing studies or to request additional trial data.

Data collection and analysis

Selection of studies

Two review authors independently examined titles and abstracts of
references identified by the electronic search strategies described
above  to  determine  whether  the  study  was  likely  to  be  relevant,
using the following three simple criteria.

1. Randomised trial.
2. Panic disorder as diagnosed by operationalised criteria.
therapies 
3. Comparison 

psychological 

between 

and

pharmacotherapy.

Next  we  obtained  the  full  texts  of  the  studies  identified  as
potentially relevant by at least one review author. Two out of three
review authors (HI, AT, PC) then independently inspected the full
texts with regard to the strict eligibility criteria. The strict eligibility
criteria  consisted  of  five  items  which  operationalised  the  above-
listed criteria for considering studies. In case of disagreements, we
made the final rating by discussion or by involving a third review

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

author  (TAF)  where  necessary.  The  inter-rater  reliability  (kappa)
of  these  judgements  was  0.81.  We  performed  this  assessment
without being blinded to the author names, journal name, or year
of publication.

Figure 1 shows the study selection process (along with the number
of references and studies, and reasons for exclusion of studies).

Data extraction and management

Two  out  of  three  review  authors  (HI,  AT,  PC)  independently
extracted  data  from  the  original  reports  using  the  pilot-tested,
prespecified  data  extraction  forms.  We  extracted  information
about  study  design,  participants  (diagnostic  criteria,  percentage
of agoraphobic participants), interventions (format and timing of
psychological  therapies  and  control  condition,  therapist  training,
intervention components and comparators, name of medication,
dosing  schedule  of  medication  and  range  and  intended  mean
dose), outcomes, and risk of bias. Any disagreements were resolved
by consensus between the two review authors in consultation with
a third review author (TAF). If necessary we contacted authors of
the original studies to obtain further clarification.

Main comparisons

• All psychological therapies versus SSRIs.
• All psychological therapies versus SNRIs.
• All psychological therapies versus tricyclic antidepressants.
• All psychological therapies versus other antidepressants.
• All psychological therapies versus benzodiazepines.
• All psychological therapies versus either antidepressants alone

or antidepressants and benzodiazepines,

Assessment of risk of bias in included studies

Two  review  authors  independently  assessed  the  methodological
quality  of  the  selected  trials.  Any  disagreements  were  resolved
by consensus between the two review authors or, if necessary, in
consultation  with  a  third  review  author.  The  criteria  for  quality
assessment were based on the recommendations of the Cochrane
Handbook  for  Systematic  Reviews  of  Interventions  (Higgins  2011).
We assessed the following domains.

1. Random  sequence  generation  and  allocation  concealment

(selection bias).

2. Blinding of participants and personnel (performance bias).
3. Blinding of outcome assessors (detection bias).
4. Incomplete outcome data reporting (attrition bias).
5. Selective reporting (reporting bias).
6. Other sources of bias.

a. Researcher allegiance (post-hoc assessment)
b. Therapist allegiance (post-hoc assessment)
c. Sponsorship bias (post-hoc assessment)

We assessed each potential risk of bias and assigned one of three
categories:  low,  high,  or  unclear  risk  of  bias  (when  there  was
insufficient information to permit judgement of high or low risk),
and described this in the 'Risk of bias' table for each trial. We made
the assessments according to prespecified criteria, mainly based on
the Cochrane Handbook.

Cochrane Database of Systematic Reviews

Measures of treatment effect

Dichotomous data

We calculated risk ratios (RRs) and their 95% confidence intervals
(CIs)  using  a  random-effects  model.  RRs  using  a  random-effects
model have been shown to be superior for clinical interpretation
and external generalisability compared to fixed-effect models and
odds ratios (ORs) or risk differences (RDs) (Furukawa 2002).

Continuous data

We calculated standardised mean differences (SMDs) and their 95%
CIs, because we expected different measures to have been used to
measure the same construct.

Unit of analysis issues

Cluster-randomised trials

We  planned  to  include  cluster-randomised  trials  only  if  the
intracluster correlation coefficient (ICC) was reported or could be
borrowed  from  similar  trials.  We  planned  to  estimate  the  effect
size in cluster-randomised trials using the ICC to adjust for cluster
effects, however there were no such trials.

Cross-over trials

We planned to use the first active treatment phase for our analysis,
however there were no such trials.

Multiple-armed trials

We combined arms as long as they could be regarded as subtypes
of the same treatment. If this was not the case, we treated each arm
as  a  separate  comparator  and  subdivided  the  sample  size  of  the
common comparator arm for pairwise meta-analysis.

Dealing with missing data

Dichotomous data

We  contacted  the  original  study  authors  for  missing  data.  We
calculated  responders  to  treatment  and  remitters  on  a  strict
intention-to-treat  (ITT)  basis  and  thus  included  all  dropouts  in
the  analyses.  Where  participants  had  been  excluded  from  a  trial
before  the  endpoint,  we  assumed  that  they  had  experienced  a
negative outcome by the end of the trial (e.g. failure to respond to
treatment). We examined the validity of this decision in sensitivity
analyses  by  applying  worst-  and  best-case  scenarios  (i.e.  missing
data  are  assumed  either  as  responder  or  non-responder  in  the
corresponding sensitivity analysis).

When  dichotomous  outcomes  were  not  reported,  but  baseline
mean,  endpoint  mean,  and  standard  deviations  (SDs)  of  the
scores  were  provided,  we  converted  continuous  outcome  data
expressed  as  mean  and  SD  into  the  number  of  responding  and
remitting participants, according to a validated imputation method
(Furukawa 2005). We examined the validity of this imputation in the
sensitivity analyses.

Continuous data

We  contacted  the  original  study  authors  for  missing  data.  When
there were missing data and the method of 'last observation carried
forward' (LOCF) had been used to perform an ITT analysis, then we
used the LOCF data.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

When only the standard error (SE) or t-statistics or P values were
reported, we planned to calculate SDs according to Altman (Altman
1996). Where SDs were not reported, we planned to contact the trial
authors and ask them to supply the data; in the absence of data
from  the  authors,  we  planned  to  borrow  SDs  from  other  studies
in  the  review  (Furukawa  2006).  We  also  planned  to  examine  the
validity of this imputation in the sensitivity analyses; however there
were no trials where SDs were not reported.

Assessment of heterogeneity

We  assessed  heterogeneity  between  trials  qualitatively,  by  visual
inspection  of  the  forest  plots,  and  quantitatively  using  the  Chi2
test  and  the  I2  statistic.  Due  to  the  known  low  sensitivity  of
the  Chi2  test,  we  took  a  P  value  of  less  than  0.10  to  be
suggestive of heterogeneity. We interpreted the I2 value according
to the recommendations in the Cochrane Handbook for Systematic
Reviews of Interventions (0% to 40% might not be important; 30%
to 60% may represent moderate heterogeneity; 50% to 90% may
represent substantial heterogeneity; 75% to 100% may represent
considerable heterogeneity) (Higgins 2011), while keeping in mind
that the importance of the observed value of I2 depends on (i) the
magnitude and direction of effects; and (ii) the strength of evidence
for heterogeneity (e.g. a confidence interval for I2) (Higgins 2003). If
we noted significant heterogeneity, we investigated its sources.

Assessment of reporting biases

We  entered  data  from  the  included  studies  into  a  funnel  plot
(trial effect against trial variance) to investigate small-study effects.
We  used  the  tests  for  funnel  plot  asymmetry  only  when  there
were  at  least  10  studies  included  in  the  meta-analysis,  and  we
interpreted  the  results  cautiously,  with  visual  inspection  of  the
funnel plots (Higgins 2011). When we identified evidence of small-
study  effects,  we  investigated  possible  reasons  for  funnel  plot
asymmetry, including publication bias.

Data synthesis

We  used  a  random-effects  model  to  calculate  the  intervention
effect, as it assumes heterogeneity of intervention effects. Although
the random-effects model gives a more conservative estimate than
the fixed-effect model, it gives weight to small studies, which can
increase or decrease the effect size. Taking this into consideration,
we also used a fixed-effect model for the primary outcome to see if
there was a large difference between the two models.

Subgroup analysis and investigation of heterogeneity

We performed the following subgroup analyses at the study level,
where possible, for the following a priori reasons.

• For  each  type  of  psychological  therapy  separately  (CBT,
cognitive therapy, behaviour therapy, psychodynamic therapy,
and  others),  because  they  may  not  have  the  same  degree  of
efficacy.

• For  studies  including  agoraphobic  participants  and  those
excluding them, because the same treatment may have varying
efficacy with regard to panic and agoraphobia.

• For studies including participants with and without depressive
disorder,  because  it  is  likely  that  antidepressants  may  confer
more  benefit  on  those  patients  with  panic  disorder  comorbid
with depression.

Cochrane Database of Systematic Reviews

We added the following post-hoc subgroup analyses to investigate
heterogeneity:  studies  excluding  group  psychological  therapies;
outcomes  using  the  same  scales;  and  studies  without  extreme
results.

Sensitivity analysis

We conducted the following sensitivity analyses.

• Limiting  to  participants  without  any  comorbid  physical  or

mental disorders.

• Limiting  to  trials  where  quality  control  of  the  psychological
therapies  administered  was  adequate,  because  we  consider
therapists'  adherence  to  the  model  of  psychological  therapy
to  be  important  in  establishing  its  true  effects.  We  assessed
the  adequacy  of  the  psychological  therapies  administered  as
follows. We carried out a sensitivity analysis by limiting to trials
with a rating of 'A' or 'B'.
◦ A:  When  the  conduct  of  the  psychological  therapies  was
examined  by  a  third  author  through  audiotapes,  etc.,  and
when the authors gave sufficiently detailed description of the
therapy procedure in the text or provided information about
the treatment manual.

◦ B: When the trial fulfilled either of the two conditions stated

above.

◦ C: When none of these applied.

• Limiting  to  trials  that  met  both  of  the  following  criteria:
allocation  concealment  is  rated  as  at  low  risk  of  bias,  and
outcome assessors are rated as at low risk of bias.

• Calculating  ORs  and  their  95%  CIs  instead  of  RRs  and  their
95% CIs for the primary outcomes (dichotomous data) in order
to  investigate  whether  our  choice  of  RRs  is  critical  to  the
conclusions of the review.

• Limiting to studies including participants with agoraphobia.
• Excluding  studies  in  which  some,  but  possibly  not  all,  of  the

participants had panic disorder.

We added the following post-hoc sensitivity analyses: calculating
primary outcomes using worst-case and best-case scenarios; and
limiting to studies without imputed data.

'Summary of findings' tables

for  dichotomous  outcomes  and  SMDs 

'Summary  of  findings'  tables  included  a  list  of  all  important
outcomes,  RRs 
for
continuous  outcomes,  numbers  of  participants  and  studies
addressing these outcomes, and a rating of the overall quality of
the evidence, using the GRADE approach. The included population
were people with panic disorder with or without agoraphobia.

R E S U L T S

Description of studies

Results of the search

Our  search  identified  3320  references.  We  excluded  3224  studies
after  assessment  of  the  titles  and  abstracts.  We  retrieved  96  full-
text  papers  for  full  inspection.  Of  these,  we  excluded  79  studies.
We finally included 17 reports, but information for one report was
insufficient, and we were unable to obtain further information from
the study authors. As a result, we included 16 reports with a total
of 966 participants in our meta-analysis. Cohen's kappa among the

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

three review authors for the selection from 96 full-text papers was
0.81, which means an excellent agreement. We contacted authors
of the eight studies (Ataoglu 2000; Azhar 2000; Bressi 2010; Dannon
2004;  Prasko  2004;  Taylor  1982;  Tyrer  1988;  van  Apeldoorn  2008)

for  additional  information,  and  three  authors  responded  (Bressi
2010; Spinhoven 1996; Tyrer 1988). See Figure 1 for a PRISMA flow
diagram depicting the study selection process (Moher 2009).

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.

Cochrane Database of Systematic Reviews

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   (Continued)

Cochrane Database of Systematic Reviews

Included studies

Seventeen studies were eligible for this review, but one study did
not  report  extractable  data.  We  finally  included  16  studies  in  the
analyses, with characteristics as follows (see also Characteristics of
included studies).

Design

All  of  the  included  studies  were  parallel-group,  individually
randomised controlled trials. Two studies were two-armed (Ataoglu
2000; Bressi 2010), and the other studies were multi-armed.

Sample sizes

The mean sample size per arm was 28 (range 6 to 83). One study
recruited fewer than 10 participants overall (Prasko 2004).

Setting

All  trials  were  conducted  in  the  outpatient  setting.  Eight  studies
were carried out in European countries, five in the USA, two in the
Middle East, and one in Southeast Asia.

psychological  therapy  with  tricyclic  antidepressant  (imipramine)
(Shear 2000).

Outcomes

Eleven studies reported short-term remission, of which six studies
used panic-free as the definition of remission. Four studies reported
short-term response, of which two studies used an improvement
in  Clinical  Global  Impression  (CGI),  one  study  used  a  reduction
in  Panic  Disorder  Severity  Scale  (PDSS),  and  one  study  used
a  clinically  relevant  improvement.  All  of  the  included  studies
reported the number of dropouts. Of our secondary outcomes only
information  on  short-term  improvement  was  available.  Fourteen
studies reported continuous outcomes at post-treatment; however,
two of these studies lacked the number of participants assessed at
post-treatment. Among the 14 studies with continuous outcomes,
four studies used CGI, three studies used PDSS, two studies used the
Agoraphobic Cognitions Questionnaire, and two studies used the
State-Trait Anxiety Inventory. The other studies used the Hamilton
Anxiety  Scale,  Hopkins  Symptom  Checklist,  the  Brief  Scale  for
Anxiety, and global clinical severity.

Participants

Excluded studies

The proportion of women ranged from 19% to 82%. One study had
a proportion of less than 30% women (Clark 1994), and two studies
had  proportions  of  more  than  30%  women  (Black  1993;  Klosko
1988;  Sharp  1996).  Two  studies  did  not  report  the  percentage  of
women with panic disorder (Azhar 2000; Bressi 2010; Tyrer 1988).

The mean ages of the participants were in the 30s in the majority
of studies (12 out of 15 studies). The mean age was in the 40s in
one  study  (Dannon  2004),  and  in  the  60s  in  one  study  (Hendriks
2010).  One  study  reported  the  mean  age  of  all  the  participants,
including participants with panic disorder and other disorders, but
not exclusively for participants with panic disorder (Tyrer 1988).

Interventions

We  found  seven  studies  comparing  CBT  with  SSRI/SNRI  (three
studies versus fluvoxamine (Azhar 2000; Black 1993; Sharp 1996),
two  studies  versus  paroxetine  (Dannon  2004;  Hendriks  2010),
two  studies  versus  non-specific  SSRI/SNRI  where  clinician  could
choose  any  SSRI/SNRI  (Prasko  2004;  van  Apeldoorn  2008));  one
study  comparing  CBT  with  tricyclic  antidepressant  (imipramine)
(Barlow  2000);  two  studies  comparing  CBT  with  benzodiazepine
(alprazolam)  (Ataoglu  2000;  Klosko  1988);  one  study  comparing
psychodynamic psychological therapy with non-specific SSRI/SNRI
(Bressi 2010); and one study comparing physiological therapy with
benzodiazepine  (diazepam)  (Taylor  1982).  Four  studies  included
multiple  comparisons:  one  study  comparing  CBT  with  SSRI
(paroxetine)  or  tricyclic  antidepressant  (clomipramine)  (Bakker
1999);  one  study  comparing  CBT  with  tricyclic  antidepressant
(dosulepin) or benzodiazepine (diazepam) (Tyrer 1988); one study
comparing CBT or behaviour therapy with tricyclic antidepressant
(imipramine) (Clark 1994); one study comparing CBT or supportive

Of  the  96  references  retrieved  for  more  detailed  evaluation,
79  references  did  not  meet  our  inclusion  criteria  and  were
excluded  or  are  awaiting  classification.  Twenty-three  studies
dealt  with  combination  therapy,  15  studies  included  participants
who  did  not  meet  our  inclusion  criteria,  14  studies  had  no
pharmacological  intervention  arm,  10  studies  were  duplicate
report,  seven  studies  were  not  a  randomised  controlled  trial,  six
studies  had  a  heterogeneous  treatment  arm,  and  two  studies
had  no  psychological  therapy  arm.  Among  the  studies  with
inappropriate  participants,  three  studies  included  participants
with  panic  disorder;  however,  stratified  randomisation  was  not
performed  (Borkovec  1988;  Huppert  2004;  Schuurmans  2006),
and  participants  of  one  study  had  agoraphobia  without  panic
attacks (Echeburua 1993). Among the studies with a heterogeneous
treatment  arm,  doctors  chose  treatment  in  a  control  arm  or  a
pharmacological  treatment  arm  in  two  studies  (Echeburua  2006;
Lang 2006), and one study permitted regular benzodiazepine use
in the psychological therapy arm, and some of the participants in
this  arm  used  benzodiazepine,  which  is  regarded  as  a  mixture  of
combination therapy and psychological therapy (Spinhoven 1996).
(See also Characteristics of excluded studies.)

Studies awaiting classification

One study lacked information required for inclusion (Prasko 2004b),
and the full text of one study could not be retrieved (Takriti 1989).

Ongoing studies

We did not find any ongoing studies.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of bias in included studies

For  details  of  the  'Risk  of  bias'  judgements  for  each  study,  see
Characteristics  of  included  studies.  Graphical  representations  of

the overall risk of bias in included studies are presented in Figure
2 and Figure 3.

Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Allocation

Only three studies reported sufficient details regarding allocation
concealment  (Bressi  2010;  Tyrer  1988;  van  Apeldoorn  2008).  The
agreement between the two independent raters in the assessment
of risk of allocation bias was 100%.

Blinding

Performance bias

Participants and personnel were aware of the intervention, as all
studies included psychological therapies. We judged that all of the
included studies were at high risk of performance bias.

Detection bias

Asessors  in  seven  studies  were  not  blinded  (Bakker  1999;  Black
1993;  Dannon  2004;  Hendriks  2010;  Sharp  1996;  Tyrer  1988;  van
Apeldoorn  2008);  those  in  three  studies  were  blinded  (Barlow
2000; Klosko 1988; Shear 2000); and seven studies did not provide
information regarding the blinding of the assessors (Ataoglu 2000;
Azhar  2000;  Bressi  2010;  Clark  1994;  Muncy  1991;  Prasko  2004;
Taylor  1982).  The  agreement  between  two  independent  raters
in  the  assessment  of  risk  of  bias  due  to  lack  of  blinding  was
66%. The inter-rater reliability (quadratic weighted kappa) of these
judgements was 0.53.

Incomplete outcome data

Twelve  studies  had  no  or  few  dropouts  or  included  all  the
participants  in  the  analysis  (Barlow  2000;  Black  1993;  Bressi
2010;  Clark  1994;  Dannon  2004;  Hendriks  2010;  Klosko  1988;
Prasko  2004;  Shear  2000;  Taylor  1982;  Tyrer  1988;  van  Apeldoorn
2008).  Four  studies  had  a  dropout  rate  of  more  than  20%  of  the
randomised  participants  (Azhar  2000;  Bakker  1999;  Muncy  1991;
Sharp 1996). One study did not report the number of participants
assessed post-treatment (Ataoglu 2000). The agreement between
two  independent  raters  in  the  assessment  of  allocation  bias  was
61%. The inter-rater reliability (quadratic weighted kappa) of these
judgements was 0.48.

Selective reporting

One study did not report some outcomes that had been indicated
in  the  trial  registration  (van  Apeldoorn  2008).  Other  studies  did
not  include  the  study  protocol.  The  agreement  between  two
independent raters in the assessment of risk of bias due to selective
reporting was 87%. The inter-rater reliability (quadratic weighted
kappa) of these judgements was -0.063.

Other potential sources of bias

Researcher allegiance

We rated the risk of bias due to researcher allegiance as high risk
if  the  authors  had  allegiance  to  one  of  the  treatment  arms,  such
as authors who had created a treatment manual for psychological
therapy  or  authors  with  connections  to  the  manufacturer  of
the  medication  that  was  used.  We  rated  47%  of  the  studies  as
having  an  unclear  risk  of  bias,  35%  as  having  a  low  risk  of
bias,  and  18%  as  having  a  high  risk  of  bias.  Researchers  in  two
studies  had  an  allegiance  to  the  psychological  therapy  because
of  involvement  in  the  creation  of  a  treatment  manual  (Barlow
2000;  Clark  1994),  and  another  researcher  had  an  allegiance  to
the  pharmacological  intervention  because  of  employment  with
the manufacturer of the medication (Sharp 1996). The agreement

Cochrane Database of Systematic Reviews

between two independent raters in the assessment of risk of bias
due  to  researcher  allegiance  was  47%.  The  inter-rater  reliability
(quadratic weighted kappa) of these judgements was 0.36.

Therapist allegiance

We  rated  the  risk  of  bias  due  to  therapist  allegiance  as  high  risk
if  therapists  had  allegiance  to  one  of  the  treatments,  such  as  a
psychological  therapist  who  was  a  specialist  in  the  treatment  or
a psychopharmacologist who conducted the medical intervention.
We rated 65% of the studies as having an unclear risk of bias, 18% as
having a low risk of bias, and 18% as having a high risk of bias. The
therapists in three studies had an allegiance to the psychological
therapy  (Bakker  1999;  Black  1993;  Bressi  2010).  The  agreement
between the two independent raters in the assessment of risk of
bias due to therapist allegiance was 70%. The inter-rater reliability
(quadratic weighted kappa) of these judgements was 0.41.

Sponsorship bias

Eight  studies  were  sponsored  by  the  manufacturer  of  the
medication  involved  (Bakker  1999;  Barlow  2000;  Black  1993;
Hendriks 2010; Klosko 1988; Sharp 1996; Taylor 1982; Tyrer 1988).
One study reported no conflict of interest (van Apeldoorn 2008). The
other studies did not mention conflicts of interest. The agreement
between two independent raters in the assessment of risk of bias
due to sponsorship was 65%. The inter-rater reliability (quadratic
weighted kappa) of these judgements was 0.41.

Effects of interventions

See:  Summary  of  findings  for  the  main  comparison  All
psychological  therapies  compared  to  SSRI  for  panic  disorder
with  or  without  agoraphobia  in  adults;  Summary  of  findings  2
All psychological therapies compared to tricyclic antidepressants
for  panic  disorder  with  or  without  agoraphobia 
in  adults;
Summary  of  findings  3  All  psychological  therapies  compared
to  other  antidepressants  for  panic  disorder  with  or  without
agoraphobia  in  adults;  Summary  of  findings  4  All  psychological
therapies  compared  to  benzodiazepines  for  panic  disorder  with
or  without  agoraphobia  in  adults;  Summary  of  findings  5  All
psychological  therapies  compared  to  antidepressants  alone  or
antidepressants  and  benzodiazepines  for  panic  disorder  with  or
without agoraphobia in adults

The  agreement  between  two  independent  raters  in  the  primary
efficacy outcomes was 71% for short-term remission and 82% for
short-term response, and 71% for the treatment acceptability.

In  the  results  shown  below,  the  psychological  therapies  were
favoured with a RR over 1.0 for short-term remission and response
and a negative SMD for short-term improvement. Pharmacological
interventions were favoured with a RR over 1.0 for dropouts for any
reason.

Comparison 1: All psychological therapies versus SSRI

See: Summary of findings for the main comparison

Primary outcomes

1.1 Short-term remission

There  was  no  evidence  of  a  difference  between  psychological
therapies  and  SSRI  in  terms  of  short-term  remission  (RR  0.85,
95% CI 0.62 to 1.17; 6 studies; 334 participants) (very low-quality

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

evidence) (Analysis 1.1). There was substantial heterogeneity in the
study  results  (I2  =  69%,  Tau2  =  0.09)  and  a  lack  of  precision.  The
95% confidence interval around the pooled estimate of the effect
included both no effect and an appreciable benefit or appreciable
harm.

1.2 Short-term response

There  was  no  evidence  of  a  difference  between  psychological
therapies  and  SSRI  in  terms  of  short-term  response  (RR  0.97,
95% CI 0.51 to 1.86; 5 studies; 277 participants) (very low-quality
evidence) (Analysis 1.2). There was substantial heterogeneity in the
study  results  (I2  =  78%,  Tau2  =  0.42)  and  a  lack  of  precision.  The
95% confidence interval around the pooled estimate of the effect
included both no effect and an appreciable benefit or appreciable
harm.

1.3 Dropouts for any reason

There  was  no  evidence  of  a  difference  between  psychological
therapies  and  SSRI  in  terms  of  dropouts  for  any  reason  (RR  1.33,
95%  CI  0.80  to  2.22;  6  studies;  334  participants)  (low-quality
evidence) (Analysis 1.3). The heterogeneity was negligible (I2 = 15%,
Tau2  =  0.06).  There  was  a  lack  of  precision.  The  95%  confidence
interval around the pooled estimate of the effect included both no
effect and an appreciable benefit or appreciable harm.

Secondary outcomes

Only short-term improvement was available among the secondary
outcomes.

1.4 Short-term improvement

There  was  no  evidence  of  a  difference  between  psychological
therapies and SSRI in terms of short-term improvement (SMD -0.20,
95% CI -1.09 to 0.69; 5 studies; 242 participants) (moderate-quality
evidence) (Analysis 1.4). There was considerable heterogeneity in
the study results (I2 = 91%, Tau2 = 0.92) and a lack of precision. The
95% confidence interval around the pooled estimate of the effect
included both no effect and an appreciable benefit or appreciable
harm.

Comparison 2: All psychological therapies versus SNRIs

There were no data to contribute to this comparison.

Comparison 3: All psychological therapies versus tricyclic
antidepressants

See: Summary of findings 2

Primary outcomes

3.1 Short-term remission

There  was  no  evidence  of  a  difference  between  psychological
therapies  and  tricyclic  antidepressants  in  terms  of  short-term
remission (RR 0.82, 95% CI 0.62 to 1.09; 3 studies; 229 participants)
(low-quality  evidence)  (Analysis  2.1).  The  heterogeneity  was
negligible (I2 = 0%, Tau2 = 0.00). There was a lack of precision. The
95% confidence interval around the pooled estimate of the effect
included both no effect and an appreciable benefit or appreciable
harm.

Cochrane Database of Systematic Reviews

3.2 Short-term response

There  was  no  evidence  of  a  difference  between  psychological
therapies  and  tricyclic  antidepressants  in  terms  of  short-term
response (RR 0.75, 95% CI 0.51 to 1.10; 4 studies; 270 participants)
(low-quality  evidence)  (Analysis  2.2).  The  heterogeneity  was
negligible (I2 = 0%, Tau2 = 0.00). There was a lack of precision. The
95% confidence interval around the pooled estimate of the effect
included both no effect and an appreciable benefit or appreciable
harm.

3.3 Dropouts for any reason

There  was  no  evidence  of  a  difference  between  psychological
therapies and tricyclic antidepressants in terms of dropouts for any
reason  (RR  0.83,  95%  CI  0.53  to  1.30;  5  studies;  430  participants)
(low-quality  evidence)  (Analysis  2.3).  The  heterogeneity  was
negligible (I2 = 25%, Tau2 = 0.07). There was a lack of precision. The
95% confidence interval around the pooled estimate of the effect
included both no effect and an appreciable benefit or appreciable
harm.

Secondary outcomes

Only short-term improvement was available among the secondary
outcomes.

3.4 Short-term improvement

There  was  no  evidence  of  a  difference  between  psychological
therapies  and  tricyclic  antidepressants  in  terms  of  short-term
improvement  (SMD  0.20,  95%  CI  -0.03  to  0.43;  5  studies;  414
participants)  (moderate-quality  evidence)  (Analysis  2.4).  The
heterogeneity was negligible (I2 = 12%, Tau2 = 0.01).

Comparison 4: All psychological therapies versus other
antidepressants

See: Summary of findings 3

Primary outcomes

4.1 Short-term remission

There  was  no  evidence  of  a  difference  between  psychological
therapies  and  other  antidepressants  in  terms  of  short-term
remission (RR 0.90, 95% CI 0.48 to 1.67; 3 studies; 135 participants)
(very  low-quality  evidence)  (Analysis  3.1).  There  was  substantial
heterogeneity (I2 = 61%, Tau2 = 0.19) and a lack of precision. The
95% confidence interval around the pooled estimate of the effect
included both no effect and an appreciable benefit or appreciable
harm.

4.2 Short-term response

There  was  no  evidence  of  a  difference  between  psychological
therapies  and  other  antidepressants  in  terms  of  short-term
response (RR 0.96, 95% CI 0.67 to 1.37; 3 studies; 128 participants)
(low-quality  evidence)  (Analysis  3.2).  The  heterogeneity  was
negligible (I2 = 33%, Tau2 = 0.04). There was a lack of precision. The
95% confidence interval around the pooled estimate of the effect
included both no effect and an appreciable benefit or appreciable
harm.

4.3 Dropouts for any reason

There  was  no  evidence  of  a  difference  between  psychological
therapies and other antidepressants in terms of dropouts for any

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

reason  (RR  1.55,  95%  CI  0.91  to  2.65;  3  studies;  180  participants)
(low-quality  evidence)  (Analysis  3.3).  The  heterogeneity  was
negligible (I2 = 1%, Tau2 = 0.00). There was a lack of precision.

Secondary outcomes

Only short-term improvement was available among the secondary
outcomes.

Secondary outcomes

5.4 Short-term improvement

Only short-term improvement was available among the secondary
outcomes.

4.4 Short-term improvement

There  was  no  evidence  of  a  difference  between  psychological
therapies  and  other  antidepressants  in  terms  of  short-term
improvement  (SMD  -0.43,  95%  CI  -1.36  to  0.51;  2  studies;
27  participants)  (moderate-quality  evidence)  (Analysis  3.4).  The
heterogeneity was negligible (I2 = 29%, Tau2 = 0.14). There was a
lack of precision. The 95% confidence interval around the pooled
estimate of the effect included both no effect and an appreciable
benefit or appreciable harm.

Comparison 5: All psychological therapies versus
benzodiazepines

See: Summary of findings 4

Primary outcomes

5.1 Short-term remission

There  was  no  evidence  of  a  difference  between  psychological
therapies  and  benzodiazepines  in  terms  of  short-term  remission
(RR 1.08, 95% CI 0.70 to 1.65; 3 studies; 95 participants) (very low-
quality evidence) (Analysis 4.1). The heterogeneity was negligible
(I2  =  0%,  Tau2  =  0.00).  There  was  a  lack  of  precision.  The  95%
confidence  interval  around  the  pooled  estimate  of  the  effect
included both no effect and an appreciable benefit or appreciable
harm.

5.2 Short-term response

Two studies including 69 participants contributed data. There was
no evidence of a difference between psychological therapies and
benzodiazepines in terms of short-term response (RR 1.58, 95% CI
0.70 to 3.58; 2 studies; 69 participants) (very low-quality evidence)
(Analysis  4.2).  The  heterogeneity  was  negligible  (I2  =  0%,  Tau2  =
0.00). There was a lack of precision. The 95% confidence interval
around the pooled estimate of the effect included both no effect
and an appreciable benefit or appreciable harm.

5.3 Dropouts for any reason

Three  studies  including  116  participants  contributed  data.  There
was no evidence of a difference between psychological therapies
and benzodiazepines in terms of dropouts for any reason (RR 1.12,
95% CI 0.54 to 2.36; 3 studies; 116 participants) (very low-quality
evidence) (Analysis 4.3). The heterogeneity was negligible (I2 = 0%,
Tau2  =  0.00).  There  was  a  lack  of  precision.  The  95%  confidence
interval around the pooled estimate of the effect included both no
effect and an appreciable benefit or appreciable harm.

in 

terms  of 

There  was  no  evidence  of  a  difference  between  psychological
therapies  and  benzodiazepines 
short-term
improvement  (SMD  -0.23,  95%  CI  -0.69  to  0.23;  3  studies;
89  participants)  (very  low-quality  evidence)  (Analysis  4.4).  The
heterogeneity  was  negligible  (I2  =  0%,  Tau2  =  0.00).  There  was  a
lack of precision. The 95% confidence interval around the pooled
estimate of the effect included both no effect and an appreciable
benefit or appreciable harm.

Comparison 6: All psychological therapies versus either
antidepressant alone or antidepressants and benzodiazepines

See: Summary of findings 5

Primary outcomes

6.1 Short-term remission

There  was  no  evidence  of  a  difference  between  psychological
therapies and either antidepressant alone or antidepressants and
benzodiazepines  in  terms  of  short-term  remission  (RR  0.86,  95%
CI 0.71 to 1.05; 11 studies; 663 participants) (low-quality evidence)
(Analysis 5.1). There was moderate heterogeneity (I2 = 46%, Tau2 =
0.05) and a lack of precision. The 95% confidence interval around
the  pooled  estimate  of  the  effect  included  both  no  effect  and  an
appreciable benefit or appreciable harm. The Egger's test for funnel
plot asymmetry was non-significant (P = 0.44).

6.2 Short-term response

There  was  no  evidence  of  a  difference  between  psychological
therapies and either antidepressant alone or antidepressants and
benzodiazepines in terms of short-term response (RR 0.95, 95% CI
0.76  to  1.18;  12  studies;  800  participants)  (low-quality  evidence)
(Analysis 5.2). The heterogeneity was negligible (I2 = 37%, Tau2 =
0.05). There was a lack of precision. The 95% confidence interval
around the pooled estimate of the effect included both no effect
and an appreciable benefit or appreciable harm. The Egger's test
for funnel plot asymmetry was non-significant (P = 0.78).

6.3 Dropouts for any reason

There  was  no  evidence  of  a  difference  between  psychological
therapies and either antidepressant alone or antidepressants and
benzodiazepines  in  terms  of  dropouts  for  any  reason  (RR  1.08,
95% CI 0.77 to 1.51; 13 studies; 909 participants) (very low-quality
evidence) (Analysis 5.3). The heterogeneity was negligible (I2 = 36%,
Tau2  =  0.12).  There  was  a  lack  of  precision.  The  95%  confidence
interval  around  the  pooled  estimate  of  the  effect  included  both
no  effect  and  an  appreciable  benefit  or  appreciable  harm.  The
Egger's test for funnel plot asymmetry was significant (P = 0.047)
(Figure 4). However, contour-enhanced funnel plot did not suggest
publication bias (Figure 5).

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 4.   Funnel plot of comparison: 5 All psychological therapies versus either antidepressants alone or
antidepressants and benzodiazepines, outcome: 5.3 Dropouts for any reason.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 5.   Contour-enhanced funnel plot: 5 All psychological therapies versus either antidepressants alone or
antidepressants and benzodiazepines, outcome: 5.3 Dropouts for any reason.

Secondary outcomes

Subgroup analyses

Only short-term improvement was available among the secondary
outcomes.

6.4 Short-term improvement

There  was  no  evidence  of  a  difference  between  psychological
therapies and either antidepressant alone or antidepressants and
benzodiazepines  in  terms  of  short-term  improvement  (SMD  0.01,
95%  CI  -0.34  to  0.35;  11  studies;  638  participants)  (low-quality
evidence) (Analysis 5.4). There was substantial heterogeneity (I2 =
73%, Tau2 = 0.30). The Egger's test for funnel plot asymmetry was
non-significant (P = 0.36).

1. For each type of psychological therapy separately

1.1 Psychological therapies versus SSRI

The studies included only CBT.

1.2. Psychological therapies versus tricyclic antidepressants

The studies included CBT, behaviour therapy (BT), and supportive
psychological therapy. However, there was only one study each for
BT  or  supportive  psychological  therapy  (Clark  1994;  Shear  2000).
There  was  no  significant  difference  in  the  efficacy  of  CBT  and
tricyclic antidepressants as measured using short-term remission
(RR 0.88, 95% CI 0.63 to 1.22; 3 studies; 151 participants) (Analysis
2.1), short-term response (RR 0.79, 95% CI 0.51 to 1.25; 4 studies;
192  participants),  or  short-term  improvement  (SMD  0.13,  95%
CI  -0.14  to  0.40;  5  studies;  342  participants)  or  in  treatment
acceptability as measured using dropouts for any reason (RR 0.93,
95% CI 0.53 to 1.64; 5 studies; 352 participants) (Analysis 2.2).

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

1.3. Psychological therapies versus other antidepressants

The studies included CBT and psychodynamic therapies. However,
only one study examined psychodynamic therapies (Bressi 2010).
There was no significant difference in the efficacy of CBT and other
antidepressants as measured using short-term remission (RR 0.92,
95%  CI  0.38  to  2.24;  2  studies;  120  participants)  (Analysis  3.1.1),
or  short-term  response  (RR  1.03,  95%  CI  0.63  to  1.68;  2  studies;
113 participants) (Analysis 3.2.1), or in treatment acceptability as
measured using dropouts for any reason (RR 1.84, 95% CI 0.99 to
3.43;  2  studies;  120  participants)  (Analysis  3.3.1).  Only  one  study
including CBT was available for short-term improvement.

1.4. Psychological therapies versus benzodiazepines

The  studies  included  CBT  and  physiological  therapies.  However,
only  one  study  examined  physiological  therapies  (Taylor  1982).
There  was  no  significant  difference  in  the  efficacy  of  CBT  and
benzodiazepines as measured using short-term remission (RR 1.08,
95%  CI  0.70  to  1.65;  2  studies;  75  participants)  (Analysis  4.1.1),
short-term  response  (RR  1.58,  95%  CI  0.70  to  3.58;  2  studies;  69
participants)  (Analysis  4.2.1),  or  short-term  improvement  (SMD
-0.16,  95%  CI  -0.82  to  0.50;  2  studies;  69  participants)  (Analysis
4.4.1). All psychological therapies used in the studies included in
the analysis of dropouts for any reason were CBT.

1.5. Psychological therapies versus either antidepressants alone or
antidepressants and benzodiazepines

The  studies  included  CBT,  BT,  psychodynamic  therapies,  and
supportive  psychological  therapy.  However,  there  was  only  one
study  each  for  BT,  psychodynamic  therapies,  or  supportive
psychological  therapy  (Bressi  2010;  Clark  1994;  Shear  2000).
There  was  no  significant  difference  between  CBT  and  either
antidepressants alone or antidepressants and benzodiazepines in
terms of efficacy as measured using short-term remission (RR 0.88,
95%  CI  0.71  to  1.10;  10  studies;  570  participants)  (Analysis  5.1.1),
short-term response (RR 0.99, 95% CI 0.78 to 1.26; 11 studies; 707
participants) (Analysis 5.2.1), short-term improvement (SMD -0.09,
95% CI -0.50 to 0.32; 10 studies; 551 participants) (Analysis 5.4.1)
or in treatment acceptability as measured using dropouts for any
reason (RR 1.16, 95% CI 0.79 to 1.70; 12 studies; 771 participants)
(Analysis 5.3.1).

2. For participants with and without agoraphobia

We  found  no  study  where  all  the  participants  were  without
agoraphobia, while almost all of the participants had panic disorder
with agoraphobia in one study (100% in SSRI arm, 97% in tricyclic
antidepressant  arm,  and  91%  in  CBT  arm)  (Bakker  1999).  It  was
therefore not possible to execute this subgroup analysis.

3. For participants with and without depressive disorder

included  only  participants  without  depressive
Two  studies 
disorder  (Dannon  2004;  Prasko  2004),  and  we  were  able  to
conduct  a  subgroup  analysis  for  this  subtype,  i.e.  participants
without  depressive  disorder  only.  The  comparison  between
all  psychological  therapies  and  either  antidepressant  alone  or
antidepressants and benzodiazepines included these studies with
69  participants.  There  was  high-quality  evidence  that  either
antidepressant  alone  or  antidepressants  and  benzodiazepines
were  marginally  more  effective  than  psychological  therapies  as
measured  using  the  short-term  response  (RR  1.19,  95%  CI  1.00
to  1.42;  2  studies;  69  participants)  (Analysis  6.1).  However,  there

Cochrane Database of Systematic Reviews

was  no  difference  in  treatment  acceptability  as  measured  using
dropouts for any reason (RR 0.23, 95% CI 0.03 to 1.78; 2 studies; 69
participants) (Analysis 6.2).

All of the other studies included both participants with and without
depressive disorder.

4. For length of intervention (investigation of heterogeneity)

4.1. All psychological therapies versus other antidepressants (short-
term remission)

Two studies were relatively consistent (Bressi 2010; van Apeldoorn
2008), while the results of Prasko 2004 were opposite. The studies
had  different  study  periods  (36  weeks  in  van  Apeldoorn  2008,  44
weeks in Bressi 2010, and 12 weeks in Prasko 2004) and risk of bias
(low risk of selection bias in Bressi 2010 and van Apeldoorn 2008
and  unclear  risk  of  selection  bias  in  Prasko  2004).  An  analysis  of
the two studies with longer duration of intervention indicated that
other  antidepressants  were  more  effective  than  all  psychological
therapies (RR 0.65, 95% CI 0.44 to 0.96; 2 studies; 123 participants).
There  was  no  evidence  of  heterogeneity  (I2  =  0%,  Tau2  =  0.00)
(Analysis 8.1).

5. For studies excluding group psychological therapies
(investigation of heterogeneity, post-hoc analysis)

5.1. All psychological therapies versus SSRI (short-term remission)

Four  studies  indicated  that  SSRI  tended  to  be  more  effective
than  psychological  therapies  (Bakker  1999;  Black  1993;  Hendriks
2010;  Sharp  1996),  whereas  the  results  of  one  study  tended
to  show  the  opposite  (Dannon  2004).  The  former  studies  used
individual  psychological  therapy,  whereas  the  latter  study  used
group  psychological  therapy.  The  analysis  with  the  four  former
studies with individual psychological therapy indicated that SSRI
was more effective than psychological therapies (RR 0.79, 95% CI
0.62  to  0.99;  5  studies;  275  participants).  The  results  of  the  three
studies were homogeneous (I2 = 0%, Tau2 = 0.01) (Analysis 7.1).

5.2. All psychological therapies versus either antidepressant alone or
antidepressants and benzodiazepines (short-term remission)

The results of one study seemed to be inconsistent with those of the
other studies (Dannon 2004). The study used group psychological
therapy,  while  the  others  did  not,  which  might  have  been  the
source of the heterogeneity. An analysis excluding this one study
indicated  that  either  antidepressant  alone  or  antidepressants
and  benzodiazepines  were  more  effective  than  all  psychological
therapies (RR 0.80, 95% CI 0.69 to 0.94; 10 studies; 606 participants).
The results of the nine studies were homogeneous (I2 = 0%, Tau2 =
0.00) (Analysis 9.1).

6. For outcome using same scales (investigation of
heterogeneity, post-hoc analysis)

6.1. All psychological therapies versus SSRI (short-term response)

The  results  of  two  studies,  Bakker  1999  and  Black  1993,  were
inconsistent with those of three studies (Azhar 2000; Hendriks 2010;
Sharp 1996). This discrepancy could be because the response was
defined by the same scale (Clinical Global Impression) in the former
two studies, whereas it was defined by different scales in the latter
three studies (panic frequency in Azhar 2000, Fear Questionnaire in
Sharp 1996, and Agoraphobic Cognitions Questionnaire in Hendriks
2010). An analysis excluding the latter three studies indicated that

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

psychological  therapies  were  more  effective  than  SSRI  (RR  0.47,
95% CI 0.29 to 0.76; 2 studies; 117 participants). The results of the
two studies were consistent (I2 = 0%, Tau2 = 0.00) (Analysis 7.2).

7. For studies without extreme results (investigation of
heterogeneity, post-hoc analysis)

7.1. All psychological therapies versus either antidepressant alone or
antidepressants and benzodiazepines (short-term improvement)

One study had an extreme result (Azhar 2000), which might have
caused  heterogeneity.  The  results  excluding  this  study  indicated
that there was no significant difference between all psychological
therapies  versus  either  antidepressant  alone  or  antidepressants
and benzodiazepines (SMD 0.19, 95% CI -0.03 to 0.40; 10 studies;
604  participants).  The  results  of  the  10  studies  were  relatively
homogeneous (I2 = 29%, Tau2 = 0.04) (Analysis 9.2).

Sensitivity analyses

1. Limited to participants without any comorbid physical or
mental disorders

As  all  of  the  studies  included  some  comorbid  physical  or  mental
disorders, it was not possible to execute this preplanned sensitivity
analysis.

2. Limited to trials where quality control of the psychological
therapies was adequate

Eleven  studies  reported  the  provision  of  a  treatment  manual  or
supervision of the psychological therapies, or both. Among these
studies, eight studies included CBT only (Bakker 1999; Barlow 2000;
Black 1993; Hendriks 2010; Klosko 1988; Tyrer 1988; van Apeldoorn
2008); one included CBT and BT (Clark 1994); one included CBT and
supportive psychological therapy (Shear 2000); and one included
only psychodynamic therapy (Bressi 2010).

2.1 All psychological therapies versus SSRI

Psychological therapies produced a significantly lower short-term
remission  than  SSRI  (RR  0.75,  95%  CI  0.61  to  0.94;  4  studies;  233
participants)  (Analysis  10.1).  However,  there  was  no  significant
difference in efficacy in terms of the short-term response (RR 0.72,
95%  CI  0.46  to  1.12;  4  studies;  233  participants)  (Analysis  10.2),
short-term improvement (SMD 0.33, 95% CI -0.15 to 0.80; 4 studies;
208  participants)  (Analysis  10.4),  or  in  treatment  acceptability  as
measured using dropouts for any reason (RR 1.65, 95% CI 0.98 to
2.78; 4 studies; 233 participants) (Analysis 10.3).

2.2. All psychological therapies versus tricyclic antidepressants

All of the studies included in this comparison dealt with CBT with
quality control for the psychological therapies, therefore the results
were the same as in the main analyses (Analysis 2.1; Analysis 2.2;
Analysis 2.3).

2.3. All psychological therapies versus other antidepressants

Other antidepressants were more effective than all psychological
therapies  in  terms  of  short-term  remission  (RR  0.65,  95%  CI  0.44
to 0.96; 2 studies; 123 participants) (Analysis 11.1). However, there
was  no  significant  difference  in  efficacy  between  the  two  arms
as  measured  using  short-term  response  (RR  0.85,  95%  CI  0.68  to
1.06;  2  studies;  116  participants)  (Analysis  11.2)  or  in  treatment
acceptability as measured using dropouts for any reason (RR 1.55,
95% CI 0.91 to 2.65; 2 studies; 168 participants) (Analysis 11.3). Only

Cochrane Database of Systematic Reviews

one study with data on short-term improvement was available, and
there was no significant difference between the two groups in terms
of short-term improvement (SMD -0.01, 95% CI -1.02 to 1.01; 1 study;
15 participants).

2.4. All psychological therapies versus benzodiazepines

There  was  no  significant  difference  in  efficacy  between  all
psychological  therapies  and  benzodiazepines  as  measured  using
short-term  response  (RR  1.41,  95%  CI  0.61  to  3.27;  2  studies;
76  participants)  (Analysis  12.1)  or  in  treatment  acceptability  as
measured  using  dropouts  for  any  reason  (RR  1.41,  95%  CI  0.61
to 3.27; 2 studies; 76 participants) (Analysis 12.2). Only one study
was included in the analysis of short-term remission. The studies
included in the analysis of short-term improvement were the same
as those included in Analysis 4.4.1.

2.5. All psychological therapies versus either antidepressants alone or
antidepressants and benzodiazepines

Antidepressants alone and antidepressants plus benzodiazepines
were more effective than all of the psychological therapies in terms
of  short-term  remission  (RR  0.76,  95%  CI  0.65  to  0.90;  8  studies;
550 participants) (Analysis 13.1) and short-term improvement (SMD
0.21,  95%  CI  0.02  to  0.41;  9  studies;  592  participants)  (Analysis
13.4).  However,  there  were  no  significant  differences  in  efficacy
between  all  psychological  therapies  and  either  antidepressants
alone or antidepressants and benzodiazepines as measured using
short-term  response  (RR  0.89,  95%  CI  0.77  to  1.03;  10  studies;
724  participants)  (Analysis  13.2)  or  in  treatment  acceptability  as
measured using dropouts for any reason (RR 1.13, 95% CI 0.79 to
1.62; 10 studies; 796 participants) (Analysis 13.3).

3. Limited to trials that met both of the following criteria as
described in the 'Assessment of risk of bias in included studies'
section: allocation concealment rated as low risk of bias, and
detection bias rated as low risk of bias

No study met this criteria.

4. Calculating ORs and their 95% CIs instead of RRs and their
95% CIs for the primary outcomes (dichotomous data), in order
to investigate whether our choice of RRs was critical to the
conclusions of the review

4.1. All psychological therapies versus SSRI

There  were  no  significant  differences 
in  efficacy  between
psychological  therapies  and  SSRI  as  measured  using  short-term
remission (OR 0.64, 95% CI 0.32 to 1.28; 6 studies; 334 participants),
short-term  response  (OR  1.01,  95%  CI  0.30  to  3.37;  5  studies;
277 participants), or in treatment acceptability as measured using
dropouts for any reason (OR 1.38, 95% CI 0.71 to 2.69; 6 studies; 334
participants).

4.2: All psychological therapies versus tricyclic antidepressants

There  were  no  significant  differences 
in  efficacy  between
psychological therapies and tricyclic antidepressants as measured
using short-term remission (OR 0.67, 95% CI 0.38 to 1.17; 3 studies;
229  participants),  short-term  response  (OR  0.66,  95%  CI  0.36  to
1.21; 4 studies; 270 participants), or in treatment acceptability as
measured using dropouts for any reason (OR 0.80, 95% CI 0.40 to
1.57; 5 studies; 430 participants).

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

4.3. All psychological therapies versus other antidepressants

8. Limited to studies without imputed data (post-hoc analysis)

There  were  no  significant  differences 
in  efficacy  between
psychological  therapies  and  other  antidepressants  as  measured
using short-term remission (OR 0.67, 95% CI 0.20 to 2.29; 3 studies;
135  participants),  short-term  response  (OR  0.66,  95%  CI  0.23  to
1.88; 3 studies; 128 participants), or in treatment acceptability as
measured using dropouts for any reason (OR 1.75, 95% CI 0.79 to
3.90; 3 studies; 180 participants).

4.4. All psychological therapies versus benzodiazepines

There  were  no  significant  differences 
in  efficacy  between
psychological  therapies  and  benzodiazepines  as  measured  using
short-term  remission  (OR  1.17,  95%  CI  0.47  to  2.91;  3  studies;  95
participants), short-term response (OR 2.07, 95% CI 0.61 to 7.07; 2
studies; 69 participants), or in treatment acceptability as measured
using  dropouts  for  any  reason  (OR  1.13,  95%  CI  0.42  to  3.07;  3
studies; 116 participants).

4.5: All psychological therapies versus either antidepressant alone or
antidepressants and benzodiazepines

There  were  no  significant  differences 
in  efficacy  between
psychological  therapies  and  either  antidepressant  alone  or
antidepressants  and  benzodiazepines  as  measured  using  short-
term  response  (OR  0.87,  95%  CI  0.55  to  1.40;  12  studies;  800
participants)  or  in  treatment  acceptability  as  measured  using
dropouts  for  any  reason  (OR  1.10,  95%  CI  0.70  to  1.73;  13
studies;  909  participants).  However,  either  antidepressant  alone
or antidepressants plus benzodiazepines was more effective than
psychological therapies in terms of short-term remission (OR 0.60,
95% CI 0.42 to 0.85; 11 studies; 663 participants).

5. Limited to participants with agoraphobia

We examined this analysis in the subgroup analysis.

As none of the data on dropouts for any reason were missing, we
carried  out  this  sensitivity  analysis  for  short-term  remission  and
response.

8.1. All psychological therapies versus SSRI

There  were  no  significant  differences 
in  efficacy  between
psychological  therapies  and  SSRI  as  measured  using  short-term
remission (RR 0.84, 95% CI 0.60 to 1.16; 5 studies; 290 participants)
(Analysis 24.1). As there was only one study without imputed data
for the short-term response, it was not meaningful to execute the
sensitivity analysis for this outcome.

8.2: All psychological therapies versus tricyclic antidepressants

All  of  the  studies  used  the  imputed  data  of  this  comparison,
therefore it was not meaningful to execute the sensitivity analysis
for this comparison.

8.3. All psychological therapies versus other antidepressants

There  were  no  significant  differences 
in  efficacy  between
psychological  therapies  and  other  antidepressants  as  measured
using short-term remission (RR 0.65, 95% CI 0.44 to 0.96; 2 studies;
123  participants)  (Analysis  25.1).  As  there  was  only  one  study
without  imputed  data  for  the  short-term  response,  it  was  not
possible to execute the sensitivity analysis for this outcome.

8.4. All psychological therapies versus benzodiazepines

There  were  no  significant  differences 
in  efficacy  between
psychological  therapies  and  benzodiazepines  as  measured  using
short-term  remission  (RR  1.08,  95%  CI  0.70  to  1.65;  2  studies;  75
participants) (Analysis 26.1). As no study was without imputed data
for the short-term response, it was not meaningful to execute the
sensitivity analysis for this outcome.

6. Excluding studies in which some, but possibly not all, of the
participants had panic disorder

8.5: All psychological therapies versus either antidepressant alone or
antidepressants and benzodiazepines

No such studies were included in the analysis. It was therefore not
meaningful to execute this preplanned sensitivity analysis.

7. Calculating primary outcomes using worst- and best-case
scenarios (post-hoc analysis)

the 

14-23 

showed 

sensitivity 
the  primary  outcomes  using 

analyses 
by
Analyses 
calculating 
the  best-case
(favouring  psychological  therapies)  and  worst-case  (favouring
pharmacological  intervention)  scenarios.  Psychological  therapies
were  more  effective  than  SSRI  in  terms  of  short-term  remission
in the best-case scenario (RR 1.18, 95% CI 1.05 to 1.32; 6 studies;
334 participants), and tricyclic antidepressants were more effective
than  psychological  therapies  in  terms  of  short-term  remission  in
the  worst-case  scenario  (RR  0.59,  95%  CI  0.45  to  0.79;  3  studies;
229 participants). However, there were no considerable differences
between these extreme scenarios and the original results in other
comparisons.  For  example,  there  was  no  significant  difference
between all psychological therapies and SSRI in terms of short-term
response either in the best-case scenario (RR 1.01, 95% CI 0.53 to
1.95; 5 studies; 277 participants) or in the worst-case scenario (RR
0.91, 95% CI 0.48 to 1.69; 5 studies; 277 participants). In other words,
the dropouts did not appear to influence the overall study results
substantively.

There  were  no  significant  differences 
in  efficacy  between
psychological  therapies  and  either  antidepressants  alone  or
antidepressants  and  benzodiazepines  as  measured  using  short-
term  remission  (RR  0.83,  95%  CI  0.67  to  1.01;  9  studies;  652
participants) (Analysis 27.1) and short-term response (RR 0.97, 95%
CI 0.80 to 1.17; 3 studies; 305 participants) (Analysis 27.2).

9. Calculating primary outcomes with fixed-effect model

9.1. All psychological therapies versus SSRI

There  were  no  significant  differences 
in  efficacy  between
psychological  therapies  and  SSRI  as  measured  using  short-term
remission (RR 0.85, 95% CI 0.72 to 1.01; 6 studies; 334 participants),
short-term  response  (RR  0.96,  95%  CI  0.72  to  1.26;  5  studies;
277 participants), or in treatment acceptability as measured using
dropouts for any reason (RR 1.29, 95% CI 0.83 to 2.00; 6 studies; 334
participants).

9.2: All psychological therapies versus tricyclic antidepressants

There  were  no  significant  differences 
in  efficacy  between
psychological therapies and tricyclic antidepressants as measured
using short-term remission (RR 0.81, 95% CI 0.61 to 1.08; 3 studies;
229  participants),  short-term  response  (RR  0.75,  95%  CI  0.51  to
1.10; 4 studies; 270 participants), or in treatment acceptability as

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

measured using dropouts for any reason (RR 0.84, 95% CI 0.60 to
1.17; 5 studies; 430 participants).

9.3. All psychological therapies versus other antidepressants

in  efficacy  between
There  were  no  significant  differences 
psychological  therapies  and  other  antidepressants  as  measured
using short-term remission (RR 0.73, 95% CI 0.52 to 1.03; 3 studies;
135  participants),  short-term  response  (RR  0.89,  95%  CI  0.73  to
1.10; 3 studies; 128 participants), or in treatment acceptability as
measured using dropouts for any reason (RR 1.55, 95% CI 0.91 to
2.62; 3 studies; 180 participants).

9.4. All psychological therapies versus benzodiazepines

in  efficacy  between
There  were  no  significant  differences 
psychological  therapies  and  benzodiazepines  as  measured  using
short-term  remission  (RR  1.08,  95%  CI  0.70  to  1.65;  3  studies;  95
participants), short-term response (RR 1.63, 95% CI 0.70 to 3.77; 2
studies; 69 participants), or in treatment acceptability as measured
using  dropouts  for  any  reason  (RR  1.10,  95%  CI  0.53  to  2.29;  3
studies; 116 participants).

9.5: All psychological therapies versus either antidepressant alone or
antidepressants and benzodiazepines

or 

alone 

antidepressant 

antidepressants 

Either 
and
benzodiazepines was more effective than psychological therapies
in  terms  of  short-term  remission  (RR  0.83,  95%  CI  0.72  to  0.95;
11  studies;  663  participants).  However,  there  were  no  significant
differences in efficacy between psychological therapies and either
antidepressant alone or antidepressants and benzodiazepines as
measured  using  short-term  response  (RR  0.94,  95%  CI  0.81  to
1.10; 12 studies; 800 participants) or in treatment acceptability as
measured using dropouts for any reason (RR 1.07, 95% CI 0.84 to
1.36; 13 studies; 909 participants).

Reporting bias

We  could  not  perform  a  funnel  plot  analysis  for  most  of  the
comparisons. Only the comparisons of all psychological therapies
versus  either  antidepressants  alone  or  antidepressants  plus
benzodiazepines  included  more  than  10  studies.  We  observed  a
statistically significant funnel plot asymmetry for dropouts for any
reason in a comparison of all psychological therapies versus either
antidepressants alone or antidepressants and benzodiazepines. A
contour-enhanced funnel plot did not suggest a publication bias.

D I S C U S S I O N

Summary of main results

We  included  a  total  of  16  RCTs  in  this  review;  however,  the
number  of  studies  included  in  each  comparison  ranged  from  2
(27  participants)  to  13  (909  participants).  The  results  of  the  main
comparisons did not indicate any superiority or inferiority in short-
term  efficacy  and  treatment  acceptability  between  psychological
therapies  as  a  whole  and  SSRI,  tricyclic  antidepressants,  other
antidepressants, benzodiazepines, or either antidepressants alone
or  antidepressants  and  benzodiazepines.  None  of  the  studies
reported long-term outcomes.

The  studies  available  for  subgroup  analyses  comparing  each
psychological  therapy  and  pharmacological  intervention  were
limited.  Only  studies  that  included  CBT  were  available  for  a
meta-analysis,  and  the  results  did  not  indicate  any  superiority

Cochrane Database of Systematic Reviews

or  inferiority  in  efficacy  or  treatment  acceptability.  There  were
also  no  significant  differences  in  the  other  comparisons.  Other
psychological therapies examined in the RCTs included behaviour
therapy,  psychodynamic 
therapy,  supportive  psychological
therapy, and physiological therapy. However, only one study was
available for each comparison.

The  sensitivity  analysis  and  investigation  of  the  sources  of
heterogeneity  indicated  three  possible  influential  factors:  quality
control of psychological therapies, the length of intervention, and
the individual modality of psychological therapies.

Three  of  the  five  comparisons  in  the  sensitivity  analyses  limited
to  studies  with  quality  control  for  psychological  therapies
showed  a  superior  efficacy  of  pharmacological  intervention
over  psychological  therapies  in  terms  of  short-term  remission.
These  comparisons  were  psychological  therapies  versus  SSRI,
other  antidepressants,  and  either  antidepressants  alone  or
antidepressants plus benzodiazepines.

We  found  a  significant  heterogeneity  of  the  results  for  efficacy
for comparisons that included antidepressants. The heterogeneity
in the comparison between all psychological therapies and other
antidepressants seemed to be caused by the length of intervention:
trials  with  a  longer  duration  suggested  that  the  pharmacological
interventions  tended  to  be  superior.  The  heterogeneity 
in
the  comparison  between  all  psychological  therapies  and  SSRI
and  either  antidepressants  alone  or  antidepressants  plus
benzodiazepines seemed to be caused by the individual modality
of psychological therapies: SSRI and either antidepressants alone
or antidepressants plus benzodiazepines were more effective than
psychological therapies in terms of short-term remission.

Overall completeness and applicability of evidence

We  were  able  to  perform  a  meta-analysis  for  all  of  the  primary
outcomes  in  all  of  the  comparisons  we  declared  except  for
the  comparison  between  psychological  therapies  and  SNRIs.
However, the number of included studies was small for all of the
comparisons but one, which was all psychological therapies versus
either  antidepressants  or  antidepressants  with  benzodiazepines.
Furthermore,  the  psychotherapies  intervention  included  in  the
analyses  was  mostly  CBT,  and  there  were  few  studies  examining
other  psychotherapies.  We  could  not  find  any  trial  dealing  with
psychoeducation, cognitive therapy, or third-wave therapies. The
possible  reasons  for  the  scarcity  of  trials  other  than  those
examining CBT and BT are that other psychological therapies are
regarded  as  non-promising  or  time  and  personnel  consuming.
In  fact,  one  short-term  psychodynamic  therapy  that  we  included
required  40  weekly  sessions  of  45  minutes  in  duration,  and  the
therapist  had  10  to  15  years  of  experience  with  psychodynamic
therapy (Bressi 2010). As for third-wave therapies, such treatments
are  relatively  new  and  may  not  be  available  for  the  treatment  of
panic  disorder.  Although  we  performed  a  thorough  search,  it  is
possible  that  unpublished  studies  exist.  If  there  are  unpublished
trials, we assume that the reasons for the lack of publication may
vary:  some  trials  may  have  had  negative  results,  and  other  trials
may have been influenced by the allegiances of researchers to their
sponsors or their therapeutic preferences.

Among  the  secondary  outcomes,  only  information  on  the  short-
term improvement of panic disorder was available. We could not
retrieve other secondary outcomes, including long-term remission/

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

response, short-term improvements in quality of life, and adverse
events.  Adverse  events  arising  from  psychological  therapies
are  often  not  reported  because  they  are  difficult  to  recognise
and  study  (Linden  2013).  The  nature  of  adverse  events  arising
from  psychological  therapies  also  differs  from  those  caused  by
pharmacological intervention. Nevertheless, adverse events are an
important outcome for decision making, so the use of a structured
checklist  for  the  adverse  events  of  psychological  therapies  and
comparison  with  adverse  events  according  to  severity  may  be
useful when reporting adverse events.

Quality of the evidence

The quality of the evidence for each outcome ranged from low to
moderate.  In  all  of  the  studies  participants  were  not  blinded  to
treatment because of the psychological therapy arm.

the  obtained 

Many  of 
results  demonstrated  substantial
heterogeneity, some of which seemed to be related to the length
of  psychological  therapy  and  one  particular  study  with  extreme
results.

As  the  number  of  participants  included  in  the  meta-analysis  was
909 at most, the evidence tended to be imprecise.

The  number  of  studies  included  in  each  comparison  for  the
detection of publication bias was small. The comparison between
all  psychological  therapies  versus  antidepressants  alone  or
antidepressants and benzodiazepines had a sufficient number of
studies for a funnel plot analysis, and we suspected publication bias
for dropouts for any reason and short-term improvement.

Most  of  the  included  studies  had  an  unclear  risk  of  bias
for  several  domains.  Only  three  studies  reported  adequate
random  sequence  generation  and
information  concerning 
allocation concealment. Blinding of the participants and personnel
was difficult as all the comparisons included psychological therapy.
However,  the  use  of  psychological  and  pharmacological  placebo
could  mitigate  the  performance  bias.  The  blinding  of  outcome
assessments  was  not  appropriately  reported  or  broken  in  14
studies.  Selective  outcome  reporting  was  unclear,  as  the  study
protocol  was  only  available  for  one  study.  The  attrition  in  many
studies  was  negligible.  We  evaluated  researcher  and  therapist
allegiance  and  sponsorship  bias  as  other  potential  sources  of
bias.  Researcher  allegiance  was  balanced  between  the  arms  in
many studies; however, many studies lacked information regarding
therapist  allegiance.  Many  studies  had  a  sponsorship  bias,  or
conflicts of interest were not appropriately reported.

Potential biases in the review process

Study-level limitations

Quality of interventions

We  performed  a  sensitivity  analysis  limited  to  studies  with
quality control (adequate supervision and the use of a treatment
manual) for the psychological therapies, which changed the results,
favouring  pharmacological  interventions  in  some  comparisons.
This  may  be  because  studies  with  good  quality  control  against
psychological therapies are less biased to psychological therapies.
We evaluated adequate supervision and the use of a manual in the
sensitivity analysis, whereas we did not consider the components
of psychological therapies, and psychological therapies under the
same category included different components. For example, in one

Cochrane Database of Systematic Reviews

study CBT included breathing retraining, but in another study it did
not.  We  did  not  consider  the  quality  control  of  pharmacological
treatments.  All  pharmacological  treatments  adopted  a  flexible
dose.  However,  some  studies  did  not  report  the  mean  dose
administered during the trials. These factors may affect the results.

Length of intervention

The  length  of  the  interventions  ranged  from  6  to  40  weeks.
Investigation  of  the  sources  of  heterogeneity  suggested  that  it
might  be  due  to  the  length  of  the  intervention.  Longer  trials
tended to favour pharmacological intervention in one comparison.
Previous reports have suggested that the duration of psychological
therapy is not related to its effect (Baldwin 2009; Stiles 2015). On the
other  hand,  pharmacological  intervention  may  be  more  effective
with longer duration (Quitkin 1984; Tedeschini 2011). Considering
these facts, pharmacological therapy may be beneficial in long term
duration.

Modalities of the psychological therapies

inconsistent  with  studies  using 

therapy,  and
One  study  used  group-based  psychological 
the  efficacy  was 
individual
psychological therapies; the former study favoured psychological
favoured  pharmacological
therapy,  and  the 
intervention.  According  to  this  result,  the  therapeutic  modality
could be a potential source of bias.

latter  studies 

Number of intervention arms

The  number  of  intervention  arms  varied  among  the  included
studies,  ranging  from  two  to  five.  Greenberg  reported  that  the
effect sizes of three-arm studies including an antidepressant to be
tested, a standard antidepressant, and a placebo showed a smaller
difference between the standard antidepressant and the placebo
than  those  studies  comparing  two  arms  only  (Greenberg  1992).
Considering  this  fact,  the  various  numbers  of  intervention  arms
may have influenced the present results.

Omission of DSM-5 in the study inclusion criteria

The  DSM-5  was  not  among  the  diagnostic  criteria  that  we  had
listed as being eligible for inclusion in our original study protocol.
However, we did not find any literature that used the DSM-5 and
met our other inclusion criteria. In the DSM-5, as in the ICD-10, panic
disorder  and  agoraphobia  are  separate  diagnosable  disorders.
We  found  only  one  study  where  almost  all  of  the  participants
had agoraphobia. We planned to exclude studies that focused on
agoraphobia  without  panic  disorder,  but  no  such  studies  were
found.  The  omission  of  the  DSM-5  criteria  in  the  present  review
therefore did not affect our results. However, we should consider
this factor in future reviews.

Outcome-level limitations

Assessment

By  global  judgement  of  the  original  investigators  our  primary
outcomes  were  remission  and  response,  which  included  several
different  scales,  including  the  number  of  panic  attacks,  CGI,
and  PDSS.  The  investigation  of  heterogeneity  in  the  comparison
between  psychological  therapies  and  SSRI  suggested  that  using
different scales might have been a source of heterogeneity.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Risk of bias

Information  related  to  risk  of  bias  was  not  reported  in  many
studies.  In  particular,  many  studies  had  an  unclear  risk  of
bias  for  random  sequence  generation,  allocation  concealment,
and  selective  outcome  reporting.  Blinding  of  participants  was
impossible  for  the  psychological  therapies  but  was  possible
for  the  pharmacological  interventions,  which  could  have  led
to  psychological  therapies  being  favoured  in  studies  with  a
pharmacological placebo arm.

There  is  controversy  as  to  whether  industry  sponsorship  is  an
extra  factor  to  be  rated  within  'other  potential  sources  of  bias'.
A  Cochrane  methodology  review  provides  empirical  evidence
indicating  that  industry-sponsored  drug  and  device  studies  are
more  often  favourable  to  the  sponsor's  products  compared  with
non–industry-sponsored drug and device studies because of biases
that  cannot  be  explained  by  standard  'Risk  of  bias'  assessment
tools  (Lundh  2012).  We  therefore  chose  to  be  transparent  in
presenting sponsorship bias that may distort the meta-analyses.

As many risks of bias were unclear, and blinding of participants was
at high risk of bias, we downgraded the quality of the evidence by
one point for this reason.

Review-level limitations

The  inter-rater  reliability  was  relatively  fair.  This  was  because
studies that did not report information related to risk of bias were
usually judged as having an unclear risk of bias, but some studies
were  judged  as  having  low  or  high  risk  of  bias  depending  on  the
context. This caused the disagreement between two raters.

Cochrane Database of Systematic Reviews

1.23 to 2.11). These results seem to be incongruous with the present
review, which suggested that pharmacological intervention tends
to be superior to psychological intervention. However, the number
of  studies  included  in  Furukawa's  review  was  small;  the  former
comparison  included  one  study,  and  the  latter  included  eight
studies.  Additionally,  the  combination  therapy  was  superior  to
pharmacological  intervention  alone  (RR  1.63,  95%  CI  1.21  to
2.19)  or  psychological  therapy  plus  placebo  (RR  1.29,  95%  CI
1.03  to  1.62)  in  terms  of  the  long-term  remission/response  on
continued  treatment.  Considering  these  findings,  the  results  are
inconclusive. More studies are needed to determine the superiority
in  a  head-to-head  comparison  between  psychological  therapies
and pharmacological intervention in longer-term outcomes.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

We  found  no  evidence  for  the  superiority  of  one  form  of  therapy
over  another  with  regard  to  short-term  efficacy  and  treatment
acceptability.  However,  psychological  therapies  with  longer-term
duration,  quality  control,  or  an  individual  modality  may  be  less
effective than pharmacological intervention in terms of short-term
efficacy. No information was available about long-term efficacy or
quality of life.

The evidence in this review ranged between very low and moderate,
and was often imprecise. In the absence of high-quality evidence,
decisions to use pharmacotherapy or psychotherapy may depend
on the costs, time, and labour required, as well as the availability of
qualified personnel in each clinical setting in conjunction with the
individual patient's preferences.

Agreements and disagreements with other studies or
reviews

Implications for research

Three  reviews  included  a  comparison  between  psychological
therapies  and  pharmacological  interventions  (Clum  1993;  Gould
1995; Mitte 2005). Two old reviews showed psychological therapies
to  be  more  effective  than  pharmacological  intervention  (Clum
1993;  Gould  1995).  Clum  1993  indicated  that  exposure  with  a
drug placebo was more effective than antidepressants (effect size
=  0.4),  but  this  result  was  found  in  only  one  study,  and  the
control  consisted  of  combination  therapy  using  exposure  and  a
drug  placebo.  Gould  1995  included  two  studies  comparing  CBT
with  pharmacological  intervention  and  indicated  that  CBT  was
more  effective  and  had  fewer  dropouts  than  pharmacological
intervention; we included these studies in our meta-analysis. Mitte
2005  compared  pharmacological  intervention  with  psychological
therapies in terms of anxiety, depression, and clinical significance,
and the results were compatible with our results: effect size of 0.27
(95%  CI  -0.07  to  0.62)  for  anxiety,  0.21  (95%  CI  -0.34  to  0.75)  for
depression, and 0.09 (95% CI -0.30 to 0.56) for clinical significance.

2007 

compared 

combination 

Furukawa 
therapy  with
psychotherapy  or  pharmacotherapy.  Their  findings  suggested
that  the  effect  of  psychological  treatment  lasts  longer  than
that  of  pharmacological  treatment,  since  psychological  therapy
plus  pharmacological  intervention  did  not  increase  the  long-
term  remission/response  after  the  discontinuation  of  treatment
compared  with  psychological  therapy  plus  a  placebo  (RR  0.96,
95%  CI  0.79  to  1.16),  whereas  combination  therapy  was  superior
to  pharmacological  intervention  alone  in  terms  of  remission/
response  after  the  discontinuation  of  treatment  (RR  1.61,  95%  CI

Future  studies  should  examine  the  influence  of  accompanying
agoraphobia.  We  found  only  one  study  where  almost  all  of  the
participants had agoraphobia. It would be clinically meaningful to
examine which approach is more or less effective and tolerable for
patients with agoraphobia or with panic disorder.

Many studies have investigated CBT. However, other psychological
therapies, such as psychodynamic psychological therapy, BT, and
physiological  therapy,  need  further  investigation.  The  quality  of
psychological  therapies  should  be  well  controlled  and  should  be
reported in publications. The influence of the length of intervention
should  be  analysed,  and  the  long-term  effect  after  intervention
should be tested, especially in psychological therapies.

(i.e.  pill  placebo  and  non-specific
Adequately  controlled 
psychological  control)  and  powered  studies  are 
important.
Outcomes  that  can  be  appropriately  blinded  are  desirable.  The
method  of  randomisation  and  allocation  concealment  should  be
clearly reported in all publications. Trial registration or a detailed
study protocol should be made available before commencing the
trial.

There is a need for larger studies that are adequately powered to
detect differences between two active and effective treatments.

Long-term response or remission and outcome related to quality of
life should be reported. Other items that should be reported include
the  outcome  as  it  is  related  to  adverse  events  such  as  suicide  or
suicide attempts, the number of dropouts because of side effects,

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

and the number of participants experiencing at least one adverse
effect.

A C K N O W L E D G E M E N T S

Cochrane Review Group Funding Acknowledgement: The National
Institute for Health Research (NIHR) is the largest single funder of
the Cochrane Common Mental Disorders Group.

Cochrane Database of Systematic Reviews

Disclaimer: The views and opinions expressed therein are those of
the authors and do not necessarily reflect those of the NIHR, NHS,
or the Department of Health.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Ataoglu 2000 {published data only}

*  Ataoglu A, Ozkan M, Tutkun H, Maras A. Alprazolam and
cognitive behavior therapy in treatment of panic disorder.
Turkish Journal of Medical Sciences 2000;30:167-71.

Azhar 2000 {published data only}

*  Azhar MZ. Comparison of fluvoxamine alone, fluvoxamine
and cognitive psychotherapy and psychotherapy alone in
the treatment of panic disorder in Kelantan - implications for
management by family doctors. Medical Journal of Malaysia
2000;55:402-8.

Bakker 1999 {published data only}

Bakker A, Spinhoven P, van der Does AJW, van Balkom AJLM,
van Dyck R. Locus of control orientation in panic disorder
and the differential effects of treatment. Psychotherapy and
Psychosomatics 2002;71:85-9.

*  Bakker A, van Dyck R, Spinhoven P, van Balkom AJLM.
Paroxetine, clomipramine, and cognitive therapy in the
treatment of panic disorder. Journal of Clinical Psychiatry
1999;60:831-8.

Dusseldorp E, Spinhoven P, Bakker A, van Dyck R,
van Balkom AJLM. Which panic disorder patients benefit
from which treatment: cognitive therapy or antidepressants?.
Psychotherapy and Psychosomatics 2007;76:254-61.

Barlow 2000 {published data only}

*  Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-
behavioral therapy, imipramine, or their combination for panic
disorder: a randomized controlled trial. JAMA 2000;283:2529-36.

Shear MK, Houck P, Greeno C, Masters S. Emotion-focused
psychotherapy for patients with panic disorder. American
Journal of Psychiatry 2001;158(12):1993-1998.

Black 1993 {published data only}

Black DW, Monahan P, Wesner R, Gabel J, Bowers W. The effect
of fluvoxamine, cognitive therapy, and placebo on abnormal
personality traits in 44 patients with panic disorder. Journal of
Personality Disorders 1996;10(2):185-194.

*  Black DW, Wesner R, Bowers W, Gabel J. A comparison of
fluvoxamine, cognitive therapy, and placebo in the treatment of
panic disorder. Archives of General Psychiatry 1993;50:44-50.

Black DW, Wesner R, Bowers W, Monahan P, Gabel J. Acute
treatment response in outpatients with panic disorder: high
versus low depressive symptoms. Annals of Clinical Psychiatry
1995;7(4):181-188.

Black DW, Wesner RB, Gabel J, Bowers W, Patrick M. Predictors
of short-term treatment response in 66 patients with panic
disorder. Journal of Affective Disorders 1994;39:233-241.

Bressi 2010 {published data only}

Bressi C, Porcellana M, Marinaccio PM, Nocito EP, Magri L. Short-
term psychodynamic psychotherapy versus treatment as usual
for depressive and anxiety disorders. Journal of Nervous and
Mental Disease 2010;198(9):647-652.

Clark 1994 {published data only}

Clark DM, Salkovskis PM, Hackmann A, Middleton H,
Anastasiades P, Gelder M. A comparison of cognitive therapy,
applied relaxation and imipramine in the treatment of panic
disorder. British Journal of Psychiatry 1994;164:759-769.

Hicks TV, Leitenberg H, Barlow DH, Gorman JM, Shear MK,
Woods SW. Physical, mental and social catastrophic
cognitions as prognostic factors in cognitive-behavioral and
pharmacological treatments for panic disorder. Journal of
Consulting and Clinical Psychology 2005;73(3):506-14.

Dannon 2004 {published data only}

Dannon PN, Gon-usishkin M, Gelbert A, Lowengrub K,
Grunhaus L. Cognitive behavioral group therapy in panic
disorder patients: the efficacy of CBGT versus drug treatment.
Annals of Clinical Psychiatry 2004;16:41-46.

Hoffmann SG, Suvak MK, Barlow DH, Shear MK, Meuret AE,
Rosenfield D, et al. Preliminary evidence for cognitive mediation
during cognitive-behavioral therapy of panic disorder. Journal
of Consulting and Clinical Psychology 2007;75(3):374-9.

Hofmann SG, Shear MK, Barlow DH, Gorman JM, Hershberger D,
Patterson M, et al. Effects of panic disorder treatments on
personality disorder characteristics. Depression and Anxiety
1998;8:14-20.

McHugh RK, Otto MW, Barlow DH, Gorman JM, Shear MK,
Woods SW. Cost-efficacy of individual and combined
treatments for panic disorder. Journal of Clinical Psychiatry
2007;68:1038-1044.

Hendriks 2010 {published data only}

Hendriks GJ, Keijsers GPJ, Kampman M, Hoogduin CAL,
Voshaar RCO. Predictors of outcome of pharmacological
and psychological treatment of late-life panic disorder with
agoraphobia. International Journal of Geriatric Psychiatry
2012;27:146-150.

*  Hendriks GJ, Keijsers GPJ, Kampman M, Oude Voshaar RC,
Verbraak MJPM, Broekman TG, et al. A randomized controlled
study of paroxetine and cognitive-behavioural therapy
for late-life panic disorder. Acta Psychiatrica Scandinavica
2010;122:11-19.

Klosko 1988 {published data only}

Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE,
Woods SW, et al. Multicenter collaborative panic
disorder severity scale. American journal of psychiatry
1997;154(11):1571-1575.

Klosko JS, Barlow DH, Tassinari R, Cerny JA. A comparison
of alprazolam and behavior therapy in treatment of panic
disorder. Journal of Consulting and Clinical Psychology
1990;58(1):77-84.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Muncy 1991 {published data only}

Muncy SM. Panic: a Comparison of Four Treatment Methods
[Doctoral dissertation]. 1990.

Prasko 2004 {published data only}

Prasko J, Horacek J, Zalesky R, Kopecek M, Novak T, Paskova B,
et al. The change of regional brain metabolism (18FDG PET) in
panic disorder during the treatment with cognitive behavioral
therapy or antidepressants. Neuroendocrinology Letters
2004;25:340-348.

Sharp 1996 {published data only}

*  Sharp DM, Power KG. Fluvoxamine, placebo, and cognitive
behaviour therapy used alone and in combination in the
treatment of panic disorder and agoraphobia. Journal of Anxiety
Disorders 1996;10(4):219-242.

Sharp DM, Power KG. Predicting treatment outcome for panic
disorder and agoraphobia in primary care. Clinical Psychology
and Psychotherapy 1999;6:336-348.

Sharp DM, Power KG. Psychologist, patient, and general
practitioner rating of outcome of pharmacological and
psychological treatments for panic disorder and agoraphobia
in primary care. Behavioural and Cognitive Psychotherapy
1998;26:13-27.

Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA.
Global measure of outcome in a controlled comparison
of pharmacological treatment of panic disorder and
agoraphobia in primary care. British Journal of General Practice
1997;47:150-155.

Shear 2000 {published data only}

Shear MK, Houck P, Greeno C, Masters S. Emotion-focused
psychotherapy for patients with panic disorder. American
Journal of Psychiatry 2001;158(12):1993-1998.

Taylor 1982 {published data only}

Taylor CB, Kenigsberg ML, Robinson JM. A controlled
comparison of relaxation and diazepam in panic disorder.
Journal of Clinical Psychiatry 1982;43(10):423-425.

Tyrer 1988 {published data only}

Kingdon D, Tyrer P, Seivewright N, Ferguson B, Murphy S.
The Nottingham study of neurotic disorder: influence of
cognitive therapists on outcome. British Journal of Psychiatry
1996;169:93-97.

Knerer G, Byford S, Johnson T, Seivewright H, Tyrer P. The
Nottingham study of neurotic disorder: predictors of 12 year
costs. Acta Psychiatrica Scandinavica 2005;112:224-232.

Seivewright H, Tyrer P, Johnson T. Change in personality status
in neurotic disorders. Lancet 2002;359:2253-2254.

Seivewright H, Tyrer P, Johnson T. Prediction of outcome in
neurotic disorder: 5-year prospective study. Psychological
Medicine 1998;28(5):1149-1157.

Seivewright N, Tyrer P, Ferguson B, Murphy S, Johnson T.
Longitudinal study of the influence of life events and

personality status on diagnostic change in three neurotic
disorders. Depression and Anxiety 2000;11:105-113.

Tyrer P, Seivewright H, Ferguson B, Johnson T. "Cold calling" in
psychiatric follow up studies: is it justified?. journal of Medical
Ethics 2003;29:238-242.

Tyrer P, Seivewright H, Johnson T. The Nottingham study of
neurotic disorder: predictors of 12-year outcome of dysthymic,
panic and generalized anxiety disorder. Psychological Medicine
2004;34(8):1385-1394.

Tyrer P, Seivewright H, Simmonds S, Johnson T. Prospective
studies of dysthymia (mixed anxiety-depression): how do they
inform clinical practice?. European Archives of Psychiatry and
Clinical Neuroscience 2001;251(Suppl 2):II/53-II/56.

Tyrer P, Seivewright N, Ferguson B, Brothwell J, Darling C,
Murphy S. Nottingham study of neurotic disorder. Lancet
1988;30(2):235-240.

Tyrer P, Seivewright N, Ferguson B, Murphy S, Johnson AL. The
Nottingham study of neurotic disorder. Effect of personality
status on response to drug treatment, cognitive therapy
and self-help over two years. British Journal of Psychiatry
1993;162:219-226.

Tyrer P, Seivewright N, Ferguson B, Murphy S, Johnson AL. The
Nottingham study of neurotic disorder. Effect of personality
status on response to drug treatment, cognitive therapy
and self-help over two years. British journal of psychiatry
1993;162:219-226.

Tyrer P, Seivewright N, Ferguson B, Tyrer J. The general
neurotic syndrome: a coaxial diagnosis of anxiety, depression
and personality disorder. Acta Psychiatrica Scandinavica
1992;85:201-206.

*  Tyrer P, Seivewright N, Murphy S, Ferguson B, Kingdon D,
Barczak P, et al. The Nottingham study of neurotic disorder:
comparison of drug and psychological treatments. Lancet
1988;8605:235-240.

Tyrer P, Seivewright N, Seivewright H. Long-term outcome of
hypochondriacal personality disorder. Journal of Psychosomatic
Research 1999;46(2):177-185.

van Apeldoorn 2008 {published data only}

*  van Apeldoorn FJ, van Hout WJPJ, Mersch PPA, Huisman M,
Slaap BR, Hale WW, et al. Is a combined therapy more effective
than either CBT or SSRI alone? Results of a multicenter trial on
panic disorder with or without agoraphobia. Acta Psychiatrica
Scandinavica 2008;117:260-270.

van Apeldoorn PJ, van Hout WJPJ, Timmerman ME, Mersch PPA,
den Boer JA. Rate of improvement during and across three
treatments for panic disorder with or without agoraphobia:
cognitive behavioral therapy. Journal of Affective Disorders
2013;150:313-319.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

References to studies excluded from this review

Additional references

Borkovec 1988 {published data only}

Altman 1996

Borkovec TD, Mathews AM. Treatment of nonphobic anxiety
disorders: a comparison of nondirective, cognitive, and coping
desensitization therapy. Journal of Consulting and Clinical
Psychology 1988;56(6):877-884.

Echeburua 1993 {published data only}

Echeburua E, Corral PD, Bajos EG, Borda M. Interactions
between self-exposure and alprazolam in the treatment of
agoraphobia without current panic: an exploratory study.
Behavioural and Cognitive Psychotherapy 1993;21:219-238.

Echeburua 2006 {published data only}

Echeburua E, Salaberria K, Corral PD, Cenea R. Treatment
of mixed anxiety-depression disorder: long-term outcome.
Behavioural and Cognitive Psychotherapy 2006;34:95-101.

Huppert 2004 {published data only}

Huppert JD, Schultz LT, Foa EB, Barlow DH, Davidson JRT,
Gorman JM, et al. Differential response to placebo among
patients with social phobia, panic disorder, and obsessive-
compulsive disorder. American Journal of Psychiatry
2004;161:1485-1487.

Altman DG, Bland MJ. Detecting skewness for summary
information. BMJ 1996;313(7066):1200.

APA 1980

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 3rd Edition. American Psychiatric
Association, 1980.

APA 1987

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 3rd Edition. American Psychiatric
Association, 1987.

APA 2000

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 4th Edition. American Psychiatric
Association, 2000.

APA 2009

American Psychiatric Association. American Psychiatric
Association Practice Guidelines for the Treatment of Panic
Disorder. American Psychiatric Publishing, 2009.

Lang 2006 {published data only}

Baldwin 2009

Lang AJ, Norman GJ, Casmar PV. A randomized trial of a brief
mental health intervention for primary care patients. Journal of
Consulting and Clinical Psychology 2006;74(6):1173-1179.

Schuurmans 2006 {published data only}

Schuurmans J, Comijs H, Emmelkamp PMG, Gundy CMM,
Weijnen I, Hout MVD, et al. A randomized, controlled trial
of the effectiveness of cognitive-behavioral therapy and
sertraline versus a waitlist control group for anxiety disorders
in older adults. American Journal of Geriatric Psychiatry
2006;14(3):255-263.

Spinhoven 1996 {published data only}

Spinhoven P, Onstein EJ, Klinkhamer RA, Klein EAM. Panic
management, trazodone and a combination of both in
the treatment of panic disorder. Clinical Psychology and
Psychotherapy 1996;3(2):86-92.

References to studies awaiting assessment

Prasko 2004b {unpublished data only}

Prasko J, Horacek J, Paskova B. CBT or paroxetine in the
treatment of panic disorder. 32nd Congress of the British
Association for Behavioural and Cognitive Psychotherapies
(jointly with the European Association of Behavioural and
Cognitive Therapies); 2004 September 7 - 11; Manchester. 2004.

Baldwin SA, Berkeljon A, Atkins DC, Olsen JA, Nielsen SL. Rates
of change in naturalistic psychotherapy: contrasting dose–effect
and good-enough level models of change. Journal of Consulting
and Clinical Psychology 2009;77:203-211.

Bandelow 1995

Bandelow B. Assessing the efficacy of treatments for panic
disorder and agoraphobia. II. The Panic and Agoraphobia Scale.
International Clinical Psychopharmacology 1995;10(2):73-81.

BAP 2014

Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B,
den Boer JA, et al. Evidence-based pharmacological treatment
of anxiety disorders, post-traumatic stress disorder and
obsessive-compulsive disorder: revision of the 2005 guidelines
from the British Association for Psychopharmacology. Journal
of Psychopharmacology 2014;28(5):403-39.

Barlow 1988

Barlow DH. Anxiety and Its Disorders. Guilford Press, 1988.

Baudry 2011

Baudry A, Mouillet-Richard S, Launay J, Kellermann O. New
view on antidepressant action. Current Opinion in Neurobiology
2011;21(6):858-65.

Beck 1988

Takriti 1989 {published data only}

Tariti AY, Zakaria Z. Panic disorder alprazolam versus cognitive
therapy. Arab Journal of Psychiatry 1989;1:12-21.

Beck AT, Epstein N, Brown G, Steer RA. An inventory for
measuring clinical anxiety: psychometric properties. Journal of
Consulting and Clinical Psychology 1988;56(6):893-7.

Bijl 1998

Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric
disorder in the general population: results of The Netherlands

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mental Health Survey and Incidence Study (NEMESIS). Social
Psychiatry and Psychiatric Epidemiology 1998;33(6):683-91.

Bradwejn 2005

Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T.
Venlafaxine extended-release capsules in panic disorder:
flexible-dose, double-blind, placebo-controlled study. British
Journal of Psychiatry 2005;187:352-9.

Busch 1999

Busch FN, Milrod BL, Singer MB. Theory and technique in
psychodynamic treatment of panic disorder. Journal of
Psychotherapy Practice and Research 1999;8(3):234-42.

Chambless 1984

Chambless DL, Caputo GC, Bright P, Gallagher R. Assessment
of fear of in agoraphobics: the Body Sensations Questionnaire
and the Agoraphobic Cognitions Questionnaire. Journal of
Consulting and Clinical Psychology 1984;52(6):1090-7.

Chambless 1985

Chambless DL, Caputo GC, Jasin SE, Gracely EJ, Williams C. The
Mobility Inventory for Agoraphobia. Behaviour Research and
Therapy 1985;23(1):36-44.

Clum 1993

Clum GA, Surls R. A meta-analysis of treatments for panic
disorder. Journal of Consulting and Clinical Psychology
1993;61(2):317-26.

Comer 2011

Comer JS, Blanco C, Hasin DS, Liu SM, Grant BF, Turner JB, et
al. Health-related quality of life across the anxiety disorders.
Journal of Clinical Psychiatry 2011;72(1):43-50.

Endicott 1976

Endicott J,  Spitzer RL,  Fleiss JL,  Cohen J. The global
assessment scale. A procedure for measuring overall severity
of psychiatric disturbance. Archives of General Psychiatry
1976;33(6):766-71.

Falkenstrom 2013

Falkenstrom F, Markowitz JC, Jonker H, Philips B, Holmqvist R.
Can psychotherapists function as their own controls? Meta-
analysis of the crossed therapist design in comparative
psychotherapy trials. Journal of Clinical Psychiatry
2013;74(5):482-91.

Feighner 1972

Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G,
Munoz R. Diagnostic criteria for use in psychiatric research.
Archives of General Psychiatry 1972;26(1):57-63.

Freire 2011

Freire RC, Hallak JE, Nardi AE. New treatment options for
panic disorder: clinical trials from 2000 to 2010. Expert Opinion
Pharmacotherapy 2011;12(9):1419-28.

Furukawa 2002

Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the
'number needed to treat'? An empirical study of summary
effect measures in meta-analyses. International Journal of
Epidemiology 2002;31(1):72-6.

Furukawa 2005

Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N.
Imputing response rates from means and standard deviations
in meta-analysis. International Clinical Psychopharmacology
2005;20(1):49-52.

Daele 2012

Furukawa 2006

Daele T, Hermans D, Audenhove C, Bergh O. Stress reduction
through psychoeducation: a meta-analytic review. Health
Education & Behavior 2012;39(4):474-85.

Deacon 2003

Deacon B, Abramowitz J, Woods C, Tolin D. The Anxiety
Sensitivity Index - Revised: psychometric properties and factor
structure in two nonclinical samples. Behaviour Research and
Therapy 2003;41(12):1427-49.

Douglas 2008

Douglas C. Teaching supportive psychotherapy to psychiatric
residents. American Journal of Psychiatry 2008;165(4):445-52.

Eaton 1994

Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic
disorder in the United States. American Journal of Psychiatry
1994;151:413-20.

Eldridge 1981

Eldridge FL, Millhorn DE. Central regulation of respiration by
endogenous neurotransmitters and neuromodulators. Annual
Review of Physiology 1981;43:121-35.

Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N.
Imputing response rates from means and standard deviations
in meta-analysis. International Clinical Psychopharmacology
2005;20:49-52.

Furukawa 2007

Furukawa TA, Watanabe N, Churchill R. Combined
psychotherapy plus antidepressants for panic disorder with or
without agoraphobia. Cochrane Database of Systematic Reviews
2007, Issue 1. [DOI: 10.1002/14651858.CD004364.pub2]

Goldapple 2004

Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, et
al. Modulation of cortical-limbic pathways in major depression:
treatment-specific effects of cognitive behavior therapy.
Archives of General Psychiatry 2004;61(1):34-41.

Gould 1995

Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment
outcome for panic disorder. Clinical Psychology Review
1995;15(8):819-44.

Grant 2006

Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB,
Smith S, et al. The epidemiology of DSM-IV panic disorder and

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

agoraphobia in the United States: result from the National
Epidemiologic Survey on Alcohol and Related Conditions.
Journal of Clinical Psychiatry 2006;67:363-74.

Greenberg 1992

Greenberg RP, Bornstein RF, Greenberg MD, Fisher S. A
meta-analysis of antidepressant outcome under "blinder"
conditions. Journal of Consulting and Clinical Psychology
1992;60(5):664-669.

Guy 1976

Guy W. Clinical Global Impression. ECDEU Assessment Manual
for Psychopharmacology, revised. National Institute of Mental
Health, 1976:218-22.

practice attendees across Europe. British Journal of Psychiatry
2008;192(5):362-7.

Klein 1993

Klein DF. False suffocation alarms, spontaneous panics,
and related conditions. An integrative hypothesis. Archives
of General Psychiatry 1993;50(4):306-17.

Linden 2013

Linden M. How to define, find and classify side effects
in psychotherapy: from unwanted events to adverse
treatment reactions. Clinical Psychology and Psychotherapy
2013;20:286-96.

Lundh 2012

Hamilton 1959

Hamilton M. The assessment of anxiety states by rating. British
Journal of Medical Psychology 1959;32(1):50-5.

Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry
sponsorship and research outcome. Cochrane Database of
Systematic Reviews 2012;12:MR000033.

Hayes 2004

Malizia 1998

Hayes S. Acceptance and commitment therapy, relational
frame theory, and the third wave of behavioral and cognitive
therapies. Behaviour Therapy 2004;35(4):639-65.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.

Higgins 2011

Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T.
Decreased brain GABAA-benzodiazepine receptor binding in
panic disorder: preliminary results from a quantitative PET
study. Archives of General Psychiatry 1998;55(8):715-20.

Markowitz 1989

Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL.
Quality of life in panic disorder. Archives of General Psychiatry
1989;46(11):984-92.

Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.

Marks 1979

Marks IM, Mathew AM. Brief standard self-rating for phobic
patients. Behavior Research and Therapy 1979;17(3):263-7.

James 2013

Marks 1981

James A, James G, Cowdrey F, Soler A, Choke A. Cognitive
behavioural therapy for anxiety disorders in children and
adolescents. Cochrane Database of Systematic Reviews 2013,
Issue 6. [DOI: 10.1002/14651858.CD004690.pub3]

Kahl 2012

Kahl KG, Winter L, Schweiger U. The third wave of cognitive
behavioural therapies: what is new and what is effective?.
Current Opinion in Psychiatry 2012;25(6):522-8.

Kessler 2006

Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The
epidemiology of panic attacks, panic disorder, and agoraphobia
in the National Comorbidity Survey Replication. Archives of
General Psychiatry 2006;63:415-24.

Kind 1996

Kind P. The EuroQol instrument: an index of health related
quality of life. In: Spilker B editor(s). Quality of Life and
Pharmacoeconomics in Clinical Trials. 2nd Edition.
Philadelphia: Lippincott-Raven Publishers, 1996:191-201.

Marks IM. Cure and Care of Neuroses: Theory and Practice of
Behavioural Psychotherapy. New York: Wiley, 1981.

Mauret 2010

Mauret AE, Ritz T. Hyperventilation in panic disorder and
asthma: empirical evidence and clinical strategies. International
Journal of Psychophysiology 2010;78(1):68-79.

Mayberg 1999

Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK,
Jerabek PA, et al. Reciprocal limbic-cortical function and
negative mood: converging PET findings in depression
and normal sadness. American Journal of Psychiatry
1999;156:675-82.

Mayberg 2000

Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK,
McGinnis S, et al. Regional metabolic effects of fluoxetine in
major depression: serial changes and relationship to clinical
response. Biological Psychiatry 2000;48:830-43.

Michelson 1998

King 2008

King M, Nazareth I, Levy G, Walker C, Morris R, Weich S,
et al. Prevalence of common mental disorders in general

Michelson D,  Lydiard RB,  Pollack MH,  Tamura RN,  Hoog SL,
 Tepner R, et al. Outcome assessment and clinical improvement
in panic disorder: evidence from a randomised controlled

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

trial of fluoxetine and placebo. American Journal of Psychiatry
1998;155(11):1570-7.

without agoraphobia: a meta-analysis. Clinical Psychology
Review 2010;30(1):37-50.

Milrod 2007

Sareen 2005

Milrod B,  Leon AC,  Busch F,  Rudden M,  Schwalberg M,
 Clarkin J, et al. A randomized controlled clinical trial of
psychoanalytic psychotherapy for panic disorder. American
Journal of Psychiatry 2007;164(2):265-72.

Mitte 2005

Mitte K. A meta-analysis of the efficacy of psycho- and
pharmacotherapy in panic disorder with and without
agoraphobia. Journal of Affective Disorders 2005;88(1):27-45.

Sareen J, Cox BJ, Afifi TO, Graaf RD, Asmundson GJG, Have TH,
et al. Anxiety disorders and risk for suicidal ideation and suicide
attempts. Archives of General Psychiatry 2005;62:1249-57.

Schotte 2006

Schotte C, Bossche B, Doncker D, Claes S, Cosyns P. A
biopsychosocial model as a guide for psychoeducation
and treatment of depression. Depression and Anxiety
2006;23(5):312-24.

Moher 2009

Shear 1997

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA
group. Preferred Reporting Items for Systematic Reviews
and Meta-Analyses: The PRISMA Statement. PLoS Medicine
2009;6(6):e1000097.

Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE,
Woods SE, et al. Multicenter collaborative panic
disorder severity scale. American Journal of Psychiatry
1997;154(11):1571-5.

Munder 2011

Sherbourne 2010

Munder T, Gerger H, Trelle S, Barth J. Testing the allegiance
bias hypothesis: a meta-analysis. Psychotherapy Research
2011;21(6):670-84.

NICE 2011

National Institute for Health and Care Excellence. Generalised
anxiety disorder and panic disorder (with or without
agoraphobia) in adults: Management in primary, secondary and
community care (CG113). London: National Institute for Health
and Care Excellence 2011.

Ost 2008

Ost L. Efficacy of the third wave of behavioral therapies: a
systematic review and meta-analysis. Behaviour Research and
Therapy 2008;46(3):296-321.

Quitkin 1984

Quitkin FM, Rabkin JG, Ross D, McGrath PJ. Duration of
antidepressant drug treatment: what is an adequate trial?.
Archives of General Psychiatry 1984;41(3):238-245.

Ravindran 2010

Ravindran LN, Stein MB. The pharmacologic treatment of
anxiety disorders: a review of progress. Journal of Clinical
Psychiatry 2010;71(7):839-54.

Reiss 1986

Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity,
anxiety frequency, and the prediction of fearfulness. Behaviour
Research and Therapy 1986;24(1):1-8.

Sadock 2003

Sadock BJ, Kaplan HI, Sadock VA (editors). Kaplan & Sadock's
Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry.
Lippincott Williams & Wilkins, 2003.

Sherbourne C, Sullivana G, Crasked MG, Roy-Byrnee P,
Golinellia D, Rosed RD, et al. Functioning and disability levels
in primary care outpatients with one or more anxiety disorders.
Psychological Medicine 2010;40(12):2059-68.

Spielberger 1989

Spielberger CD, Gorssuch RL, Lushene PR, Vagg PR, Jacobs GA.
Manual for the State-Trait Anxiety Inventory. Consulting
Psychologists Press, 1983.

Spitzer 1978

Spitzer RL, Robins E. Research diagnostic criteria: rationale and
reliability. Archives of General Psychiatry 1978;35(6):773-82.

Starcevic 2009

Starcevic V. Anxiety Disorders in Adults: a Clinical Guide. Oxford
University Press, 2009.

Stiles 2015

Stiles WB, Barkham M, Wheeler S. Effect of duration of
psychological therapy on recovery and improvement rates:
evidence from UK routine practice. British Journal of Psychiatry
2015;207(2):115-122.

Swinson 1992

Swinson RP, Cox BJ, Woszczyna CB. Use of medical services
and treatment for panic disorder with agoraphobia and
for social phobia. Canadian Medical Association Journal
1992;147(6):878-83.

Teasdale 2002

Teasdale JD, Moore RG, Hayhurst H, Pope M, Williams S,
Segal ZV. Metacognitive awareness and prevention of relapse
in depression: empirical evidence. Journal of Consulting and
Clinical Psychology 2002;70(2):275-87.

Sanchez-Meca 2010

Tedeschini 2011

Sanchez-Meca J, Rosa-Alcazar AI, Marin-Martinez F, Gomez-
Conesa A. Psychological treatment of panic disorder with or

Tedeschini E, Fava M, Papakostas GI. Placebo-controlled,
antidepressant clinical trials cannot be shortened to less than 4
weeks' duration: a pooled analysis of randomized clinical trials

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

employing a diagnostic odds ratio–based approach. Journal of
Clinical Psychiatry 2011;72(1):98-113.

Ware 1992

Ware JE Jr, Sherbourne CD. The MOS 36-item short form health
survey (SF-36)  I. Conceptual framework and item selection.
Medical Care 1992;30(6):473-83.

WHO 1992

World Health Organization. The ICD-10 International Statistical
Classification of Diseases and Health Related Problems. Geneva:
World Health Organization, 1992.

Winston 2004

Winston A, Rosenthal RN, Pinsker H. Introduction to Supportive
Psychotherapy. Washington, DC: American Psychiatric
Publishing, 2004.

Wittchen 2002

Wittchen HU. Generalized anxiety disorder: prevalence, burden,
and cost to society. Depression and Anxiety 2002;16:162-71.

Zohar 2000

Zohar J, Westenberg HG. Anxiety disorders: a review of tricyclic
antidepressants and selective serotonin reuptake inhibitors.
Acta Psychiatrica Scandinavica 2000;101(S403):39-49.

* Indicates the major publication for the study

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Ataoglu 2000 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-III-R Panic disorder with no or mild agoraphobic avoidance

Method of diagnosis: not mentioned

Age: for benzodiazepine (alprazolam) arm, M = 31.4 (SD = no data); for CBT arm, M = 30.8 (SD = no data);
range = 18 to 65

Sex: for benzodiazepine (alprazolam) arm, 56% women; 44% men; for CBT arm, 43% women, 56% men

Location: Turkey

Comorbidities: excluded if individuals had current drug or alcohol abuse/dependency, principal diag-
nosis of major depression, and any signs of psychosis or organic brain syndrome

Adjunctive therapy: excluded if individuals had begun taking benzodiazepines or antidepressants
within the previous 6 months

Adjunctive medication: no data

Interventions

Participants were randomly assigned to either:

(1) Benzodiazepine (alprazolam) arm

• Duration: 8 weeks
• Dosing schedule: flexible (from 1 mg to 6 mg)
• Mean dose: no data

(2) CBT arm

• Duration: 8 weeks
• Treatment protocol: 8 weekly individual sessions
• Therapist/face-to-face contact: yes

Outcomes

Time points for assessment: pre- and post-treatment (2 months) and 3 and 4 months' follow-up

Outcomes:

1. Hamilton Anxiety Rating Scale

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ataoglu 2000  (Continued)

Cochrane Database of Systematic Reviews

2. Hamilton Rating Scale for Depression
3. number of panic attacks
4. subjective self monitored level of anxiety using visual analogue scale

Notes

Date of study: not mentioned

Funding source: not mentioned

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Not mentioned

High risk

Participants and personnel could know the intervention allocated.

Unclear risk

There was no description about who assessed the outcomes.

Unclear risk

Authors did not report the number of participants assessed at post-treatment.

Unclear risk

Study protocol was not available.

Researcher allegiance

Unclear risk

Not mentioned

Therapist allegiance

Unclear risk

Not mentioned

Sponsorship bias

Unclear risk

Conflict of interest and funding were not mentioned.

Other bias

Low risk

We found no other bias.

Azhar 2000 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-IV Panic disorder

Method of diagnosis: not mentioned

Age: for CBT arm, M = 31.7 (SD = 8.1); for fluvoxamine arm, M = 31.4 (SD = 7.5); range = 18 to 44

Sex: no data

Location: Malaysia

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Azhar 2000  (Continued)

Comorbidities: excluded if individuals had other psychiatric disorders

Adjunctive therapy: not mentioned

Adjunctive medication: no data

Interventions

Participants were randomly assigned to either:

(1) Fluvoxamine arm

• Duration: 9 weeks
• Dosing schedule: flexible (from 50 mg to 200 mg)
• Mean dose: 153.6 mg

(2) CBT arm

• Duration: 9 weeks
• Treatment protocol: 9 weekly individual sessions
• Therapist/face-to-face contact: yes

(3) CBT plus fluvoxamine arm

Outcomes

Time points for assessment: pre- and post-treatment (9 weeks)

Outcomes:

1. Beck Anxiety Inventory
2. Beck Depression Inventory
3. Hamilton Anxiety Scale
4. Hamilton Depression Scale
5. panic frequency per week

Notes

Date of study: not mentioned

Funding source: not mentioned

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Unclear risk

Not mentioned

High risk

Participants and personnel could know the intervention allocated.

Unclear risk

Subjective scale was used.

High risk

Over 20% of outcome data was lost.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Azhar 2000  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

Study protocol is not available.

Researcher allegiance

Unclear risk

Not mentioned

Therapist allegiance

Unclear risk

Not mentioned

Sponsorship bias

Unclear risk

Conflict of interest and funding were not mentioned.

Other bias

Low risk

We found no other bias.

Bakker 1999 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-III-R Panic disorder

Method of diagnosis: not mentioned

Age: paroxetine arm, M = 34.7 (SD = 8.9); clomipramine arm, M = 35.3 (SD = 9.3); CBT arm, M = 33.7 (SD =
8.1); range = 18 to 70

Sex: paroxetine arm, female 68%; clomipramine arm, female, 56%; CBT arm, female 66%

Location: the Netherlands

Comorbidities: severe somatic diseases were excluded

Adjunctive therapy: not mentioned

Adjunctive medication: individuals who used antidepressants, neuroleptics, or benzodiazepines were
included if they were able to stop taking the medications before the placebo run-in period

Interventions

Participants were randomly assigned to either:

(1) Paroxetine arm

• Duration: 12 weeks
• Dosing schedule: flexible (from 10 mg to 60 mg)
• Mean dose: 36.2 mg

(2) Clomipramine arm

• Duration: 12 weeks
• Dosing schedule: flexible (from 10 mg to 150 mg)
• Mean dose: 90.6 mg

(3) CBT arm

• Duration: 12 weeks
• Treatment protocol: 12 weekly individual sessions
• Therapist/face-to-face contact: yes

(4) Placebo arm

Outcomes

Time points for assessment: pre- and post-treatment (12 weeks)

Outcomes:

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bakker 1999  (Continued)

1. mean number of panic attacks per week
2. Clinical Global Impression
3. Hamilton Rating Scale for Anxiety
4. Montgomery-Asberg Depression Rating Scale
5. Marks-Sheehan Phobia Scale
6. Patient Global Evaluation
7. Sheehan Disability Scale

Cochrane Database of Systematic Reviews

Notes

Date of study: not mentioned

Funding source: SmithKline Beecham Phamaceuticals

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Not mentioned

High risk

Medication was provided in a double-blinded fashion, however psychological
therapy could not be blinded.

High risk

Subjective scale was used.

High risk

Over 20% of outcome data was lost.

Unclear risk

Study protocol is not available.

Researcher allegiance

Unclear risk

Not mentioned

Therapist allegiance

High risk

Cognitive therapy was provided by psychologists and psychiatrists with broad
experience in cognitive behavioural treatments, whereas medication was ad-
ministered by residents in psychiatry.

Sponsorship bias

High risk

The study was funded by manufacturer of the pharmacological intervention.

Other bias

Low risk

We found no other bias.

Barlow 2000 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-III-R Panic disorder with or without mild agoraphobia

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Barlow 2000  (Continued)

Cochrane Database of Systematic Reviews

Method of diagnosis: Anxiety Disorder Interview Schedule-Revised

Age: imipramine arm, M = 35.5 (SD = 9.7); CBT arm, M = 37.5 (SD = 10.9); range = 18 to 65

Sex: imipramine arm, female 60%; CBT arm, female, 63%

Location: USA

Comorbidities: bipolar, significant medical illness, suicidally, significant substance abuse were exclud-
ed. Patients with comorbid unipolar depression were included unless suicidal.

Adjunctive therapy: not mentioned

Adjunctive medication: benzodiazepines were permitted up to 20 doses during baseline and acute
treatment.

Interventions

Participants were randomly assigned to either:

(1) Imipramine arm

• Duration: 12 weeks
• Dosing schedule: flexible (from 200 mg to 300 mg)
• Mean dose: no data

(2) CBT arm

• Duration: 12 weeks
• Treatment protocol: 11 sessions during 12 weeks
• Therapist/face-to-face contact: yes

(3) Placebo arm

(4) CBT plus imipramine arm

(5) CBT plus placebo arm

Outcomes

Time points for assessment: pre- and post-treatment (12 weeks)

Outcomes:

1. Panic Disorder Severity Scale (PDSS)
2. 40% reduction from baseline on PDSS
3. Clinical Global Impression

Notes

Date of study: from May 1991 to April 1998

Funding source: National Institute of Mental Health grant. Imipramine and matching placebo were
provided by Teva Pharmaceuticals USA.

Declarations of interest among the primary researchers: Dr. Barlow has received research support
from Pfizer and the National Institute of Mental Health and has served as a consultant for or received
honoraria or royalties from Guilford Press, The Psychological Corporation, and Wyeth-Ayerst Pharma-
ceuticals.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Barlow 2000  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Not mentioned

High risk

Medication was provided in a double-blinded fashion, however psychological
therapy could not be blinded.

Low risk

Assessors were blind to treatment assignment.

Low risk

All randomised participants were entered into the analysis.

Unclear risk

Study protocol is not available.

Researcher allegiance

High risk

One of the authors made a treatment manual of one arm.

Therapist allegiance

Low risk

Both treatments were followed by treatment manuals.

Sponsorship bias

High risk

The study was supported by the manufacturer of the pharmacological inter-
vention.

Other bias

Low risk

We found no other bias.

Black 1993 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-III-R Panic disorder

Method of diagnosis: Structured Clinical Interview for DSM-III-R

Age: fluvoxamine arm, M = 35.1 (SD = 10.4); CBT arm, M = 38.7 (SD = 12.4); range = 18 to 65

Sex: fluvoxamine arm, female 60%; CBT arm, female, 88%

Location: USA

Comorbidities: individuals with current or past major depression were included. Individuals who were
psychotic, suicidal, or demented, or who had significant medical illness were excluded.

Adjunctive therapy: additional psychotherapies were not allowed.

Adjunctive medication: additional psychotropic medication was not allowed.

Interventions

Participants were randomly assigned to either:

(1) Fluvoxamine arm

• Duration: 8 weeks
• Dosing schedule: flexible (from 50 mg to 300 mg)
• Mean dose: 230 mg

(2) CBT arm

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Black 1993  (Continued)

• Duration: 8 weeks
• Treatment protocol: 8 weekly sessions
• Therapist/face-to-face contact: yes

(3) Placebo arm

Cochrane Database of Systematic Reviews

Outcomes

Time points for assessment: pre-treatment, 4 weeks, post-treatment (8 weeks)

Outcomes:

1. number of panic attacks per week
2. weekly panic attack severity score
3. Clinical Anxiety Scale
4. Clinical Global Impression
5. Sheehan Disability Scale
6. Montgomery-Asberg Rating Scale

Notes

Date of study: not mentioned

Funding source: the study was sponsored in part through a grant from Reid-Rowell Pharmaceuticals
Inc.

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Not mentioned

High risk

Medication was provided in a double-blinded fashion, however psychological
therapy could not be blinded.

High risk

The assessor was not blind to allocation.

Low risk

All randomised participants were entered into the analysis.

Unclear risk

Study protocol is not available.

Researcher allegiance

Low risk

Researchers used the existing treatment manual made by others.

Therapist allegiance

High risk

Cognitive therapy was performed by professional cognitive therapist.

Sponsorship bias

High risk

The study was funded by manufacturer of the pharmacological intervention.

Other bias

Low risk

We found no other bias.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bressi 2010 

Methods

Participants

Study design: randomised controlled trial

Diagnosis: DSM-IV-TR Anxiety disorder (panic disorder, generalised anxiety disorder, social phobia) or
depressive disorder (major depressive disorder, dysthymic disorder)

Method of diagnosis: Structured Clinical Interview for DSM-IV-TR

Age: not shown for participants with panic disorder. As a whole, for psychodynamic therapy arm, M =
35.8 (SD = 9.3); for non-specific SSRI/SNRI arm, M = 38.7 (SD = 9.3); range = 18 to 60

Sex: not shown for participants with panic disorder. As a whole, for psychodynamic therapy arm, fe-
male 77%; for non-specific SSRI/SNRI arm, female 77%

Location: Italy

Comorbidities: individuals with evidence of mental retardation, lifetime history of organic mental dis-
orders, schizophrenic disorders, bipolar disorders, substance abuse, severe axis II psychopathology
were excluded.

Adjunctive therapy: not allowed

Adjunctive medication: benzodiazepines at a maximum of 3 mg lorazepam equivalent per day and
zolpidem tartrate (5 mg to 10 mg) were allowed during the first 3 weeks of the study.

Interventions

Participants were randomly assigned to either:

(1) Psychodynamic therapy arm

• Duration: 40 weeks
• Treatment protocol: 40 weekly sessions
• Therapist/face-to-face contact: yes

(2) Non-specific SSRI/SNRI arm

• Duration: 40 weeks
• Dosing schedule: flexible. Although participants had to be taking SSRI/SNRI, drug treatment was not

standardised.

• Dose range (mean dose): sertraline, 50 mg to 100 mg (62.5 mg); paroxetine, 20 mg to 40 mg (24.0 mg);
citalopram, 10 mg to 20 mg (33.3 mg); venlafaxine, 75 mg to 225 mg (112.5 mg); duloxetine, 60 mg to
120 mg (80.0 mg)

Outcomes

Time points for assessment: pre- and post-treatment (12 weeks)

Outcomes:

1. Clnical Global Impression
2. Symptom Checklist-90-Revised

Notes

Date of study: October 2005 to October 2007

Funding source: not mentioned

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bressi 2010  (Continued)

Random sequence genera-
tion (selection bias)

Low risk

Computer-generated random numbers were used.

Allocation concealment
(selection bias)

Low risk

Allocation was made by the computer at the same time as random number
generation.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Participants and personnel could know the intervention allocated.

Unclear risk

Not mentioned

Low risk

Missing outcomes were few.

Unclear risk

Study protocol is not available.

Researcher allegiance

Low risk

Researchers used existing treatment manual made by others.

Therapist allegiance

High risk

The therapists were psychiatrists who were trained in psychodynamic psy-
chotherapy and who had long experience in practicing the intervention.

Sponsorship bias

Unclear risk

Conflict of interest and funding were not mentioned.

Other bias

Low risk

We found no other bias.

Clark 1994 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-III-R Panic disorder with no, mild, or moderate agoraphobic avoidance

Method of diagnosis: Structured Clinical Interview for DSM-III-R

Age: for included participants, M = 34.6 (SD = 9.2); range = 18 to 60

Sex: 19% female

Location: UK

Comorbidities: individuals with organic mental disorder, schizophrenia, alcohol or drug dependence,
cardiovascular disease, asthma, epilepsy were excluded.

Adjunctive therapy: not mentioned

Adjunctive medication: CBT arm, 35%; applied relaxation arm, 40%; imipramine arm, 30%

Interventions

Participants were randomly assigned to either:

(1) CBT arm

• Duration: 24 weeks

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Clark 1994  (Continued)

Cochrane Database of Systematic Reviews

• Treatment protocol: 12 weekly sessions in the first 3 months and up to 3 booster sessions in the next

3 months

• Therapist/face-to-face contact: yes

(2) Applied relaxation arm

• Duration: 24 weeks
• Treatment protocol: 2 weekly sessions in the first 3 months and up to 3 booster sessions in the next

3 months

• Therapist/face-to-face contact: yes

(3) Imipramine arm

• Duration: 24 weeks
• Dosing schedule: flexible (10 mg to 300 mg)
• Mean dose: 233 mg

(4) Waiting list

Outcomes

Time points for assessment: pre- and post-treatment (12 weeks)

Outcomes:

1. frequency of panic attacks
2. panic-related distress/disability
3. Beck Anxiety Inventory
4. Hamilton Anxiety Rating Scale
5. Fear Questionnaire
6. modified Marks & Mathews Questionnaire
7. Bodily Sensation Questionnaire
8. Body Sensation Interpretation Questionnaire
9. Agoraphobic Cognitions Questionnaire
10.Beck Depression Inventory

Notes

Date of study: not mentioned

Funding source: funded by grants from the Medical Research Council of the UK, the North Atlantic
Treaty Organization, and the Wellcome Trust

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 

Unclear risk

Not mentioned

High risk

Participants and personnel could know the intervention allocated.

Unclear risk

Subjective scale was used.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Clark 1994  (Continued)

All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Low risk

Missing outcomes were few.

Unclear risk

Study protocol is not available.

Researcher allegiance

High risk

One of the researchers made treatment manual for psychological treatment.

Therapist allegiance

Unclear risk

Not mentioned

Sponsorship bias

Unclear risk

Conflict of interest was not mentioned.

Other bias

Low risk

We found no other bias.

Dannon 2004 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-IV-TR Panic disorder or panic disorder with agoraphobia

Method of diagnosis: authors said that a semi-structured psychiatric interview was used, however
they did not mention the method.

Age: paroxetine arm, M = 45.1 (SD = 11.9); CBT arm, M = 44.8 (SD = 13.1); range = 18 to

Sex: paroxetine arm, 59% female; CBT arm, 57% female

Location: Israel

Comorbidities: individuals with comorbid psychiatric diagnosis were excluded.

Adjunctive therapy: not mentioned

Adjunctive medication: not allowed

Interventions

Participants were randomly assigned to either:

(1) CBT arm

• Duration: 8 weeks
• Treatment protocol: 8 weekly sessions
• Therapist/face-to-face contact: yes

(2) Paroxetine arm

• Duration: 8 weeks
• Dosing schedule: flexible (10 mg to 40 mg)
• Mean dose: not mentioned

Outcomes

Time points for assessment: pre-treatment, 4 weeks, and post-treatment (12 weeks)

Outcomes:

1. Hamilton Rating Scale for Anxiety

Notes

Date of study: not mentioned

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dannon 2004  (Continued)

Cochrane Database of Systematic Reviews

Funding source: partially supported by a personal grant to Dr. Pinchas Dannon from the Chief Scientist
Office, the Ministry of Health, Israel

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Not mentioned

High risk

Participants and personnel could know the intervention allocated.

High risk

Subjective scale was used.

Low risk

Missing outcomes were few.

Unclear risk

Study protocol is not available.

Researcher allegiance

Low risk

Researcher used existing treatment manual made by others.

Therapist allegiance

Unclear risk

Insufficient information

Sponsorship bias

Unclear risk

Conflict of interest was not mentioned.

Other bias

Low risk

We found no other bias.

Hendriks 2010 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-IV-TR Panic disorder or panic disorder with agoraphobia

Method of diagnosis: Anxiety Disorders Interview Schedule-Revised

Age: paroxetine arm, M = 68.8 (SD = 4.3); CBT arm, M = 69.6 (SD = 5.0); range = 60 to

Sex: paroxetine arm, 58.8% female; CBT arm, 55.0% female

Location: the Netherlands

Comorbidities: individuals with comorbid severe psychiatric disorder, dementia, substance abuse,
and severe somatic condition were excluded.

Adjunctive therapy: not mentioned

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hendriks 2010  (Continued)

Adjunctive medication: (oxazepam 10 mg): for paroxetine arm, 58.8%; for CBT arm, 55.0%

Interventions

Participants were randomly assigned to either:

(1) CBT arm

• Duration: 14 weeks
• Treatment protocol: 14 weekly sessions
• Therapist/face-to-face contact: yes

(2) Paroxetine arm

• Duration: 14 weeks
• Dosing schedule: fixed (started from 10 mg, increased by 10 mg per week, and fixed at 40 mg after

4 weeks)

• Mean dose: not mentioned

(3) Waiting list arm

Outcomes

Time points for assessment: pre-treatment, 8 weeks, and post-treatment (14 weeks)

Outcomes:

1. Agoraphobic Cognitions Questionnaire
2. Mobility Inventory Avoidance Scale
3. Symptom Checklist-90

Notes

Date of study: not mentioned

Funding source: one of the authors received an unconditional research grant from GlaxoSmithKline.

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Not mentioned

High risk

Participants and personnel could know the intervention allocated.

High risk

Self report questionnaire was used.

Low risk

Missing outcomes were few.

Unclear risk

Study protocol is not available.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hendriks 2010  (Continued)

Researcher allegiance

Unclear risk

Not mentioned

Therapist allegiance

Unclear risk

Not mentioned

Sponsorship bias

High risk

One of the authors received an unconditional research grant from the manu-
facturer of the pharmacological intervention.

Other bias

Low risk

We found no other bias.

Klosko 1988 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-III Panic disorder

Method of diagnosis: Anxiety Disorders Interview Schedule-Revised (ADIS-R) was used.

Age: alprazolam arm, M = 38.3 (SD = 6.9); CBT arm, M = 31.3 (SD = 8.0); range = 18 to 65

Sex: alprazolam arm, 75.0% female; CBT arm, 73.3% female

Location: USA

Comorbidities: individuals with major depression were excluded only if depression predominated over
panic disorder at the time of presentation and if depression preceded panic disorder chronologically.

Adjunctive therapy: not allowed

Adjunctive medication: not allowed

Interventions

Participants were randomly assigned to either:

(1) CBT arm

• Duration: 15 weeks
• Treatment protocol: 15 weekly sessions
• Therapist/face-to-face contact: yes

(2) Paroxetine arm

• Duration: 15 weeks
• Dosing schedule: flexible (from 1 mg to 10 mg)
• Mean dose: 4.6 mg

(3) Placebo arm

(4) Waiting list arm

Outcomes

Time points for assessment: pre-treatment and post-treatment (15 weeks)

Outcomes:

1. ADIS-R
2. Subjective weekly record

Notes

Date of study: not mentioned

Funding source: the study was supported in part by grants from the National Institute of Mental Health
and the Upjohn Company.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Klosko 1988  (Continued)

Risk of bias

Bias

Declarations of interest among the primary researchers: not mentioned

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Not mentioned

High risk

Medication was provided in a double-blinded fashion, however psychological
therapy could not be blinded.

Low risk

Assessor was blind to the allocation.

Low risk

Missing outcomes were few.

Unclear risk

Study protocol is not available.

Researcher allegiance

Low risk

Researcher used existing treatment manual made by others.

Therapist allegiance

Unclear risk

Not mentioned

Sponsorship bias

High risk

The study was supported by the manufacturer of the pharmacological inter-
vention.

Other bias

Low risk

We found no other bias.

Muncy 1991 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-III-R Panic disorder or agoraphobia with panic

Method of diagnosis: not mentioned

Age: p106 for G1 arm, M = 33.1 (SD = 6.0); for G2 arm, M = 36.3 (SD = 11.7); for G3 arm, M = 31.6 (SD = 3.7);
for G4 arm, M = 42.3 (SD = 10.0)

Sex: for G1 arm, 71.4% female; for G2 arm, 62.5% female; for G3 arm, 100% female; for G4 arm, 75.0%
female

Location: USA

Comorbidities: not mentioned

Adjunctive therapy: not allowed

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Muncy 1991  (Continued)

Adjunctive medication: not allowed

Interventions

Participants were randomly assigned to either:

(1) CBT arm

• Duration: 6 weeks
• Treatment protocol: 6 weekly sessions
• Therapist/face-to-face contact: yes

(2) CBT + biofeedback arm

• Duration: 6 weeks
• Treatment protocol: 6 weekly sessions
• Therapist/face-to-face contact: yes

(3) Imipramine arm

• Duration: 6 weeks
• Dosing schedule: fixed (150 mg)
• Mean dose: not mentioned

(4) No-treatment arm

Outcomes

Time points for assessment: pre-treatment and post-treatment (15 weeks)

Outcomes:

1. State-Trait Anxiety Inventory
2. Beck Depression Inventory
3. Minnesota Multiphasic Personality Inventory
4. Millon Clinical Multiaxial Inventory

Notes

Date of study: not mentioned

Funding source: not mentioned

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 

Unclear risk

Not mentioned

High risk

Participants and personnel could know the intervention allocated.

Unclear risk

Not mentioned

High risk

Over 20% of outcome data was lost.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Muncy 1991  (Continued)

All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Not mentioned

Researcher allegiance

Unclear risk

Not mentioned

Therapist allegiance

Unclear risk

Not mentioned

Sponsorship bias

Unclear risk

Conflict of interest was not mentioned.

Other bias

Low risk

We found no other bias.

Prasko 2004 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-IV Panic disorder with or without agoraphobia

Method of diagnosis: the MINI Interview was used.

Age: CBT arm, M = 31.8; SSRI or SNRI arm, M = 31; range = 21 to 44

Sex: CBT arm, 50.0% female; SSRI or SNRI arm, 50.5% female

Location: Czech Republic

Comorbidities: individuals with serious physical illness or psychiatric disorder other than panic disor-
der and agoraphobia were excluded.

Adjunctive therapy: not allowed

Adjunctive medication: not allowed

Interventions

Participants were randomly assigned to either:

(1) CBT arm

• Duration: 12 weeks
• Treatment protocol: 3 weekly sessions for 6 weeks and 2 booster sessions in the 8th and 12th week
• Therapist/face-to-face contact: yes

(2) SSRI or SNRI arm

• Duration: 12 weeks
• Dosing schedule: flexible

Outcomes

Time points for assessment: pre-treatment, 2, 4, 6 weeks, and post-treatment (12 weeks)

Outcomes:

1. Clinical Global Impression
2. Hamilton Rating Scale for Anxiety
3. Panic Disorder Severity Scale

Notes

Date of study: not mentioned

Funding source: The study was supported by the Internal Grant Agency of Ministry of Health.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Prasko 2004  (Continued)

Risk of bias

Bias

Declarations of interest among the primary researchers: not mentioned

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Not mentioned

High risk

Participants and personnel could know the intervention allocated.

Unclear risk

Not mentioned

Low risk

There were no dropouts.

Unclear risk

Study protocol is not available.

Researcher allegiance

Unclear risk

Not mentioned

Therapist allegiance

Unclear risk

Not mentioned

Sponsorship bias

Unclear risk

Conflict of interest was not mentioned.

Other bias

Low risk

We found no other bias.

Sharp 1996 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-III-R Panic disorder with or without agoraphobia

Method of diagnosis: not mentioned

Age: CBT arm, M = 33.2; fluvoxamine arm, M = 36.6; range = 18 to 70

Sex: CBT arm, 82.1% female; fluvoxamine arm, 73.3% female

Location: Scotland

Comorbidities: individuals with obsessive-compulsive disorder, psychotic disorder, manic disorder,
substance dependence, and severe somatic disease were excluded.

Adjunctive therapy: not allowed

Adjunctive medication: not allowed

Interventions

Participants were randomly assigned to either:

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sharp 1996  (Continued)

(1) CBT arm

Cochrane Database of Systematic Reviews

• Duration: 12 weeks
• Treatment protocol: 7 sessions per 12 weeks
• Therapist/face-to-face contact: yes

(2) Fluvoxamine arm

• Duration: 12 weeks
• Dosing schedule: flexible (100 mg to 150 mg)
• Mean dose: not mentioned

(3) Fluvoxamine plus CBT arm

(4) Placebo plus CBT arm

(5) Placebo arm

Outcomes

Time points for assessment: pre-treatment, 6 weeks, post-treatment (12 weeks), and follow-up (6
months)

Outcomes:

1. Fear Questionnaire
2. Hamilton Rating Scale for Anxiety
3. Panic attacks recorded by participants

Notes

Date of study: not mentioned

Funding source: the study was supported in part by Duphar Laboratories Ltd.

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Not mentioned

High risk

Medication was provided in a double-blinded fashion, however psychological
therapy could not be blinded.

High risk

Self report questionnaire was used.

High risk

Over 20% of outcome data was lost.

Unclear risk

Study protocol is not available.

Researcher allegiance

High risk

One of the authors was an employee of the manufacturer of the medication.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sharp 1996  (Continued)

Therapist allegiance

Unclear risk

Insufficient information

Sponsorship bias

High risk

The study was supported by the manufacturer of the pharmacological inter-
vention.

Other bias

Low risk

We found no other bias.

Shear 2000 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-III-R Panic disorder with no more than mild agoraphobia

Method of diagnosis: the Anxiety Disorders Interview Schedule Revised was used.

Age: CBT arm, M = 35.2 (SD = 11.2); psychological support arm, M = 39.2 (SD = 9.4); imipramine arm, M =
36.7 (SD = 11.3)

Sex: CBT arm, 52.8% female; psychological support arm, 76.7% female; imipramine arm, 54.2% female

Location: USA

Comorbidities: individuals with psychotic disorder, bipolar disorder, significant substance abuse, or
significant medical illness were excluded.

Adjunctive therapy: not allowed

Adjunctive medication: not allowed

Interventions

Participants were randomly assigned to either:

(1) CBT arm

• Duration: 12 weeks
• Treatment protocol: 12 weekly sessions
• Therapist/face-to-face contact: yes

(2) Psychological support arm

• Duration: 12 weeks
• Treatment protocol: 12 weekly sessions
• Therapist/face-to-face contact: yes

(3) Imipramine arm

• Duration: 12 weeks
• Dosing schedule: flexible (10 mg to 200 mg)
• Mean dose: not mentioned

(4) Placebo arm

Outcomes

Time points for assessment: pre-treatment, 1, 4, 8, 11 weeks, and follow-up (1, 2, 3, 4, 5, 6 months)

Outcomes:

1. Panic Disorder Severity Scale
2. Anxiety Sensitivity Index
3. Treatment Expectations Form

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Shear 2000  (Continued)

4. Clinical Global Impression

Notes

Date of study: not mentioned

Cochrane Database of Systematic Reviews

Funding source: the study was supported by National Institute of Mental Health grants and Interven-
tion Center grant.

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Not mentioned

High risk

Medication was provided in a double-blinded fashion, however psychological
therapy could not be blinded.

Low risk

Assessor was independent evaluator.

Low risk

All randomised participants were entered into the analysis.

Unclear risk

Study protocol is not available.

Researcher allegiance

Low risk

Researcher used existing treatment manual made by others.

Therapist allegiance

Low risk

Therapists in both treatment arms were trained adequately.

Sponsorship bias

Unclear risk

Conflict of interest was not mentioned.

Other bias

Low risk

We found no other bias.

Taylor 1982 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-III Panic disorder

Method of diagnosis: not mentioned

Age: not mentioned for diazepam arm and relaxation arm

Sex: not mentioned for diazepam arm and relaxation arm

Location: USA

Comorbidities: not mentioned

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Taylor 1982  (Continued)

Adjunctive therapy: not mentioned

Adjunctive medication: not allowed

Interventions

Participants were randomly assigned to either:

(1) Relaxation arm

• Duration: about 6 weeks
• Treatment protocol: up to 5 half-hour sessions
• Therapist/face-to-face contact: yes

(2) Diazepam arm

• Duration: about 6 weeks
• Dosing schedule: flexible (10 mg to 40 mg)
• Mean dose: 84 mg per week

(3) Control arm

(4) Placebo arm

Outcomes

Time points for assessment: pre- and post-treatment

Outcomes:

1. State-Trait Anxiety Scale
2. Profile of Mood States
3. Self-Report diary
4. heart rate

Notes

Date of study: not mentioned

Funding source: the study was supported by Biomedical Research Support Grant. Hoffman-La Roche
supplied diazepam and placebo.

Declarations of interest among the primary researchers: not mentioned

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not mentioned

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Unclear risk

Not mentioned

High risk

Medication was provided in a double-blinded fashion, however psychological
therapy could not be blinded.

Unclear risk

Self report questionnaire was used.

Low risk

All randomised participants were entered into the analysis.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Taylor 1982  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

Study protocol is not available.

Researcher allegiance

Unclear risk

Not mentioned

Therapist allegiance

Unclear risk

Not mentioned

Sponsorship bias

High risk

The study was supported by the manufacturer of the pharmacological inter-
vention.

Other bias

Low risk

We found no other bias.

Tyrer 1988 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-III generalised anxiety disorder, dysthymic disorder, or panic disorder

Method of diagnosis: the Structured Clinical Interview for DSM-III was used.

Age: not shown for participants with panic disorder; range = 17 to 71

Sex: not shown for participants with panic disorder

Location: UK

Comorbidities: individuals with major depressive episode or other psychiatric disorder were excluded.

Adjunctive therapy: during the study other treatments were discouraged. However, participants who
underwent additional treatment were included in the analysis.

Adjunctive medication: if further sedative treatment was necessary, the antihistamine drug promet-
hazine was prescribed in a small dose 810 mg to 30 mg daily).

Interventions

Participants were randomly assigned to either:

(1) CBT arm

• Duration: 6 weeks
• Treatment protocol: 5 sessions at 0, 1, 2, 4, and 6 weeks
• Therapist/face-to-face contact: yes

(2) Diazepam arm

• Duration: 6 weeks
• Dosing schedule: flexible (5 mg to 30 mg)
• Mean dose: not mentioned

(3) Dosulepin arm

• Duration: 6 weeks
• Dosing schedule: flexible (25 mg to 150 mg)
• Mean dose: not mentioned

(4) Placebo arm

(5) Self help arm

Outcomes

Time points for assessment: pre-treatment and 2, 4, 6, 10 weeks

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tyrer 1988  (Continued)

Outcomes:

1. Comprehensive Psychopathological Rating Scale
2. Montgomery-Asberg Depression Rating Scale
3. Brief Scale for Anxiety
4. Hospital Anxiety and Depression Scale
5. General Neurotic Syndrome Scale

Notes

Date of study: not mentioned

Cochrane Database of Systematic Reviews

Funding source: the study was supported by grants from Trent Regional Health Authority, Jessie
Spencer Trust, and Boots Pure Drug Company, who also provided the matching diazepam, dosulepin,
and placebo capsules.

Declarations of interest among the primary researchers: not mentioned

Authors' judgement

Support for judgement

Low risk

Randomisation was made by computer.

Low risk

The randomised treatments were indicated by opening a sealed envelope.

High risk

Medication was provided in a double-blinded fashion, however psychological
therapy could not be blinded.

High risk

Self report questionnaire was used.

Low risk

All randomised participants were entered into the analysis.

Unclear risk

Study protocol is not available.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Researcher allegiance

Unclear risk

Not mentioned

Therapist allegiance

Unclear risk

Not mentioned

Sponsorship bias

High risk

The study was supported by the manufacturer of the pharmacological inter-
vention.

Other bias

Low risk

We found no other bias.

van Apeldoorn 2008 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: DSM-IV Panic disorder with or without agoraphobia

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

van Apeldoorn 2008  (Continued)

Method of diagnosis: the MINI was used.

Age: CBT arm, M = 39.4 (SD = 10.2); SSRI arm, M = 38.5 (SD = 10.5); range = 18 to 65

Sex: CBT arm, 62.3% female; SSRI arm, 54.2% female

Location: the Netherlands

Comorbidities: psychotic or severely depressed patients were excluded.

Adjunctive therapy: during the study other treatments were discouraged. However, participants who
underwent additional treatment were included in the analysis.

Adjunctive medication: small dose of benzodiazepines was allowed (maximum the equivalent of 20
mg of oxazepam per day).

Interventions

Participants were randomly assigned to either:

(1) CBT arm

• Duration: 36 weeks
• Treatment protocol: up to 18 sessions
• Therapist/face-to-face contact: yes

(2) SSRI or SNRI arm

• Duration: 36 weeks
• Dosing schedule: flexible

Outcomes

Time points for assessment: pre-treatment and 2, 4, 6, 10 weeks

Outcomes:

1. Hamilton Anxiety Rating Scale
2. Panic Appraisal Inventory
3. Fear Questionnaire
4. 36-Item Short Form Health Survey (SF-36)
5. Hamilton Depression Rating Scale
6. Client Satisfaction Questionnaire

Notes

Date of study: not mentioned

Funding source: the study was funded by the Dutch Health Insurance Board.

Declarations of interest among the primary researchers: no financial or commercial involvements
that might present a conflict of interest in connection with the study were present.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Raffle tickets were used.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Low risk

The random number was contained in an envelope.

High risk

Participants and personnel could know the intervention allocated.

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

van Apeldoorn 2008  (Continued)

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Self report questionnaire was used.

Low risk

All randomised participants were entered into the analysis.

High risk

Some registered outcomes were not reported.

Researcher allegiance

Low risk

Researcher used existing treatment manual made by others.

Therapist allegiance

Low risk

Therapists in both treatment arms were trained adequately.

Sponsorship bias

Low risk

No financial and commercial involvements were present.

Other bias

Low risk

We found no other bias.

CBT: cognitive behavioural therapy
DSM: Diagnostic and Statistical Manual of Mental Disorders
M: mean
SD: standard deviation
SNRI: serotonin–norepinephrine reuptake inhibitor
SSRI: selective serotonin reuptake inhibitor

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Borkovec 1988

Participants were heterogeneous, however randomisation was not stratified.

Echeburua 1993

Participants were patients with agoraphobia but without panic attacks.

Echeburua 2006

Psychiatrist decided treatment in control arm.

Huppert 2004

Participants were heterogeneous, however randomisation was not stratified.

Lang 2006

Primary care provider decided treatment in control arm.

Schuurmans 2006

Participants were heterogeneous, however randomisation was not stratified.

Spinhoven 1996

Participants were permitted regular benzodiazepine use in the psychological therapy arm, and
some of the participants in the arm used benzodiazepine, which is regarded as a mixture of combi-
nation therapy and psychological therapy alone.

Characteristics of studies awaiting assessment [ordered by study ID]

Prasko 2004b 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: panic disorder

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Prasko 2004b  (Continued)

Cochrane Database of Systematic Reviews

Method of diagnosis: not stated

Age: not stated

Sex: 77% female

Location: not stated

Comorbidities: not stated

Adjunctive therapy: not stated

Adjunctive medication: not stated

Interventions

Participants were randomly assigned to either:

(1) CBT arm

• Duration: 12 weeks
• Treatment protocol: not stated
• Therapist/face-to-face contact: not stated

(2) Paroxetine arm

• Duration: 12 weeks
• Dosing schedule: not stated

Outcomes

Time points for assessment: every week

Outcomes:

1. Hamilton Axiety Rating Scale
2. Global Impression Scale

Notes

We contacted the author to ask for details, but have not yet received an answer.

Takriti 1989 

Methods

Study design: randomised controlled trial

Participants

Diagnosis: panic disorder with or without agoraphobia

Method of diagnosis: not stated

Age: not stated

Sex: 77% female

Location: not stated

Comorbidities: not stated

Adjunctive therapy: not stated

Adjunctive medication: not stated

Interventions

Participants were randomly assigned to either:

(1) CBT arm

• Duration: 12 weeks

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Takriti 1989  (Continued)

• Treatment protocol: not stated
• Therapist/face-to-face contact: not stated

(2) Alprazolam arm

• Duration: 12 weeks
• Dosing schedule: not stated

Cochrane Database of Systematic Reviews

Outcomes

Time points for assessment: every week

Outcomes:

1. Hamilton Axiety Rating Scale
2. Panic symptom questionnaire derived from DSM-III-R

Notes

We were unable to retrieve the article and could only refer to abstract.

CBT: cognitive behavioural therapy
DSM: Diagnostic and Statistical Manual of Mental Disorders

D A T A   A N D   A N A L Y S E S

Comparison 1.   All psychological therapies versus SSRI

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

1.1 CBT versus SSRI

2 Short-term response

2.1 CBT versus SSRI

3 Dropouts for any reason

3.1 CBT versus SSRI

4 Short-term improvement

4.1 CBT versus SSRI

6

6

5

5

6

6

5

5

334

334

277

277

334

334

242

242

Risk Ratio (M-H, Random, 95% CI)

0.85 [0.62, 1.17]

Risk Ratio (M-H, Random, 95% CI)

0.85 [0.62, 1.17]

Risk Ratio (M-H, Random, 95% CI)

0.97 [0.51, 1.86]

Risk Ratio (M-H, Random, 95% CI)

0.97 [0.51, 1.86]

Risk Ratio (M-H, Random, 95% CI)

1.33 [0.80, 2.22]

Risk Ratio (M-H, Random, 95% CI)

1.33 [0.80, 2.22]

Std. Mean Difference (IV, Random,
95% CI)

-0.20 [-1.09, 0.69]

Std. Mean Difference (IV, Random,
95% CI)

-0.20 [-1.09, 0.69]

Analysis 1.1.   Comparison 1 All psychological therapies versus SSRI, Outcome 1 Short-term remission.

Study or subgroup

1.1.1 CBT versus SSRI

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Azhar 2000

Bakker 1999

Black 1993

Dannon 2004

Hendriks 2010

Sharp 1996

Subtotal (95% CI)

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2/22

14/35

12/25

23/24

13/20

23/43

169

0/22

21/32

18/25

27/33

12/17

24/36

165

1.07%

17.16%

17.2%

25.88%

18.1%

20.6%

100%

5[0.25,98.52]

0.61[0.38,0.98]

0.67[0.41,1.07]

1.17[0.98,1.4]

0.92[0.59,1.44]

0.8[0.56,1.15]

0.85[0.62,1.17]

Total events: 87 (Psychological therapies), 102 (SSRI)

Heterogeneity: Tau2=0.09; Chi2=16.17, df=5(P=0.01); I2=69.09%

Test for overall effect: Z=0.98(P=0.33)

Total (95% CI)

169

165

100%

0.85[0.62,1.17]

Total events: 87 (Psychological therapies), 102 (SSRI)

Heterogeneity: Tau2=0.09; Chi2=16.17, df=5(P=0.01); I2=69.09%

Test for overall effect: Z=0.98(P=0.33)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 1.2.   Comparison 1 All psychological therapies versus SSRI, Outcome 2 Short-term response.

Study or subgroup

1.2.1 CBT versus SSRI

Azhar 2000

Bakker 1999

Black 1993

Hendriks 2010

Sharp 1996

Subtotal (95% CI)

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

17/22

10/35

6/25

9/20

20/43

145

5/22

20/32

12/25

7/17

15/36

132

18.52%

21.34%

18.46%

19.27%

22.41%

100%

3.4[1.52,7.59]

0.46[0.25,0.82]

0.5[0.22,1.12]

1.09[0.52,2.31]

1.12[0.68,1.84]

0.97[0.51,1.86]

Total events: 62 (Psychological therapies), 59 (SSRI)

Heterogeneity: Tau2=0.42; Chi2=18.58, df=4(P=0); I2=78.47%

Test for overall effect: Z=0.08(P=0.94)

Total (95% CI)

145

132

100%

0.97[0.51,1.86]

Total events: 62 (Psychological therapies), 59 (SSRI)

Heterogeneity: Tau2=0.42; Chi2=18.58, df=4(P=0); I2=78.47%

Test for overall effect: Z=0.08(P=0.94)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 1.3.   Comparison 1 All psychological therapies versus SSRI, Outcome 3 Dropouts for any reason.

Study or subgroup

1.3.1 CBT versus SSRI

Azhar 2000

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5/22

5/22

18.17%

1[0.34,2.97]

Favour psychotherapy

0.01

0.1

1

10

100

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Bakker 1999

Black 1993

Dannon 2004

Hendriks 2010

Sharp 1996

Subtotal (95% CI)

Psychological
therapies

n/N

SSRI

n/N

9/35

9/25

1/24

2/20

13/43

169

4/32

4/25

6/33

3/17

7/36

165

Total events: 39 (Psychological therapies), 29 (SSRI)

Heterogeneity: Tau2=0.06; Chi2=5.91, df=5(P=0.32); I2=15.36%

Test for overall effect: Z=1.1(P=0.27)

Cochrane Database of Systematic Reviews

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

18.56%

19.65%

5.84%

8.59%

29.18%

100%

2.06[0.7,6.03]

2.25[0.8,6.36]

0.23[0.03,1.78]

0.57[0.11,3.01]

1.55[0.7,3.48]

1.33[0.8,2.22]

Total (95% CI)

169

165

100%

1.33[0.8,2.22]

Total events: 39 (Psychological therapies), 29 (SSRI)

Heterogeneity: Tau2=0.06; Chi2=5.91, df=5(P=0.32); I2=15.36%

Test for overall effect: Z=1.1(P=0.27)

Favour psychotherapy

0.01

0.1

1

10

100

Favour medication

Analysis 1.4.   Comparison 1 All psychological therapies versus SSRI, Outcome 4 Short-term improvement.

Study or subgroup

Psychologi-
cal therapies

SSRI

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.4.1 CBT versus SSRI

Azhar 2000

Bakker 1999

Black 1993

Hendriks 2010

Sharp 1996

Subtotal ***

17

35

25

18

30

125

3.6 (2.2)

3.6 (1.4)

2.5 (1)

1.4 (0.4)

5.1 (5.4)

17

32

25

14

29

117

9.1 (2)

2.4 (1.1)

2 (1.7)

1.4 (0.4)

5.5 (7.9)

Heterogeneity: Tau2=0.92; Chi2=42.54, df=4(P<0.0001); I2=90.6%

Test for overall effect: Z=0.44(P=0.66)

Total ***

125

117

Heterogeneity: Tau2=0.92; Chi2=42.54, df=4(P<0.0001); I2=90.6%

Test for overall effect: Z=0.44(P=0.66)

18.01%

20.88%

20.58%

19.68%

20.86%

100%

-2.53[-3.45,-1.6]

0.94[0.43,1.44]

0.35[-0.21,0.91]

0[-0.7,0.7]

-0.06[-0.57,0.45]

-0.2[-1.09,0.69]

100%

-0.2[-1.09,0.69]

Favour psychotherapy

-2

-1

0

1

2

Favour medication

Comparison 2.   All psychological therapies versus tricyclic antidepressants

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

1.1 CBT versus Tricyclic antidepres-
sants

3

3

229

151

Risk Ratio (M-H, Random,
95% CI)

0.82 [0.62, 1.09]

Risk Ratio (M-H, Random,
95% CI)

0.88 [0.63, 1.22]

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.2 BT versus Tricyclic antidepres-
sants

1.3 Supportive psychological therapy
versus Tricyclic antidepressants

2 Short-term response

2.1 CBT versus Tricyclic antidepres-
sants

2.2 BT versus Tricyclic antidepres-
sants

2.3 Supportive psychological therapy
versus Tricyclic antidepressants

3 Dropouts for any reason

3.1 CBT versus Tricyclic antidepres-
sants

3.2 BT versus Tricyclic antidepres-
sants

3.3 Supportive psychological therapy
versus Tricyclic antidepressants

4 Short-term improvement

4.1 CBT versus Tricyclic antidepres-
sants

4.2 BT versus Tricyclic antidepres-
sants

4.3 Supportive psychological therapy
versus Tricyclic antidepressants

1

1

4

4

1

1

5

5

1

1

5

5

1

1

36

42

270

192

36

42

430

352

36

42

414

342

30

42

Risk Ratio (M-H, Random,
95% CI)

0.7 [0.28, 1.75]

Risk Ratio (M-H, Random,
95% CI)

0.69 [0.36, 1.31]

Risk Ratio (M-H, Random,
95% CI)

0.75 [0.51, 1.10]

Risk Ratio (M-H, Random,
95% CI)

0.79 [0.51, 1.25]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.10, 9.96]

Risk Ratio (M-H, Random,
95% CI)

0.6 [0.27, 1.32]

Risk Ratio (M-H, Random,
95% CI)

0.83 [0.53, 1.30]

Risk Ratio (M-H, Random,
95% CI)

0.93 [0.53, 1.64]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.56 [0.22, 1.42]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.20 [-0.03, 0.43]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.13 [-0.14, 0.40]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.47 [-0.30, 1.24]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.56 [-0.12, 1.24]

Analysis 2.1.   Comparison 2 All psychological therapies versus
tricyclic antidepressants, Outcome 1 Short-term remission.

Study or subgroup

Psychological
therapies

Tricyclic anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

2.1.1 CBT versus Tricyclic antidepressants

Bakker 1999

Clark 1994

14/35

13/24

17/32

6/12

29.46%

17.49%

0.75[0.45,1.27]

1.08[0.55,2.13]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

Tricyclic anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Shear 2000

Subtotal (95% CI)

19/36

95

7/12

56

Total events: 46 (Psychological therapies), 30 (Tricyclic antidepressants)

Heterogeneity: Tau2=0; Chi2=0.72, df=2(P=0.7); I2=0%

Test for overall effect: Z=0.77(P=0.44)

2.1.2 BT versus Tricyclic antidepressants

Clark 1994

Subtotal (95% CI)

7/24

24

5/12

12

Total events: 7 (Psychological therapies), 5 (Tricyclic antidepressants)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.76(P=0.44)

2.1.3 Supportive psychological therapy versus Tricyclic antidepres-
sants

Shear 2000

Subtotal (95% CI)

12/30

30

7/12

12

Total events: 12 (Psychological therapies), 7 (Tricyclic antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.14(P=0.25)

Total (95% CI)

149

80

Total events: 65 (Psychological therapies), 42 (Tricyclic antidepressants)

Heterogeneity: Tau2=0; Chi2=1.28, df=4(P=0.86); I2=0%

Test for overall effect: Z=1.39(P=0.17)

Test for subgroup differences: Chi2=0.56, df=1 (P=0.76), I2=0%

24.59%

71.54%

0.9[0.51,1.6]

0.88[0.63,1.22]

9.52%

9.52%

0.7[0.28,1.75]

0.7[0.28,1.75]

18.94%

18.94%

0.69[0.36,1.31]

0.69[0.36,1.31]

100%

0.82[0.62,1.09]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 2.2.   Comparison 2 All psychological therapies versus
tricyclic antidepressants, Outcome 2 Short-term response.

Study or subgroup

Psychological
therapies

Tricyclic anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

2.2.1 CBT versus Tricyclic antidepressants

Bakker 1999

Clark 1994

Shear 2000

Tyrer 1988

Subtotal (95% CI)

10/35

2/24

14/36

9/34

129

12/32

1/12

6/12

2/7

63

Total events: 35 (Psychological therapies), 21 (Tricyclic antidepressants)

Heterogeneity: Tau2=0; Chi2=0.11, df=3(P=0.99); I2=0%

Test for overall effect: Z=1(P=0.32)

2.2.2 BT versus Tricyclic antidepressants

Clark 1994

Subtotal (95% CI)

2/24

24

1/12

12

Total events: 2 (Psychological therapies), 1 (Tricyclic antidepressants)

Heterogeneity: Not applicable

31.25%

2.81%

30.39%

8.79%

73.24%

0.76[0.38,1.52]

1[0.1,9.96]

0.78[0.39,1.56]

0.93[0.25,3.39]

0.79[0.51,1.25]

2.81%

2.81%

1[0.1,9.96]

1[0.1,9.96]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

Tricyclic anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Not applicable

2.2.3 Supportive psychological therapy versus Tricyclic antidepres-
sants

Shear 2000

Subtotal (95% CI)

9/30

30

6/12

12

Total events: 9 (Psychological therapies), 6 (Tricyclic antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.27(P=0.2)

Total (95% CI)

183

87

Total events: 46 (Psychological therapies), 28 (Tricyclic antidepressants)

Heterogeneity: Tau2=0; Chi2=0.55, df=5(P=0.99); I2=0%

Test for overall effect: Z=1.48(P=0.14)

Test for subgroup differences: Chi2=0.43, df=1 (P=0.81), I2=0%

23.95%

23.95%

0.6[0.27,1.32]

0.6[0.27,1.32]

100%

0.75[0.51,1.1]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 2.3.   Comparison 2 All psychological therapies versus
tricyclic antidepressants, Outcome 3 Dropouts for any reason.

Study or subgroup

Psychological
therapies

Tricyclic anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

2.3.1 CBT versus Tricyclic antidepressants

Bakker 1999

Barlow 2000

Clark 1994

Shear 2000

Tyrer 1988

Subtotal (95% CI)

9/35

21/77

0/24

14/36

2/34

206

3/32

32/83

0/12

5/12

1/7

146

Total events: 46 (Psychological therapies), 41 (Tricyclic antidepressants)

Heterogeneity: Tau2=0.12; Chi2=4.71, df=3(P=0.19); I2=36.34%

Test for overall effect: Z=0.25(P=0.81)

2.3.2 BT versus Tricyclic antidepressants

Clark 1994

Subtotal (95% CI)

0/24

24

0/12

12

Total events: 0 (Psychological therapies), 0 (Tricyclic antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

2.3.3 Supportive psychological therapy versus Tricyclic antidepres-
sants

Shear 2000

Subtotal (95% CI)

7/30

30

5/12

12

Total events: 7 (Psychological therapies), 5 (Tricyclic antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.22(P=0.22)

11.68%

43.41%

23.16%

3.79%

82.03%

2.74[0.81,9.25]

0.71[0.45,1.11]

Not estimable

0.93[0.43,2.05]

0.41[0.04,3.94]

0.93[0.53,1.64]

Not estimable

Not estimable

17.97%

17.97%

0.56[0.22,1.42]

0.56[0.22,1.42]

Favour psychotherapy

0.01

0.1

1

10

100

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

Tricyclic anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Total (95% CI)

260

170

Total events: 53 (Psychological therapies), 46 (Tricyclic antidepressants)

Heterogeneity: Tau2=0.07; Chi2=5.36, df=4(P=0.25); I2=25.34%

Test for overall effect: Z=0.81(P=0.42)

Test for subgroup differences: Chi2=0.84, df=1 (P=0.36), I2=0%

100%

0.83[0.53,1.3]

Favour psychotherapy

0.01

0.1

1

10

100

Favour medication

Analysis 2.4.   Comparison 2 All psychological therapies versus
tricyclic antidepressants, Outcome 4 Short-term improvement.

Study or subgroup

Psychologi-
cal therapies

Tricyclic anti-
depressants

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.4.1 CBT versus Tricyclic antidepressants

Bakker 1999

Barlow 2000

Clark 1994

Shear 2000

Tyrer 1988

Subtotal ***

3.6 (1.4)

1.1 (0.7)

20.5 (5.3)

1.1 (0.8)

15.6 (6.9)

35

77

20

36

31

199

Heterogeneity: Tau2=0.02; Chi2=4.95, df=4(P=0.29); I2=19.22%

Test for overall effect: Z=0.92(P=0.36)

2.4.2 BT versus Tricyclic antidepressants

Clark 1994

Subtotal ***

28.2 (8.7)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=1.19(P=0.24)

3.1 (1.2)

1.1 (0.8)

24.3 (6.8)

0.9 (0.6)

13.2 (7.5)

24.3 (6.8)

32

83

10

12

6

143

10

10

2.4.3 Supportive psychological therapy versus Tricyclic antidepressants

Shear 2000

Subtotal ***

30

30

1.4 (0.8)

12

12

0.9 (0.6)

Heterogeneity: Not applicable

Test for overall effect: Z=1.61(P=0.11)

Total ***

249

165

Heterogeneity: Tau2=0.01; Chi2=6.83, df=6(P=0.34); I2=12.17%

Test for overall effect: Z=1.72(P=0.09)

Test for subgroup differences: Chi2=1.81, df=1 (P=0.4), I2=0%

18.81%

36.9%

8.1%

11.12%

6.46%

81.39%

0.38[-0.11,0.86]

0.12[-0.19,0.43]

-0.63[-1.41,0.14]

0.18[-0.48,0.83]

0.34[-0.54,1.21]

0.13[-0.14,0.4]

8.27%

8.27%

0.47[-0.3,1.24]

0.47[-0.3,1.24]

10.34%

10.34%

0.56[-0.12,1.24]

0.56[-0.12,1.24]

100%

0.2[-0.03,0.43]

Favour psychotherapy

-2

-1

0

1

2

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 3.   All psychological therapies versus other antidepressants

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

1.1 CBT versus other antidepressants

1.2 Psychodynamic therapies versus
other antidepressants

2 Short-term response

2.1 CBT versus other antidepressants

2.2 Psychodynamic therapies versus
other antidepressants

3 Dropouts for any reason

3.1 CBT versus other antidepressants

3.2 Psychodynamic therapy versus
other antidepressants

4 Short-term improvement

4.1 CBT versus either antidepressants
alone or antidepressants and benzo-
diazepines

4.2 Psychodynamic therapy versus ei-
ther antidepressants alone or antide-
pressants and benzodiazepines

3

2

1

3

2

1

3

2

1

2

1

1

135

120

15

128

113

15

180

120

60

27

12

15

Risk Ratio (M-H, Random,
95% CI)

0.90 [0.48, 1.67]

Risk Ratio (M-H, Random,
95% CI)

0.92 [0.38, 2.24]

Risk Ratio (M-H, Random,
95% CI)

0.88 [0.34, 2.25]

Risk Ratio (M-H, Random,
95% CI)

0.96 [0.67, 1.37]

Risk Ratio (M-H, Random,
95% CI)

1.03 [0.63, 1.68]

Risk Ratio (M-H, Random,
95% CI)

0.66 [0.22, 1.97]

Risk Ratio (M-H, Random,
95% CI)

1.55 [0.91, 2.65]

Risk Ratio (M-H, Random,
95% CI)

1.84 [0.99, 3.43]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.36, 2.75]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-1.36, 0.51]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.97 [-2.20, 0.25]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.01 [-1.02, 1.01]

Analysis 3.1.   Comparison 3 All psychological therapies versus
other antidepressants, Outcome 1 Short-term remission.

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

3.1.1 CBT versus other antidepressants

Prasko 2004

van Apeldoorn 2008

Subtotal (95% CI)

6/6

19/55

61

4/6

30/53

59

Total events: 25 (Psychological therapies), 34 (Other antidepressants)

35.24%

41.28%

76.52%

1.44[0.8,2.6]

0.61[0.4,0.94]

0.92[0.38,2.24]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0.35; Chi2=5.96, df=1(P=0.01); I2=83.21%

Test for overall effect: Z=0.19(P=0.85)

3.1.2 Psychodynamic therapies versus other antidepressants

Bressi 2010

Subtotal (95% CI)

4/8

8

4/7

7

Total events: 4 (Psychological therapies), 4 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=0.28(P=0.78)

Total (95% CI)

69

66

Total events: 29 (Psychological therapies), 38 (Other antidepressants)

Heterogeneity: Tau2=0.19; Chi2=5.9, df=2(P=0.05); I2=66.08%

Test for overall effect: Z=0.33(P=0.74)

Test for subgroup differences: Chi2=0.01, df=1 (P=0.94), I2=0%

23.48%

23.48%

0.88[0.34,2.25]

0.88[0.34,2.25]

100%

0.9[0.48,1.67]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 3.2.   Comparison 3 All psychological therapies versus
other antidepressants, Outcome 2 Short-term response.

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

3.2.1 CBT versus other antidepressants

Prasko 2004

van Apeldoorn 2008

Subtotal (95% CI)

6/6

37/53

59

4/6

39/48

54

Total events: 43 (Psychological therapies), 43 (Other antidepressants)

Heterogeneity: Tau2=0.08; Chi2=2.61, df=1(P=0.11); I2=61.71%

Test for overall effect: Z=0.13(P=0.89)

3.2.2 Psychodynamic therapies versus other antidepressants

Bressi 2010

Subtotal (95% CI)

3/8

8

4/7

7

Total events: 3 (Psychological therapies), 4 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=0.75(P=0.45)

25.96%

64.56%

90.52%

1.44[0.8,2.6]

0.86[0.69,1.07]

1.03[0.63,1.68]

9.48%

9.48%

0.66[0.22,1.97]

0.66[0.22,1.97]

Total (95% CI)

67

61

100%

0.96[0.67,1.37]

Total events: 46 (Psychological therapies), 47 (Other antidepressants)

Heterogeneity: Tau2=0.04; Chi2=2.97, df=2(P=0.23); I2=32.66%

Test for overall effect: Z=0.23(P=0.82)

Test for subgroup differences: Chi2=0.55, df=1 (P=0.46), I2=0%

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.3.   Comparison 3 All psychological therapies versus
other antidepressants, Outcome 3 Dropouts for any reason.

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

3.3.1 CBT versus other antidepressants

Prasko 2004

van Apeldoorn 2008

Subtotal (95% CI)

0/6

21/55

61

0/6

11/53

59

Total events: 21 (Psychological therapies), 11 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.91(P=0.06)

3.3.2 Psychodynamic therapy versus other antidepressants

Bressi 2010

Subtotal (95% CI)

6/30

30

6/30

30

Total events: 6 (Psychological therapies), 6 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

91

89

Total events: 27 (Psychological therapies), 17 (Other antidepressants)

Heterogeneity: Tau2=0; Chi2=1.01, df=1(P=0.31); I2=0.97%

Test for overall effect: Z=1.61(P=0.11)

Test for subgroup differences: Chi2=1.01, df=1 (P=0.32), I2=0.93%

72.22%

72.22%

Not estimable

1.84[0.99,3.43]

1.84[0.99,3.43]

27.78%

27.78%

1[0.36,2.75]

1[0.36,2.75]

100%

1.55[0.91,2.65]

Favour psychotherapy

0.02

0.1

1

10

50

Favour medication

Analysis 3.4.   Comparison 3 All psychological therapies versus
other antidepressants, Outcome 4 Short-term improvement.

Study or subgroup

Psychologi-
cal therapies

Other Anti-
depressants

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.4.1 CBT versus either antidepressants alone or antidepressants and benzodi-
azepines

Prasko 2004

Subtotal ***

2.3 (2.3)

6

6

5.8 (4.1)

6

6

Heterogeneity: Not applicable

Test for overall effect: Z=1.55(P=0.12)

3.4.2 Psychodynamic therapy versus either antidepressants alone or antide-
pressants and benzodiazepines

43.35%

43.35%

-0.97[-2.2,0.25]

-0.97[-2.2,0.25]

Bressi 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.01(P=0.99)

Total ***

8

8

14

0.7 (0.6)

7

7

13

Heterogeneity: Tau2=0.14; Chi2=1.42, df=1(P=0.23); I2=29.38%

Test for overall effect: Z=0.89(P=0.37)

Test for subgroup differences: Chi2=1.42, df=1 (P=0.23), I2=29.38%

0.7 (0.5)

56.65%

56.65%

-0.01[-1.02,1.01]

-0.01[-1.02,1.01]

100%

-0.43[-1.36,0.51]

Favour psychotherapy

-1

-0.5

0

0.5

1

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 4.   All psychological therapies versus benzodiazepines

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

1.1 CBT versus benzodi-
azepines

1.2 Physiological therapies
versus benzodiazepines

2 Short-term response

2.1 CBT versus benzodi-
azepines

3 Dropouts for any reason

3.1 CBT versus benzodi-
azepines

4 Short-term improvement

4.1 CBT versus benzodi-
azepines

4.2 Physiological therapies
versus benzodiazepines

3

2

1

2

2

3

3

3

2

1

95

75

20

69

69

116

116

89

69

20

Risk Ratio (M-H, Random, 95% CI)

1.08 [0.70, 1.65]

Risk Ratio (M-H, Random, 95% CI)

1.08 [0.70, 1.65]

Risk Ratio (M-H, Random, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95% CI)

1.58 [0.70, 3.58]

Risk Ratio (M-H, Random, 95% CI)

1.58 [0.70, 3.58]

Risk Ratio (M-H, Random, 95% CI)

1.12 [0.54, 2.36]

Risk Ratio (M-H, Random, 95% CI)

1.12 [0.54, 2.36]

Std. Mean Difference (IV, Random,
95% CI)

-0.23 [-0.69, 0.23]

Std. Mean Difference (IV, Random,
95% CI)

-0.16 [-0.82, 0.50]

Std. Mean Difference (IV, Random,
95% CI)

-0.38 [-1.26, 0.51]

Analysis 4.1.   Comparison 4 All psychological therapies versus benzodiazepines, Outcome 1 Short-term remission.

Study or subgroup

Psychological
therapies

n/N

Benzodi-
azepines

n/N

4.1.1 CBT versus benzodiazepines

Ataoglu 2000

Klosko 1988

Subtotal (95% CI)

10/20

11/18

38

11/20

8/17

37

Total events: 21 (Psychological therapies), 19 (Benzodiazepines)

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%

Test for overall effect: Z=0.33(P=0.74)

4.1.2 Physiological therapies versus benzodiazepines

Taylor 1982

Subtotal (95% CI)

0/10

10

0/10

10

Total events: 0 (Psychological therapies), 0 (Benzodiazepines)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

52.76%

47.24%

100%

0.91[0.5,1.64]

1.3[0.7,2.42]

1.08[0.7,1.65]

Not estimable

Not estimable

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

n/N

Benzodi-
azepines

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total (95% CI)

48

47

100%

1.08[0.7,1.65]

Total events: 21 (Psychological therapies), 19 (Benzodiazepines)

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%

Test for overall effect: Z=0.33(P=0.74)

Test for subgroup differences: Not applicable

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 4.2.   Comparison 4 All psychological therapies versus benzodiazepines, Outcome 2 Short-term response.

Study or subgroup

Psychological
therapies

n/N

Benzodi-
azepines

n/N

4.2.1 CBT versus benzodiazepines

Klosko 1988

Tyrer 1988

Subtotal (95% CI)

7/15

9/31

46

5/16

1/7

23

Total events: 16 (Psychological therapies), 6 (Benzodiazepines)

Heterogeneity: Tau2=0; Chi2=0.09, df=1(P=0.77); I2=0%

Test for overall effect: Z=1.1(P=0.27)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

81.41%

18.59%

100%

1.49[0.6,3.7]

2.03[0.31,13.54]

1.58[0.7,3.58]

Total (95% CI)

46

23

100%

1.58[0.7,3.58]

Total events: 16 (Psychological therapies), 6 (Benzodiazepines)

Heterogeneity: Tau2=0; Chi2=0.09, df=1(P=0.77); I2=0%

Test for overall effect: Z=1.1(P=0.27)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 4.3.   Comparison 4 All psychological therapies
versus benzodiazepines, Outcome 3 Dropouts for any reason.

Study or subgroup

Psychological
therapies

n/N

Benzodi-
azepines

n/N

4.3.1 CBT versus benzodiazepines

Ataoglu 2000

Klosko 1988

Tyrer 1988

Subtotal (95% CI)

2/20

7/18

9/34

72

4/20

5/17

1/7

44

Total events: 18 (Psychological therapies), 10 (Benzodiazepines)

Heterogeneity: Tau2=0; Chi2=1.39, df=2(P=0.5); I2=0%

Test for overall effect: Z=0.31(P=0.76)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

22.04%

62.7%

15.26%

100%

0.5[0.1,2.43]

1.32[0.52,3.37]

1.85[0.28,12.38]

1.12[0.54,2.36]

Total (95% CI)

72

44

100%

1.12[0.54,2.36]

Total events: 18 (Psychological therapies), 10 (Benzodiazepines)

Heterogeneity: Tau2=0; Chi2=1.39, df=2(P=0.5); I2=0%

Test for overall effect: Z=0.31(P=0.76)

Favour psychotherapy

0.01

0.1

1

10

100

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.4.   Comparison 4 All psychological therapies versus
benzodiazepines, Outcome 4 Short-term improvement.

Study or subgroup

Psychologi-
cal therapies

Benzodiazepines

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.6 (1.9)

14.1 (5)

47.6 (16)

4.4.1 CBT versus benzodiazepines

Klosko 1988

Tyrer 1988

Subtotal ***

2.7 (1.5)

15.6 (6.9)

15

31

46

Heterogeneity: Tau2=0.08; Chi2=1.49, df=1(P=0.22); I2=32.96%

Test for overall effect: Z=0.47(P=0.64)

4.4.2 Physiological therapies versus benzodiazepines

42.5 (8.9)

Taylor 1982

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.83(P=0.4)

Total ***

10

10

56

Heterogeneity: Tau2=0; Chi2=1.64, df=2(P=0.44); I2=0%

Test for overall effect: Z=0.97(P=0.33)

Test for subgroup differences: Chi2=0.15, df=1 (P=0.7), I2=0%

16

7

23

10

10

33

41.51%

31.45%

72.96%

-0.47[-1.18,0.25]

0.21[-0.61,1.03]

-0.16[-0.82,0.5]

27.04%

27.04%

-0.38[-1.26,0.51]

-0.38[-1.26,0.51]

100%

-0.23[-0.69,0.23]

Favour pschotherapy

-1

-0.5

0

0.5

1

Favour medication

Comparison 5.   All psychological therapies versus either antidepressants alone or antidepressants and
benzodiazepines

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

1.1 CBT versus either antidepressants alone
or antidepressants and benzodiazepines

1.2 Psychodynamic therapies versus either
antidepressants alone or antidepressants and
benzodiazepines

1.3 BT versus either antidepressants alone or
antidepressants and benzodiazepines

1.4 Supportive psychotherapies versus either
antidepressants alone or antidepressants and
benzodiazepines

2 Short-term response

2.1 CBT versus either antidepressants alone
or antidepressants and benzodiazepines

11

10

1

1

1

12

11

663

570

15

36

42

800

707

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.86 [0.71, 1.05]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.88 [0.71, 1.10]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.88 [0.34, 2.25]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.7 [0.28, 1.75]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.69 [0.36, 1.31]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.95 [0.76, 1.18]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.99 [0.78, 1.26]

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.2 Psychodynamic therapies versus either
antidepressants or antidepressants and ben-
zodiazepines

2.3 Behaviour therapy versus either antide-
pressants alone or antidepressants and ben-
zodiazepines

2.4 Supportive psychotherapies versus either
antidepressants alone or antidepressants and
benzodiazepines

3 Dropouts for any reason

3.1 CBT versus either antidepressants alone
or antidepressants and benzodiazepines

3.2 Psychodynamic therapy versus either an-
tidepressants alone or antidepressants and
benzodiazepines

3.3 BT versus antidepressants alone or anti-
depressants and benzodiazepines

3.4 Supportive psychological therapy versus
either antidepressants alone or antidepres-
sants and benzodiazepines

4 Short-term improvement

4.1 CBT versus either antidepressants alone
or antidepressants and benzodiazepines

4.2 Psychodynamic therapy versus either an-
tidepressants alone or antidepressants and
benzodiazepines

4.3 Behaviour therapy versus either antide-
pressants alone or antidepressants and ben-
zodiazepines

4.4 Supportive psychological therapy versus
either antidepressants alone or antidepres-
sants and benzodiazepines

1

1

1

13

12

1

1

1

11

10

1

1

1

15

36

42

909

771

60

36

42

638

551

15

30

42

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.66 [0.22, 1.97]

Risk Ratio (M-H, Ran-
dom, 95% CI)

1.0 [0.10, 9.96]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.6 [0.27, 1.32]

Risk Ratio (M-H, Ran-
dom, 95% CI)

1.08 [0.77, 1.51]

Risk Ratio (M-H, Ran-
dom, 95% CI)

1.16 [0.79, 1.70]

Risk Ratio (M-H, Ran-
dom, 95% CI)

1.0 [0.36, 2.75]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.56 [0.22, 1.42]

Std. Mean Difference
(IV, Random, 95% CI)

0.01 [-0.34, 0.35]

Std. Mean Difference
(IV, Random, 95% CI)

-0.09 [-0.50, 0.32]

Std. Mean Difference
(IV, Random, 95% CI)

-0.01 [-1.02, 1.01]

Std. Mean Difference
(IV, Random, 95% CI)

0.47 [-0.30, 1.24]

Std. Mean Difference
(IV, Random, 95% CI)

0.56 [-0.12, 1.24]

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.1.   Comparison 5 All psychological therapies versus either antidepressants
alone or antidepressants and benzodiazepines, Outcome 1 Short-term remission.

Study or subgroup

Psychological
treatments

n/N

Antide-
pressants

n/N

5.1.1 CBT versus either antidepressants alone or antidepressants and
benzodiazepines

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Azhar 2000

Bakker 1999

Bakker 1999

Black 1993

Clark 1994

Dannon 2004

Hendriks 2010

Prasko 2004

Sharp 1996

Shear 2000

van Apeldoorn 2008

Subtotal (95% CI)

2/22

7/18

7/17

12/25

13/24

23/24

13/20

6/6

23/43

19/36

19/55

290

0/22

21/32

17/32

18/25

6/12

27/33

12/17

4/6

24/36

7/12

30/53

280

Total events: 144 (Psychological treatments), 166 (Antidepressants)

Heterogeneity: Tau2=0.07; Chi2=22.43, df=10(P=0.01); I2=55.42%

Test for overall effect: Z=1.13(P=0.26)

5.1.2 Psychodynamic therapies versus either antidepressants alone or
antidepressants and benzodiazepines

Bressi 2010

Subtotal (95% CI)

4/8

8

4/7

7

Total events: 4 (Psychological treatments), 4 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=0.28(P=0.78)

5.1.3 BT versus either antidepressants alone or antidepressants and
benzodiazepines

Clark 1994

Subtotal (95% CI)

7/24

24

5/12

12

Total events: 7 (Psychological treatments), 5 (Antidepressants)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.76(P=0.44)

5.1.4 Supportive psychotherapies versus either antidepressants alone
or antidepressants and benzodiazepines

Shear 2000

Subtotal (95% CI)

12/30

30

7/12

12

Total events: 12 (Psychological treatments), 7 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.14(P=0.25)

0.41%

6.22%

5.92%

8.73%

5.68%

15.98%

9.36%

6.8%

11.24%

7.1%

9.59%

87.01%

5[0.25,98.52]

0.59[0.32,1.11]

0.78[0.4,1.49]

0.67[0.41,1.07]

1.08[0.55,2.13]

1.17[0.98,1.4]

0.92[0.59,1.44]

1.44[0.8,2.6]

0.8[0.56,1.15]

0.9[0.51,1.6]

0.61[0.4,0.94]

0.88[0.71,1.1]

3.41%

3.41%

0.88[0.34,2.25]

0.88[0.34,2.25]

3.59%

3.59%

0.7[0.28,1.75]

0.7[0.28,1.75]

5.99%

5.99%

0.69[0.36,1.31]

0.69[0.36,1.31]

Total (95% CI)

352

311

100%

0.86[0.71,1.05]

Total events: 167 (Psychological treatments), 182 (Antidepressants)

Heterogeneity: Tau2=0.05; Chi2=24.03, df=13(P=0.03); I2=45.9%

Test for overall effect: Z=1.51(P=0.13)

Test for subgroup differences: Chi2=0.7, df=1 (P=0.87), I2=0%

Favour medication

0.1

0.2

0.5

1

2

5

10

Favour antidepressant

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.2.   Comparison 5 All psychological therapies versus either antidepressants
alone or antidepressants and benzodiazepines, Outcome 2 Short-term response.

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

5.2.1 CBT versus either antidepressants alone or antidepressants and
benzodiazepines

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Azhar 2000

Bakker 1999

Barlow 2000

Black 1993

Clark 1994

Hendriks 2010

Prasko 2004

Sharp 1996

Shear 2000

Tyrer 1988

van Apeldoorn 2008

Subtotal (95% CI)

17/22

10/35

37/77

6/25

2/24

9/20

6/6

20/43

14/36

9/34

37/53

375

5/22

32/64

38/83

12/25

1/12

7/17

4/6

15/36

6/12

2/7

39/48

332

Total events: 167 (Psychological therapies), 161 (Antidepressants)

Heterogeneity: Tau2=0.07; Chi2=19.04, df=10(P=0.04); I2=47.49%

Test for overall effect: Z=0.08(P=0.94)

5.2.2 Psychodynamic therapies versus either antidepressants or anti-
depressants and benzodiazepines

Bressi 2010

Subtotal (95% CI)

3/8

8

4/7

7

Total events: 3 (Psychological therapies), 4 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=0.75(P=0.45)

5.2.3 Behaviour therapy versus either antidepressants alone or anti-
depressants and benzodiazepines

Clark 1994

Subtotal (95% CI)

2/24

24

1/12

12

Total events: 2 (Psychological therapies), 1 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

5.2.4 Supportive psychotherapies versus either antidepressants alone
or antidepressants and benzodiazepines

Shear 2000

Subtotal (95% CI)

9/30

30

6/12

12

Total events: 9 (Psychological therapies), 6 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.27(P=0.2)

5.6%

8.86%

15.36%

5.55%

0.86%

6.25%

8.66%

10.48%

6.88%

2.51%

18.99%

90%

3.4[1.52,7.59]

0.57[0.32,1.02]

1.05[0.75,1.46]

0.5[0.22,1.12]

1[0.1,9.96]

1.09[0.52,2.31]

1.44[0.8,2.6]

1.12[0.68,1.84]

0.78[0.39,1.56]

0.93[0.25,3.39]

0.86[0.69,1.07]

0.99[0.78,1.26]

3.35%

3.35%

0.66[0.22,1.97]

0.66[0.22,1.97]

0.86%

0.86%

1[0.1,9.96]

1[0.1,9.96]

5.78%

5.78%

0.6[0.27,1.32]

0.6[0.27,1.32]

Total (95% CI)

437

363

100%

0.95[0.76,1.18]

Total events: 181 (Psychological therapies), 172 (Antidepressants)

Heterogeneity: Tau2=0.05; Chi2=20.69, df=13(P=0.08); I2=37.16%

Test for overall effect: Z=0.49(P=0.62)

Test for subgroup differences: Chi2=1.84, df=1 (P=0.61), I2=0%

Favour medication

0.02

0.1

1

10

50

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.3.   Comparison 5 All psychological therapies versus either antidepressants
alone or antidepressants and benzodiazepines, Outcome 3 Dropouts for any reason.

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

5.3.1 CBT versus either antidepressants alone or antidepressants and
benzodiazepines

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Azhar 2000

Bakker 1999

Barlow 2000

Black 1993

Clark 1994

Dannon 2004

Hendriks 2010

Prasko 2004

Sharp 1996

Shear 2000

Tyrer 1988

van Apeldoorn 2008

Subtotal (95% CI)

5/22

9/35

21/77

9/25

0/24

1/24

2/20

0/6

13/43

14/36

2/34

21/55

401

5/22

7/64

32/83

4/25

0/12

6/33

3/17

0/6

7/36

5/12

1/7

11/53

370

Total events: 97 (Psychological therapies), 81 (Antidepressants)

Heterogeneity: Tau2=0.14; Chi2=15.28, df=9(P=0.08); I2=41.1%

Test for overall effect: Z=0.76(P=0.45)

5.3.2 Psychodynamic therapy versus either antidepressants alone or
antidepressants and benzodiazepines

Bressi 2010

Subtotal (95% CI)

6/30

30

6/30

30

Total events: 6 (Psychological therapies), 6 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

5.3.3 BT versus antidepressants alone or antidepressants and benzo-
diazepines

Clark 1994

Subtotal (95% CI)

0/24

24

0/12

12

Total events: 0 (Psychological therapies), 0 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

5.3.4 Supportive psychological therapy versus either antidepressants
alone or antidepressants and benzodiazepines

Shear 2000

Subtotal (95% CI)

7/30

30

5/12

12

Total events: 7 (Psychological therapies), 5 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.22(P=0.22)

6.96%

9.08%

17.44%

7.45%

2.44%

3.52%

10.39%

10.71%

2.05%

13.61%

83.63%

1[0.34,2.97]

2.35[0.96,5.77]

0.71[0.45,1.11]

2.25[0.8,6.36]

Not estimable

0.23[0.03,1.78]

0.57[0.11,3.01]

Not estimable

1.55[0.7,3.48]

0.93[0.43,2.05]

0.41[0.04,3.94]

1.84[0.99,3.43]

1.16[0.79,1.7]

7.73%

7.73%

1[0.36,2.75]

1[0.36,2.75]

Not estimable

Not estimable

8.64%

8.64%

0.56[0.22,1.42]

0.56[0.22,1.42]

Total (95% CI)

485

424

100%

1.08[0.77,1.51]

Total events: 110 (Psychological therapies), 92 (Antidepressants)

Heterogeneity: Tau2=0.12; Chi2=17.23, df=11(P=0.1); I2=36.17%

Test for overall effect: Z=0.44(P=0.66)

Test for subgroup differences: Chi2=2.01, df=1 (P=0.37), I2=0.47%

Favour psychotherapy

0.01

0.1

1

10

100

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.4.   Comparison 5 All psychological therapies versus either antidepressants
alone or antidepressants and benzodiazepines, Outcome 4 Short-term improvement.

Study or subgroup

Psychologi-
cal therapies

Antidepressants

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

5.4.1 CBT versus either antidepressants alone or antidepressants and benzodi-
azepines

Azhar 2000

Bakker 1999

Bakker 1999

Barlow 2000

Black 1993

Clark 1994

Hendriks 2010

Prasko 2004

Sharp 1996

Shear 2000

Tyrer 1988

Subtotal ***

17

13

12

77

25

20

18

6

30

36

31

3.6 (2.2)

3.6 (1.4)

3.6 (1.4)

1.1 (0.7)

2.5 (1)

20.5 (5.3)

1.4 (0.4)

2.3 (2.3)

5.1 (5.4)

1.1 (0.8)

15.6 (6.9)

17

32

32

83

25

10

14

6

29

12

6

9.1 (2)

3.1 (1.2)

2.4 (1.1)

1.1 (0.8)

2 (1.7)

24.3 (6.8)

1.4 (0.4)

5.8 (4.1)

5.5 (7.9)

0.9 (0.6)

13.2 (7.5)

5.99%

7.66%

7.36%

9.68%

8.24%

6.86%

7.35%

4.52%

8.55%

7.63%

6.26%

-2.53[-3.45,-1.6]

0.39[-0.26,1.04]

0.99[0.3,1.69]

0.12[-0.19,0.43]

0.35[-0.21,0.91]

-0.63[-1.41,0.14]

0[-0.7,0.7]

-0.97[-2.2,0.25]

-0.06[-0.57,0.45]

0.18[-0.48,0.83]

0.34[-0.54,1.21]

285

266

80.11%

-0.09[-0.5,0.32]

Heterogeneity: Tau2=0.36; Chi2=45.43, df=10(P<0.0001); I2=77.99%

Test for overall effect: Z=0.43(P=0.67)

5.4.2 Psychodynamic therapy versus either antidepressants alone or antide-
pressants and benzodiazepines

Bressi 2010

Subtotal ***

0.7 (0.6)

8

8

0.7 (0.5)

7

7

Heterogeneity: Not applicable

Test for overall effect: Z=0.01(P=0.99)

5.4.3 Behaviour therapy versus either antidepressants alone or antidepres-
sants and benzodiazepines

Clark 1994

Subtotal ***

28.2 (8.7)

20

20

24.3 (6.8)

10

10

Heterogeneity: Not applicable

Test for overall effect: Z=1.19(P=0.24)

5.4.4 Supportive psychological therapy versus either antidepressants alone or
antidepressants and benzodiazepines

Shear 2000

Subtotal ***

30

30

1.4 (0.8)

12

12

0.9 (0.6)

Heterogeneity: Not applicable

Test for overall effect: Z=1.61(P=0.11)

Total ***

343

295

Heterogeneity: Tau2=0.3; Chi2=48.48, df=13(P<0.0001); I2=73.19%

Test for overall effect: Z=0.05(P=0.96)

Test for subgroup differences: Chi2=3.43, df=1 (P=0.33), I2=12.5%

5.52%

5.52%

-0.01[-1.02,1.01]

-0.01[-1.02,1.01]

6.91%

6.91%

0.47[-0.3,1.24]

0.47[-0.3,1.24]

7.46%

7.46%

0.56[-0.12,1.24]

0.56[-0.12,1.24]

100%

0.01[-0.34,0.35]

Favour psychotherapy

-2

-1

0

1

2

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 6.   Subgroup analysis: All psychological therapies versus either antidepressants alone or
antidepressants and benzodiazepines (participants without depressive disorder)

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

1.1 CBT versus either antidepressants
alone or antidepressants and benzodi-
azepines

2 Dropouts for any reason

2.1 CBT versus either antidepressants
alone or antidepressants and benzodi-
azepines

2

2

2

2

69

69

69

69

Risk Ratio (M-H, Random,
95% CI)

1.19 [1.00, 1.42]

Risk Ratio (M-H, Random,
95% CI)

1.19 [1.00, 1.42]

Risk Ratio (M-H, Random,
95% CI)

0.23 [0.03, 1.78]

Risk Ratio (M-H, Random,
95% CI)

0.23 [0.03, 1.78]

Analysis 6.1.   Comparison 6 Subgroup analysis: All psychological therapies versus either antidepressants alone or
antidepressants and benzodiazepines (participants without depressive disorder), Outcome 1 Short-term remission.

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

6.1.1 CBT versus either antidepressants alone or antidepressants and
benzodiazepines

Dannon 2004

Prasko 2004

Subtotal (95% CI)

23/24

6/6

30

27/33

4/6

39

Total events: 29 (Psychological therapies), 31 (Antidepressants)

Heterogeneity: Tau2=0; Chi2=0.49, df=1(P=0.48); I2=0%

Test for overall effect: Z=1.99(P=0.05)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

91.36%

8.64%

100%

1.17[0.98,1.4]

1.44[0.8,2.6]

1.19[1,1.42]

Total (95% CI)

30

39

100%

1.19[1,1.42]

Total events: 29 (Psychological therapies), 31 (Antidepressants)

Heterogeneity: Tau2=0; Chi2=0.49, df=1(P=0.48); I2=0%

Test for overall effect: Z=1.99(P=0.05)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 6.2.   Comparison 6 Subgroup analysis: All psychological therapies
versus either antidepressants alone or antidepressants and benzodiazepines
(participants without depressive disorder), Outcome 2 Dropouts for any reason.

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

6.2.1 CBT versus either antidepressants alone or antidepressants and
benzodiazepines

Dannon 2004

Prasko 2004

1/24

0/6

6/33

0/6

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.23[0.03,1.78]

Not estimable

Favour psychotherapy

0.02

0.1

1

10

50

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

30

39

100%

0.23[0.03,1.78]

Total events: 1 (Psychological therapies), 6 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.41(P=0.16)

Total (95% CI)

30

39

100%

0.23[0.03,1.78]

Total events: 1 (Psychological therapies), 6 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.41(P=0.16)

Favour psychotherapy

0.02

0.1

1

10

50

Favour medication

Comparison 7.   Subgroup analysis (investigation of heterogeneity): All psychological therapies versus SSRI

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

1.1 CBT versus SSRI

2 Short-term response

2.1 CBT versus SSRI

3 Short-term improve-
ment

3.1 CBT versus SSRI

5

5

2

2

2

2

275

275

117

117

91

91

Risk Ratio (M-H, Random, 95% CI)

0.79 [0.62, 0.99]

Risk Ratio (M-H, Random, 95% CI)

0.79 [0.62, 0.99]

Risk Ratio (M-H, Random, 95% CI)

0.47 [0.29, 0.76]

Risk Ratio (M-H, Random, 95% CI)

0.47 [0.29, 0.76]

Std. Mean Difference (IV, Random, 95%
CI)

-0.04 [-0.45, 0.37]

Std. Mean Difference (IV, Random, 95%
CI)

-0.04 [-0.45, 0.37]

Analysis 7.1.   Comparison 7 Subgroup analysis (investigation of heterogeneity):
All psychological therapies versus SSRI, Outcome 1 Short-term remission.

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2/22

14/35

12/25

13/18

23/43

143

0/22

21/32

18/25

12/17

24/36

132

0.6%

20.58%

20.68%

25.58%

32.56%

100%

5[0.25,98.52]

0.61[0.38,0.98]

0.67[0.41,1.07]

1.02[0.67,1.56]

0.8[0.56,1.15]

0.79[0.62,0.99]

Study or subgroup

7.1.1 CBT versus SSRI

Azhar 2000

Bakker 1999

Black 1993

Hendriks 2010

Sharp 1996

Subtotal (95% CI)

Total events: 64 (Psychological therapies), 75 (SSRI)

Heterogeneity: Tau2=0.01; Chi2=4.57, df=4(P=0.33); I2=12.44%

Test for overall effect: Z=2.04(P=0.04)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total (95% CI)

143

132

100%

0.79[0.62,0.99]

Total events: 64 (Psychological therapies), 75 (SSRI)

Heterogeneity: Tau2=0.01; Chi2=4.57, df=4(P=0.33); I2=12.44%

Test for overall effect: Z=2.04(P=0.04)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 7.2.   Comparison 7 Subgroup analysis (investigation of heterogeneity):
All psychological therapies versus SSRI, Outcome 2 Short-term response.

Study or subgroup

7.2.1 CBT versus SSRI

Bakker 1999

Black 1993

Subtotal (95% CI)

Psychological
therapies

n/N

SSRI

n/N

10/35

6/25

60

20/32

12/25

57

Total events: 16 (Psychological therapies), 32 (SSRI)

Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.86); I2=0%

Test for overall effect: Z=3.1(P=0)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

65.34%

34.66%

100%

0.46[0.25,0.82]

0.5[0.22,1.12]

0.47[0.29,0.76]

Total (95% CI)

60

57

100%

0.47[0.29,0.76]

Total events: 16 (Psychological therapies), 32 (SSRI)

Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.86); I2=0%

Test for overall effect: Z=3.1(P=0)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 7.3.   Comparison 7 Subgroup analysis (investigation of heterogeneity):
All psychological therapies versus SSRI, Outcome 3 Short-term improvement.

Study or subgroup

Psychologi-
cal therapies

SSRI

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.3.1 CBT versus SSRI

Hendriks 2010

Sharp 1996

Subtotal ***

1.4 (0.4)

5.1 (5.4)

18

30

48

Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%

Test for overall effect: Z=0.18(P=0.86)

Total ***

48

Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%

Test for overall effect: Z=0.18(P=0.86)

14

29

43

43

1.4 (0.4)

5.5 (7.9)

34.82%

65.18%

100%

0[-0.7,0.7]

-0.06[-0.57,0.45]

-0.04[-0.45,0.37]

100%

-0.04[-0.45,0.37]

Favour psychotherapy

-2

-1

0

1

2

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 8.   Subgroup analysis (investigation of heterogeneity): All psychological therapies versus other
antidepressants

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

1.1 CBT versus other antidepres-
sants

1.2 Psychodynamic therapies versus
other antidepressants

2

1

1

123

108

15

Risk Ratio (M-H, Random, 95%
CI)

0.65 [0.44, 0.96]

Risk Ratio (M-H, Random, 95%
CI)

0.61 [0.40, 0.94]

Risk Ratio (M-H, Random, 95%
CI)

0.88 [0.34, 2.25]

Analysis 8.1.   Comparison 8 Subgroup analysis (investigation of heterogeneity): All
psychological therapies versus other antidepressants, Outcome 1 Short-term remission.

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

8.1.1 CBT versus other antidepressants

van Apeldoorn 2008

Subtotal (95% CI)

19/55

55

30/53

53

Total events: 19 (Psychological therapies), 30 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=2.23(P=0.03)

8.1.2 Psychodynamic therapies versus other antidepressants

Bressi 2010

Subtotal (95% CI)

4/8

8

4/7

7

Total events: 4 (Psychological therapies), 4 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=0.28(P=0.78)

Total (95% CI)

63

60

Total events: 23 (Psychological therapies), 34 (Other antidepressants)

Heterogeneity: Tau2=0; Chi2=0.46, df=1(P=0.5); I2=0%

Test for overall effect: Z=2.14(P=0.03)

Test for subgroup differences: Chi2=0.46, df=1 (P=0.5), I2=0%

82.6%

82.6%

0.61[0.4,0.94]

0.61[0.4,0.94]

17.4%

17.4%

0.88[0.34,2.25]

0.88[0.34,2.25]

100%

0.65[0.44,0.96]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Comparison 9.   Subgroup analysis (investigation of heterogeneity): All psychological therapies versus either
antidepressants alone or antidepressants and benzodiazepines

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

10

606

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.80 [0.69, 0.94]

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.1 CBT versus either antidepressants alone
or antidepressants and benzodiazepines

1.2 Psychodynamic therapies versus either
antidepressants alone or antidepressants
and benzodiazepines

1.3 BT versus either antidepressants alone
or antidepressants and benzodiazepines

1.4 Supportive psychotherapies versus ei-
ther antidepressants alone or antidepres-
sants and benzodiazepines

9

1

1

1

2 Short-term improvement

10

2.1 CBT versus either antidepressants alone
or antidepressants and benzodiazepines

2.2 Psychodynamic therapy versus either
antidepressants alone or antidepressants
and benzodiazepines

2.3 Behaviour therapy versus either antide-
pressants alone or antidepressants and ben-
zodiazepines

2.4 Supportive psychological therapy versus
either antidepressants alone or antidepres-
sants and benzodiazepines

9

1

1

1

513

15

36

42

604

517

15

30

42

Risk Ratio (M-H, Ran-
dom, 95% CI)

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.82 [0.68, 0.97]

0.88 [0.34, 2.25]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.7 [0.28, 1.75]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.69 [0.36, 1.31]

Std. Mean Difference (IV,
Random, 95% CI)

0.19 [-0.03, 0.40]

Std. Mean Difference (IV,
Random, 95% CI)

0.14 [-0.12, 0.39]

Std. Mean Difference (IV,
Random, 95% CI)

-0.01 [-1.02, 1.01]

Std. Mean Difference (IV,
Random, 95% CI)

0.47 [-0.30, 1.24]

Std. Mean Difference (IV,
Random, 95% CI)

0.56 [-0.12, 1.24]

Analysis 9.1.   Comparison 9 Subgroup analysis (investigation of heterogeneity): All psychological therapies
versus either antidepressants alone or antidepressants and benzodiazepines, Outcome 1 Short-term remission.

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

9.1.1 CBT versus either antidepressants alone or antidepressants and
benzodiazepines

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Azhar 2000

Bakker 1999

Bakker 1999

Black 1993

Clark 1994

Hendriks 2010

Prasko 2004

Sharp 1996

Shear 2000

van Apeldoorn 2008

Subtotal (95% CI)

2/22

7/18

7/17

12/25

13/24

13/20

6/6

23/43

19/36

19/55

266

0/22

21/32

17/32

18/25

6/12

12/17

4/6

24/36

7/12

30/53

247

0.28%

6.24%

5.8%

10.98%

5.45%

12.58%

7.16%

18.96%

7.67%

13.22%

88.34%

5[0.25,98.52]

0.59[0.32,1.11]

0.78[0.4,1.49]

0.67[0.41,1.07]

1.08[0.55,2.13]

0.92[0.59,1.44]

1.44[0.8,2.6]

0.8[0.56,1.15]

0.9[0.51,1.6]

0.61[0.4,0.94]

0.82[0.68,0.97]

Favour medication

0.1

0.2

0.5

1

2

5

10

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

Total events: 121 (Psychological therapies), 139 (Antidepressants)

Heterogeneity: Tau2=0.01; Chi2=9.7, df=9(P=0.38); I2=7.17%

Test for overall effect: Z=2.26(P=0.02)

9.1.2 Psychodynamic therapies versus either antidepressants alone or
antidepressants and benzodiazepines

Bressi 2010

Subtotal (95% CI)

4/8

8

4/7

7

Total events: 4 (Psychological therapies), 4 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=0.28(P=0.78)

9.1.3 BT versus either antidepressants alone or antidepressants and
benzodiazepines

Clark 1994

Subtotal (95% CI)

7/24

24

5/12

12

Total events: 7 (Psychological therapies), 5 (Antidepressants)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.76(P=0.44)

9.1.4 Supportive psychotherapies versus either antidepressants alone
or antidepressants and benzodiazepines

Shear 2000

Subtotal (95% CI)

12/30

30

7/12

12

Total events: 12 (Psychological therapies), 7 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.14(P=0.25)

Cochrane Database of Systematic Reviews

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2.79%

2.79%

0.88[0.34,2.25]

0.88[0.34,2.25]

2.97%

2.97%

0.7[0.28,1.75]

0.7[0.28,1.75]

5.91%

5.91%

0.69[0.36,1.31]

0.69[0.36,1.31]

Total (95% CI)

328

278

100%

0.8[0.69,0.94]

Total events: 144 (Psychological therapies), 155 (Antidepressants)

Heterogeneity: Tau2=0; Chi2=10.06, df=12(P=0.61); I2=0%

Test for overall effect: Z=2.72(P=0.01)

Test for subgroup differences: Chi2=0.38, df=1 (P=0.94), I2=0%

Favour medication

0.1

0.2

0.5

1

2

5

10

Favour psychotherapy

Analysis 9.2.   Comparison 9 Subgroup analysis (investigation of heterogeneity): All psychological therapies versus
either antidepressants alone or antidepressants and benzodiazepines, Outcome 2 Short-term improvement.

Study or subgroup

Psychologi-
cal therapies

Antidepressants

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

9.2.1 CBT versus either antidepressants alone or antidepressants and benzodi-
azepines

Bakker 1999

Bakker 1999

Barlow 2000

Black 1993

Clark 1994

Hendriks 2010

Prasko 2004

13

12

77

25

20

18

6

3.6 (1.4)

3.6 (1.4)

1.1 (0.7)

2.5 (1)

20.5 (5.3)

1.4 (0.4)

2.3 (2.3)

32

32

83

25

10

14

6

3.1 (1.2)

2.4 (1.1)

1.1 (0.8)

2 (1.7)

24.3 (6.8)

1.4 (0.4)

5.8 (4.1)

7.93%

7.14%

17.98%

9.77%

6.03%

7.13%

2.78%

0.39[-0.26,1.04]

0.99[0.3,1.69]

0.12[-0.19,0.43]

0.35[-0.21,0.91]

-0.63[-1.41,0.14]

0[-0.7,0.7]

-0.97[-2.2,0.25]

Favour psychotherapy

-2

-1

0

1

2

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychologi-
cal therapies

Antidepressants

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Sharp 1996

Shear 2000

Tyrer 1988

Subtotal ***

30

36

31

268

5.1 (5.4)

1.1 (0.8)

15.6 (6.9)

29

12

6

249

5.5 (7.9)

0.9 (0.6)

13.2 (7.5)

Heterogeneity: Tau2=0.06; Chi2=14.79, df=9(P=0.1); I2=39.16%

Test for overall effect: Z=1.07(P=0.29)

9.2.2 Psychodynamic therapy versus either antidepressants alone or antide-
pressants and benzodiazepines

Bressi 2010

Subtotal ***

0.7 (0.6)

8

8

0.7 (0.5)

7

7

Heterogeneity: Not applicable

Test for overall effect: Z=0.01(P=0.99)

9.2.3 Behaviour therapy versus either antidepressants alone or antidepres-
sants and benzodiazepines

Clark 1994

Subtotal ***

28.2 (8.7)

20

20

24.3 (6.8)

10

10

Heterogeneity: Not applicable

Test for overall effect: Z=1.19(P=0.24)

9.2.4 Supportive psychological therapy versus either antidepressants alone or
antidepressants and benzodiazepines

Shear 2000

Subtotal ***

30

30

1.4 (0.8)

12

12

0.9 (0.6)

Heterogeneity: Not applicable

Test for overall effect: Z=1.61(P=0.11)

Total ***

326

278

Heterogeneity: Tau2=0.04; Chi2=16.81, df=12(P=0.16); I2=28.63%

Test for overall effect: Z=1.7(P=0.09)

Test for subgroup differences: Chi2=1.91, df=1 (P=0.59), I2=0%

10.98%

7.85%

4.97%

82.56%

-0.06[-0.57,0.45]

0.18[-0.48,0.83]

0.34[-0.54,1.21]

0.14[-0.12,0.39]

3.89%

3.89%

-0.01[-1.02,1.01]

-0.01[-1.02,1.01]

6.14%

6.14%

0.47[-0.3,1.24]

0.47[-0.3,1.24]

7.4%

7.4%

0.56[-0.12,1.24]

0.56[-0.12,1.24]

100%

0.19[-0.03,0.4]

Favour psychotherapy

-2

-1

0

1

2

Favour medication

Comparison 10.   Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus SSRI

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

1.1 CBT versus SSRI

2 Short-term response

2.1 CBT versus SSRI

3 Dropouts for any reason

3.1 CBT versus SSRI

4

4

4

4

4

4

233

233

233

233

233

233

Risk Ratio (M-H, Random, 95% CI)

0.75 [0.61, 0.94]

Risk Ratio (M-H, Random, 95% CI)

0.75 [0.61, 0.94]

Risk Ratio (M-H, Random, 95% CI)

0.72 [0.46, 1.12]

Risk Ratio (M-H, Random, 95% CI)

0.72 [0.46, 1.12]

Risk Ratio (M-H, Random, 95% CI)

1.65 [0.98, 2.78]

Risk Ratio (M-H, Random, 95% CI)

1.65 [0.98, 2.78]

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

4 Short-term improvement

4

4.1 CBT versus SSRI

4

208

208

Std. Mean Difference (IV, Random,
95% CI)

0.33 [-0.15, 0.80]

Std. Mean Difference (IV, Random,
95% CI)

0.33 [-0.15, 0.80]

Analysis 10.1.   Comparison 10 Sensitivity analysis (psychological therapies with quality
control): All psychological therapies versus SSRI, Outcome 1 Short-term remission.

Study or subgroup

10.1.1 CBT versus SSRI

Bakker 1999

Black 1993

Hendriks 2010

Sharp 1996

Subtotal (95% CI)

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

14/35

12/25

13/20

23/43

123

21/32

18/25

12/17

24/36

110

20.44%

20.55%

23.53%

35.48%

100%

0.61[0.38,0.98]

0.67[0.41,1.07]

0.92[0.59,1.44]

0.8[0.56,1.15]

0.75[0.61,0.94]

Total events: 62 (Psychological therapies), 75 (SSRI)

Heterogeneity: Tau2=0; Chi2=1.95, df=3(P=0.58); I2=0%

Test for overall effect: Z=2.56(P=0.01)

Total (95% CI)

123

110

100%

0.75[0.61,0.94]

Total events: 62 (Psychological therapies), 75 (SSRI)

Heterogeneity: Tau2=0; Chi2=1.95, df=3(P=0.58); I2=0%

Test for overall effect: Z=2.56(P=0.01)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 10.2.   Comparison 10 Sensitivity analysis (psychological therapies with quality
control): All psychological therapies versus SSRI, Outcome 2 Short-term response.

Study or subgroup

10.2.1 CBT versus SSRI

Bakker 1999

Black 1993

Hendriks 2010

Sharp 1996

Subtotal (95% CI)

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

10/35

6/25

9/20

20/43

123

20/32

12/25

7/17

17/36

110

27.12%

19.2%

21.12%

32.56%

100%

0.46[0.25,0.82]

0.5[0.22,1.12]

1.09[0.52,2.31]

0.98[0.61,1.58]

0.72[0.46,1.12]

Total events: 45 (Psychological therapies), 56 (SSRI)

Heterogeneity: Tau2=0.1; Chi2=5.99, df=3(P=0.11); I2=49.95%

Test for overall effect: Z=1.45(P=0.15)

Total (95% CI)

123

110

100%

0.72[0.46,1.12]

Total events: 45 (Psychological therapies), 56 (SSRI)

Heterogeneity: Tau2=0.1; Chi2=5.99, df=3(P=0.11); I2=49.95%

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

n/N

SSRI

n/N

Test for overall effect: Z=1.45(P=0.15)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 10.3.   Comparison 10 Sensitivity analysis (psychological therapies with quality
control): All psychological therapies versus SSRI, Outcome 3 Dropouts for any reason.

Study or subgroup

10.3.1 CBT versus SSRI

Bakker 1999

Black 1993

Hendriks 2010

Sharp 1996

Subtotal (95% CI)

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

9/35

9/25

2/20

13/43

123

4/32

4/25

3/17

7/36

110

23.4%

25.08%

9.73%

41.78%

100%

2.06[0.7,6.03]

2.25[0.8,6.36]

0.57[0.11,3.01]

1.55[0.7,3.48]

1.65[0.98,2.78]

Total events: 33 (Psychological therapies), 18 (SSRI)

Heterogeneity: Tau2=0; Chi2=2.1, df=3(P=0.55); I2=0%

Test for overall effect: Z=1.89(P=0.06)

Total (95% CI)

123

110

100%

1.65[0.98,2.78]

Total events: 33 (Psychological therapies), 18 (SSRI)

Heterogeneity: Tau2=0; Chi2=2.1, df=3(P=0.55); I2=0%

Test for overall effect: Z=1.89(P=0.06)

Favour psychotherapy

0.01

0.1

1

10

100

Favour medication

Analysis 10.4.   Comparison 10 Sensitivity analysis (psychological therapies with quality
control): All psychological therapies versus SSRI, Outcome 4 Short-term improvement.

Study or subgroup

Psychologi-
cal therapies

SSRI

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.4.1 CBT versus SSRI

Bakker 1999

Black 1993

Hendriks 2010

Sharp 1996

Subtotal ***

35

25

18

30

108

3.6 (1.4)

2.5 (1)

1.4 (0.4)

5.1 (5.4)

32

25

14

29

100

2.4 (1.1)

2 (1.7)

1.4 (0.4)

5.5 (7.9)

Heterogeneity: Tau2=0.15; Chi2=8.58, df=3(P=0.04); I2=65.05%

Test for overall effect: Z=1.34(P=0.18)

Total ***

108

100

Heterogeneity: Tau2=0.15; Chi2=8.58, df=3(P=0.04); I2=65.05%

Test for overall effect: Z=1.34(P=0.18)

26.9%

25.22%

21.1%

26.77%

100%

0.94[0.43,1.44]

0.35[-0.21,0.91]

0[-0.7,0.7]

-0.06[-0.57,0.45]

0.33[-0.15,0.8]

100%

0.33[-0.15,0.8]

Favour psychotherapy

-2

-1

0

1

2

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 11.   Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus other antidepressants

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

1.1 CBT versus other antidepres-
sants

1.2 Psychodynamic therapies versus
other antidepressants

2 Short-term response

2.1 CBT versus other antidepres-
sants

2.2 Psychodynamic therapies versus
other antidepressants

3 Dropouts for any reason

3.1 CBT versus other antidepres-
sants

3.2 Psychodynamic therapy versus
other antidepressants

2

1

1

2

1

1

2

1

1

123

108

15

116

101

15

168

108

60

Risk Ratio (M-H, Random, 95%
CI)

0.65 [0.44, 0.96]

Risk Ratio (M-H, Random, 95%
CI)

0.61 [0.40, 0.94]

Risk Ratio (M-H, Random, 95%
CI)

0.88 [0.34, 2.25]

Risk Ratio (M-H, Random, 95%
CI)

0.85 [0.68, 1.06]

Risk Ratio (M-H, Random, 95%
CI)

0.86 [0.69, 1.07]

Risk Ratio (M-H, Random, 95%
CI)

0.66 [0.22, 1.97]

Risk Ratio (M-H, Random, 95%
CI)

1.55 [0.91, 2.65]

Risk Ratio (M-H, Random, 95%
CI)

1.84 [0.99, 3.43]

Risk Ratio (M-H, Random, 95%
CI)

1.0 [0.36, 2.75]

Analysis 11.1.   Comparison 11 Sensitivity analysis (psychological therapies with quality control):
All psychological therapies versus other antidepressants, Outcome 1 Short-term remission.

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

11.1.1 CBT versus other antidepressants

van Apeldoorn 2008

Subtotal (95% CI)

19/55

55

30/53

53

Total events: 19 (Psychological therapies), 30 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=2.23(P=0.03)

11.1.2 Psychodynamic therapies versus other antidepressants

Bressi 2010

Subtotal (95% CI)

4/8

8

4/7

7

Total events: 4 (Psychological therapies), 4 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=0.28(P=0.78)

82.6%

82.6%

0.61[0.4,0.94]

0.61[0.4,0.94]

17.4%

17.4%

0.88[0.34,2.25]

0.88[0.34,2.25]

Total (95% CI)

63

60

100%

0.65[0.44,0.96]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 23 (Psychological therapies), 34 (Other antidepressants)

Heterogeneity: Tau2=0; Chi2=0.46, df=1(P=0.5); I2=0%

Test for overall effect: Z=2.14(P=0.03)

Test for subgroup differences: Chi2=0.46, df=1 (P=0.5), I2=0%

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 11.2.   Comparison 11 Sensitivity analysis (psychological therapies with quality control):
All psychological therapies versus other antidepressants, Outcome 2 Short-term response.

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

11.2.1 CBT versus other antidepressants

van Apeldoorn 2008

Subtotal (95% CI)

37/53

53

39/48

48

Total events: 37 (Psychological therapies), 39 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.33(P=0.18)

11.2.2 Psychodynamic therapies versus other antidepressants

Bressi 2010

Subtotal (95% CI)

3/8

8

4/7

7

Total events: 3 (Psychological therapies), 4 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=0.75(P=0.45)

Total (95% CI)

61

55

Total events: 40 (Psychological therapies), 43 (Other antidepressants)

Heterogeneity: Tau2=0; Chi2=0.23, df=1(P=0.63); I2=0%

Test for overall effect: Z=1.45(P=0.15)

Test for subgroup differences: Chi2=0.22, df=1 (P=0.64), I2=0%

96.05%

96.05%

0.86[0.69,1.07]

0.86[0.69,1.07]

3.95%

3.95%

0.66[0.22,1.97]

0.66[0.22,1.97]

100%

0.85[0.68,1.06]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 11.3.   Comparison 11 Sensitivity analysis (psychological therapies with quality control):
All psychological therapies versus other antidepressants, Outcome 3 Dropouts for any reason.

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

11.3.1 CBT versus other antidepressants

van Apeldoorn 2008

Subtotal (95% CI)

21/55

55

11/53

53

Total events: 21 (Psychological therapies), 11 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.91(P=0.06)

72.22%

72.22%

1.84[0.99,3.43]

1.84[0.99,3.43]

Favour psychotherapy

0.02

0.1

1

10

50

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

11.3.2 Psychodynamic therapy versus other antidepressants

Bressi 2010

Subtotal (95% CI)

6/30

30

6/30

30

Total events: 6 (Psychological therapies), 6 (Other antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

85

83

Total events: 27 (Psychological therapies), 17 (Other antidepressants)

Heterogeneity: Tau2=0; Chi2=1.01, df=1(P=0.31); I2=0.97%

Test for overall effect: Z=1.61(P=0.11)

Test for subgroup differences: Chi2=1.01, df=1 (P=0.32), I2=0.93%

27.78%

27.78%

1[0.36,2.75]

1[0.36,2.75]

100%

1.55[0.91,2.65]

Favour psychotherapy

0.02

0.1

1

10

50

Favour medication

Comparison 12.   Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus benzodiazepines

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term response

1.1 CBT versus benzodi-
azepines

2 Dropouts for any reason

2.1 CBT versus benzodi-
azepines

3 Short-term improvement

3.1 CBT versus benzodi-
azepines

2

2

2

2

2

2

76

76

76

76

69

69

Risk Ratio (M-H, Random, 95% CI)

1.41 [0.61, 3.27]

Risk Ratio (M-H, Random, 95% CI)

1.41 [0.61, 3.27]

Risk Ratio (M-H, Random, 95% CI)

1.41 [0.61, 3.27]

Risk Ratio (M-H, Random, 95% CI)

1.41 [0.61, 3.27]

Std. Mean Difference (IV, Random,
95% CI)

-0.16 [-0.82, 0.50]

Std. Mean Difference (IV, Random,
95% CI)

-0.16 [-0.82, 0.50]

Analysis 12.1.   Comparison 12 Sensitivity analysis (psychological therapies with quality
control): All psychological therapies versus benzodiazepines, Outcome 1 Short-term response.

Study or subgroup

Psychological
therapies

n/N

Benzodi-
azepines

n/N

12.1.1 CBT versus benzodiazepines

Klosko 1988

Tyrer 1988

Subtotal (95% CI)

7/18

9/34

52

5/17

1/7

24

Total events: 16 (Psychological therapies), 6 (Benzodiazepines)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

80.43%

19.57%

100%

1.32[0.52,3.37]

1.85[0.28,12.38]

1.41[0.61,3.27]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Psychological
therapies

n/N

Benzodi-
azepines

n/N

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=0.81(P=0.42)

Cochrane Database of Systematic Reviews

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total (95% CI)

52

24

100%

1.41[0.61,3.27]

Total events: 16 (Psychological therapies), 6 (Benzodiazepines)

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=0.81(P=0.42)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 12.2.   Comparison 12 Sensitivity analysis (psychological therapies with quality control):
All psychological therapies versus benzodiazepines, Outcome 2 Dropouts for any reason.

Study or subgroup

Psychological
therapies

n/N

Benzodi-
azepines

n/N

12.2.1 CBT versus benzodiazepines

Klosko 1988

Tyrer 1988

Subtotal (95% CI)

7/18

9/34

52

5/17

1/7

24

Total events: 16 (Psychological therapies), 6 (Benzodiazepines)

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=0.81(P=0.42)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

80.43%

19.57%

100%

1.32[0.52,3.37]

1.85[0.28,12.38]

1.41[0.61,3.27]

Total (95% CI)

52

24

100%

1.41[0.61,3.27]

Total events: 16 (Psychological therapies), 6 (Benzodiazepines)

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=0.81(P=0.42)

Favour psychotherapy

0.01

0.1

1

10

100

Favour medication

Analysis 12.3.   Comparison 12 Sensitivity analysis (psychological therapies with quality control):
All psychological therapies versus benzodiazepines, Outcome 3 Short-term improvement.

Study or subgroup

Psychologi-
cal therapies

Benzodiazepines

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.3.1 CBT versus benzodiazepines

Klosko 1988

Tyrer 1988

Subtotal ***

2.7 (1.5)

15.6 (6.9)

15

31

46

Heterogeneity: Tau2=0.08; Chi2=1.49, df=1(P=0.22); I2=32.96%

Test for overall effect: Z=0.47(P=0.64)

Total ***

46

Heterogeneity: Tau2=0.08; Chi2=1.49, df=1(P=0.22); I2=32.96%

Test for overall effect: Z=0.47(P=0.64)

16

7

23

23

3.6 (1.9)

14.1 (5)

54.62%

45.38%

100%

-0.47[-1.18,0.25]

0.21[-0.61,1.03]

-0.16[-0.82,0.5]

100%

-0.16[-0.82,0.5]

Favour psychotherapy

-1

-0.5

0

0.5

1

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 13.   Sensitivity analysis (psychological therapies with quality control): All psychological therapies
versus either antidepressants alone or antidepressants and benzodiazepines

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

1.1 CBT versus either antidepressants alone
or antidepressants and benzodiazepines

1.2 Psychodynamic therapies versus either
antidepressants alone or antidepressants and
benzodiazepines

1.3 BT versus either antidepressants alone or
antidepressants and benzodiazepines

1.4 Supportive psychotherapies versus either
antidepressants alone or antidepressants and
benzodiazepines

2 Short-term response

2.1 CBT versus either antidepressants alone
or antidepressants and benzodiazepines

2.2 Psychodynamic therapies versus either
antidepressants or antidepressants and ben-
zodiazepines

2.3 Behaviour therapy versus either antide-
pressants alone or antidepressants and ben-
zodiazepines

2.4 Supportive psychotherapies versus either
antidepressants alone or antidepressants and
benzodiazepines

3 Dropouts for any reason

3.1 CBT versus either antidepressants alone
or antidepressants and benzodiazepines

3.2 Psychodynamic therapy versus either an-
tidepressants alone or antidepressants and
benzodiazepines

3.3 BT versus antidepressants alone or anti-
depressants and benzodiazepines

3.4 Supportive psychological therapy versus
either antidepressants alone or antidepres-
sants and benzodiazepines

8

7

1

1

1

10

9

1

1

1

10

9

1

1

1

550

457

15

36

42

724

631

15

36

42

796

658

60

36

42

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.76 [0.65, 0.90]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.77 [0.65, 0.92]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.88 [0.34, 2.25]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.7 [0.28, 1.75]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.69 [0.36, 1.31]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.89 [0.77, 1.03]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.90 [0.77, 1.07]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.66 [0.22, 1.97]

Risk Ratio (M-H, Ran-
dom, 95% CI)

1.0 [0.10, 9.96]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.6 [0.27, 1.32]

Risk Ratio (M-H, Ran-
dom, 95% CI)

1.13 [0.79, 1.62]

Risk Ratio (M-H, Ran-
dom, 95% CI)

1.25 [0.82, 1.89]

Risk Ratio (M-H, Ran-
dom, 95% CI)

1.0 [0.36, 2.75]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.56 [0.22, 1.42]

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4 Short-term improvement

4.1 CBT versus either antidepressants alone
or antidepressants and benzodiazepines

4.2 Psychodynamic therapy versus either an-
tidepressants alone or antidepressants and
benzodiazepines

4.3 Behaviour therapy versus either antide-
pressants alone or antidepressants and ben-
zodiazepines

4.4 Supportive psychological therapy versus
either antidepressants alone or antidepres-
sants and benzodiazepines

9

8

1

1

1

592

505

15

30

42

Std. Mean Difference
(IV, Random, 95% CI)

0.21 [0.02, 0.41]

Std. Mean Difference
(IV, Random, 95% CI)

0.18 [-0.06, 0.42]

Std. Mean Difference
(IV, Random, 95% CI)

-0.01 [-1.02, 1.01]

Std. Mean Difference
(IV, Random, 95% CI)

0.47 [-0.30, 1.24]

Std. Mean Difference
(IV, Random, 95% CI)

0.56 [-0.12, 1.24]

Analysis 13.1.   Comparison 13 Sensitivity analysis (psychological therapies with
quality control): All psychological therapies versus either antidepressants alone
or antidepressants and benzodiazepines, Outcome 1 Short-term remission.

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

13.1.1 CBT versus either antidepressants alone or antidepressants and
benzodiazepines

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Bakker 1999

Bakker 1999

Black 1993

Clark 1994

Hendriks 2010

Sharp 1996

Shear 2000

van Apeldoorn 2008

Subtotal (95% CI)

7/17

7/18

12/25

13/24

13/20

23/43

19/36

19/55

238

17/32

21/32

18/25

6/12

12/17

24/36

7/12

30/53

219

Total events: 113 (Psychological therapies), 135 (Antidepressants)

Heterogeneity: Tau2=0; Chi2=4.16, df=7(P=0.76); I2=0%

Test for overall effect: Z=2.94(P=0)

13.1.2 Psychodynamic therapies versus either antidepressants alone
or antidepressants and benzodiazepines

Bressi 2010

Subtotal (95% CI)

4/8

8

4/7

7

Total events: 4 (Psychological therapies), 4 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=0.28(P=0.78)

13.1.3 BT versus either antidepressants alone or antidepressants and
benzodiazepines

Clark 1994

7/24

5/12

6.26%

6.74%

11.87%

5.89%

13.59%

20.49%

8.28%

14.29%

87.4%

0.78[0.4,1.49]

0.59[0.32,1.11]

0.67[0.41,1.07]

1.08[0.55,2.13]

0.92[0.59,1.44]

0.8[0.56,1.15]

0.9[0.51,1.6]

0.61[0.4,0.94]

0.77[0.65,0.92]

3.01%

3.01%

0.88[0.34,2.25]

0.88[0.34,2.25]

3.21%

0.7[0.28,1.75]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

24

12

3.21%

0.7[0.28,1.75]

Total events: 7 (Psychological therapies), 5 (Antidepressants)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.76(P=0.44)

13.1.4 Supportive psychotherapies versus either antidepressants
alone or antidepressants and benzodiazepines

Shear 2000

Subtotal (95% CI)

12/30

30

7/12

12

Total events: 12 (Psychological therapies), 7 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.14(P=0.25)

6.38%

6.38%

0.69[0.36,1.31]

0.69[0.36,1.31]

Total (95% CI)

300

250

100%

0.76[0.65,0.9]

Total events: 136 (Psychological therapies), 151 (Antidepressants)

Heterogeneity: Tau2=0; Chi2=4.38, df=10(P=0.93); I2=0%

Test for overall effect: Z=3.22(P=0)

Test for subgroup differences: Chi2=0.23, df=1 (P=0.97), I2=0%

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 13.2.   Comparison 13 Sensitivity analysis (psychological therapies
with quality control): All psychological therapies versus either antidepressants
alone or antidepressants and benzodiazepines, Outcome 2 Short-term response.

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

13.2.1 CBT versus either antidepressants alone or antidepressants and
benzodiazepines

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Bakker 1999

Barlow 2000

Black 1993

Clark 1994

Hendriks 2010

Sharp 1996

Shear 2000

Tyrer 1988

van Apeldoorn 2008

Subtotal (95% CI)

10/35

37/77

6/25

2/24

9/20

20/30

14/36

9/34

37/53

334

32/64

38/83

12/25

1/12

7/17

15/29

6/12

2/7

39/48

297

Total events: 144 (Psychological therapies), 152 (Antidepressants)

Heterogeneity: Tau2=0; Chi2=8.54, df=8(P=0.38); I2=6.34%

Test for overall effect: Z=1.18(P=0.24)

13.2.2 Psychodynamic therapies versus either antidepressants or anti-
depressants and benzodiazepines

Bressi 2010

Subtotal (95% CI)

3/8

8

4/7

7

Total events: 3 (Psychological therapies), 4 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=0.75(P=0.45)

6.45%

19.83%

3.3%

0.41%

3.87%

11.49%

4.42%

1.28%

43.29%

94.33%

0.57[0.32,1.02]

1.05[0.75,1.46]

0.5[0.22,1.12]

1[0.1,9.96]

1.09[0.52,2.31]

1.29[0.84,1.99]

0.78[0.39,1.56]

0.93[0.25,3.39]

0.86[0.69,1.07]

0.9[0.77,1.07]

1.78%

1.78%

0.66[0.22,1.97]

0.66[0.22,1.97]

Favour psychotherapy

0.01

0.1

1

10

100

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

13.2.3 Behaviour therapy versus either antidepressants alone or anti-
depressants and benzodiazepines

Clark 1994

Subtotal (95% CI)

2/24

24

1/12

12

Total events: 2 (Psychological therapies), 1 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.2.4 Supportive psychotherapies versus either antidepressants
alone or antidepressants and benzodiazepines

Shear 2000

Subtotal (95% CI)

9/30

30

6/12

12

Total events: 9 (Psychological therapies), 6 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.27(P=0.2)

0.41%

0.41%

1[0.1,9.96]

1[0.1,9.96]

3.48%

3.48%

0.6[0.27,1.32]

0.6[0.27,1.32]

Total (95% CI)

396

328

100%

0.89[0.77,1.03]

Total events: 158 (Psychological therapies), 163 (Antidepressants)

Heterogeneity: Tau2=0; Chi2=9.88, df=11(P=0.54); I2=0%

Test for overall effect: Z=1.6(P=0.11)

Test for subgroup differences: Chi2=1.3, df=1 (P=0.73), I2=0%

Favour psychotherapy

0.01

0.1

1

10

100

Favour medication

Analysis 13.3.   Comparison 13 Sensitivity analysis (psychological therapies with
quality control): All psychological therapies versus either antidepressants alone
or antidepressants and benzodiazepines, Outcome 3 Dropouts for any reason.

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

13.3.1 CBT versus either antidepressants alone or antidepressants and
benzodiazepines

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Bakker 1999

Barlow 2000

Black 1993

Clark 1994

Hendriks 2010

Sharp 1996

Shear 2000

Tyrer 1988

van Apeldoorn 2008

Subtotal (95% CI)

9/35

21/77

9/25

0/24

2/20

13/43

14/36

2/34

21/55

349

7/64

32/83

4/25

0/12

3/17

7/36

5/12

1/7

11/53

309

Total events: 91 (Psychological therapies), 70 (Antidepressants)

Heterogeneity: Tau2=0.15; Chi2=12.95, df=7(P=0.07); I2=45.93%

Test for overall effect: Z=1.04(P=0.3)

13.3.2 Psychodynamic therapy versus either antidepressants alone or
antidepressants and benzodiazepines

Bressi 2010

6/30

6/30

10.08%

18.9%

8.3%

3.96%

11.49%

11.83%

2.32%

14.91%

81.79%

2.35[0.96,5.77]

0.71[0.45,1.11]

2.25[0.8,6.36]

Not estimable

0.57[0.11,3.01]

1.55[0.7,3.48]

0.93[0.43,2.05]

0.41[0.04,3.94]

1.84[0.99,3.43]

1.25[0.82,1.89]

8.61%

1[0.36,2.75]

Favour psychotherapy

0.02

0.1

1

10

50

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

30

30

8.61%

1[0.36,2.75]

Total events: 6 (Psychological therapies), 6 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.3.3 BT versus antidepressants alone or antidepressants and benzo-
diazepines

Clark 1994

Subtotal (95% CI)

0/24

24

0/12

12

Total events: 0 (Psychological therapies), 0 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.3.4 Supportive psychological therapy versus either antidepres-
sants alone or antidepressants and benzodiazepines

Shear 2000

Subtotal (95% CI)

7/30

30

5/12

12

Total events: 7 (Psychological therapies), 5 (Antidepressants)

Heterogeneity: Not applicable

Test for overall effect: Z=1.22(P=0.22)

Not estimable

Not estimable

9.6%

9.6%

0.56[0.22,1.42]

0.56[0.22,1.42]

Total (95% CI)

433

363

100%

1.13[0.79,1.62]

Total events: 104 (Psychological therapies), 81 (Antidepressants)

Heterogeneity: Tau2=0.12; Chi2=15.12, df=9(P=0.09); I2=40.48%

Test for overall effect: Z=0.67(P=0.5)

Test for subgroup differences: Chi2=2.39, df=1 (P=0.3), I2=16.33%

Favour psychotherapy

0.02

0.1

1

10

50

Favour medication

Analysis 13.4.   Comparison 13 Sensitivity analysis (psychological therapies with
quality control): All psychological therapies versus either antidepressants alone
or antidepressants and benzodiazepines, Outcome 4 Short-term improvement.

Study or subgroup

Psychologi-
cal therapies

Antidepressants

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.4.1 CBT versus either antidepressants alone or antidepressants and benzo-
diazepines

Bakker 1999

Bakker 1999

Barlow 2000

Black 1993

Clark 1994

Hendriks 2010

Sharp 1996

Shear 2000

Tyrer 1988

Subtotal ***

13

12

77

25

20

18

30

36

31

3.6 (1.4)

3.6 (1.4)

1.1 (0.7)

2.5 (1)

20.5 (5.3)

1.4 (0.4)

5.1 (5.4)

1.1 (0.8)

15.6 (6.9)

32

32

83

25

10

14

29

12

6

3.1 (1.2)

2.4 (1.1)

1.1 (0.8)

2 (1.7)

24.3 (6.8)

1.4 (0.4)

5.5 (7.9)

0.9 (0.6)

13.2 (7.5)

262

243

Heterogeneity: Tau2=0.04; Chi2=11.55, df=8(P=0.17); I2=30.71%

Test for overall effect: Z=1.48(P=0.14)

7.81%

6.92%

22.19%

9.99%

5.72%

6.91%

11.51%

7.72%

4.62%

83.4%

0.39[-0.26,1.04]

0.99[0.3,1.69]

0.12[-0.19,0.43]

0.35[-0.21,0.91]

-0.63[-1.41,0.14]

0[-0.7,0.7]

-0.06[-0.57,0.45]

0.18[-0.48,0.83]

0.34[-0.54,1.21]

0.18[-0.06,0.42]

Favour psychotherapy

-1

-0.5

0

0.5

1

Favour medication

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychologi-
cal therapies

Antidepressants

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.4.2 Psychodynamic therapy versus either antidepressants alone or antide-
pressants and benzodiazepines

Bressi 2010

Subtotal ***

0.7 (0.6)

8

8

0.7 (0.5)

7

7

Heterogeneity: Not applicable

Test for overall effect: Z=0.01(P=0.99)

13.4.3 Behaviour therapy versus either antidepressants alone or antidepres-
sants and benzodiazepines

Clark 1994

Subtotal ***

28.2 (8.7)

20

20

24.3 (6.8)

10

10

Heterogeneity: Not applicable

Test for overall effect: Z=1.19(P=0.24)

13.4.4 Supportive psychological therapy versus either antidepressants alone
or antidepressants and benzodiazepines

Shear 2000

Subtotal ***

30

30

1.4 (0.8)

12

12

0.9 (0.6)

Heterogeneity: Not applicable

Test for overall effect: Z=1.61(P=0.11)

Total ***

320

272

Heterogeneity: Tau2=0.02; Chi2=13.35, df=11(P=0.27); I2=17.63%

Test for overall effect: Z=2.12(P=0.03)

Test for subgroup differences: Chi2=1.65, df=1 (P=0.65), I2=0%

3.54%

3.54%

-0.01[-1.02,1.01]

-0.01[-1.02,1.01]

5.84%

5.84%

0.47[-0.3,1.24]

0.47[-0.3,1.24]

7.22%

7.22%

0.56[-0.12,1.24]

0.56[-0.12,1.24]

100%

0.21[0.02,0.41]

Favour psychotherapy

-1

-0.5

0

0.5

1

Favour medication

Comparison 14.   Sensitivity analysis (best case): All psychological therapies versus SSRI

Outcome or subgroup title

No. of studies

1 Short-term remission

2 Short-term response

6

5

No. of partici-
pants

334

277

Statistical method

Effect size

Risk Ratio (M-H, Random, 95% CI)

1.18 [1.05, 1.32]

Risk Ratio (M-H, Random, 95% CI)

1.01 [0.53, 1.95]

Analysis 14.1.   Comparison 14 Sensitivity analysis (best case): All
psychological therapies versus SSRI, Outcome 1 Short-term remission.

Study or subgroup

Azhar 2000

Bakker 1999

Black 1993

Dannon 2004

Hendriks 2010

Sharp 1996

Psychological
therapies

n/N

SSRI

n/N

7/22

23/35

21/25

24/24

15/20

36/43

0/22

21/32

18/25

27/33

12/17

24/36

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

0.17%

11.3%

15.25%

45.5%

8.58%

19.2%

15[0.91,247.6]

1[0.71,1.42]

1.17[0.87,1.57]

1.21[1.02,1.44]

1.06[0.71,1.58]

1.26[0.96,1.64]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total (95% CI)

169

165

100%

1.18[1.05,1.32]

Total events: 126 (Psychological therapies), 102 (SSRI)

Heterogeneity: Tau2=0; Chi2=4.9, df=5(P=0.43); I2=0%

Test for overall effect: Z=2.77(P=0.01)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Study or subgroup

Azhar 2000

Bakker 1999

Black 1993

Hendriks 2010

Sharp 1996

Total (95% CI)

Analysis 14.2.   Comparison 14 Sensitivity analysis (best case): All
psychological therapies versus SSRI, Outcome 2 Short-term response.

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

17/22

10/35

6/25

11/20

20/43

145

5/22

20/32

12/25

7/17

15/36

132

18.42%

21.17%

18.36%

19.84%

22.21%

3.4[1.52,7.59]

0.46[0.25,0.82]

0.5[0.22,1.12]

1.34[0.67,2.67]

1.12[0.68,1.84]

100%

1.01[0.53,1.95]

Total events: 64 (Psychological therapies), 59 (SSRI)

Heterogeneity: Tau2=0.43; Chi2=19.36, df=4(P=0); I2=79.34%

Test for overall effect: Z=0.04(P=0.97)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Comparison 15.   Sensitivity analysis (worst case): All psychological therapies versus SSRI

Outcome or subgroup title

No. of studies

1 Short-term remission

2 Short-term response

6

5

No. of partici-
pants

334

277

Statistical method

Effect size

Risk Ratio (M-H, Random, 95% CI)

0.72 [0.49, 1.08]

Risk Ratio (M-H, Random, 95% CI)

0.91 [0.48, 1.69]

Analysis 15.1.   Comparison 15 Sensitivity analysis (worst case): All
psychological therapies versus SSRI, Outcome 1 Short-term remission.

Study or subgroup

Azhar 2000

Bakker 1999

Black 1993

Dannon 2004

Psychological
therapies

n/N

SSRI

n/N

2/22

14/35

12/25

23/24

0/22

24/32

22/25

33/33

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1.64%

18.02%

18.38%

23.18%

5[0.25,98.52]

0.53[0.34,0.84]

0.55[0.35,0.84]

0.95[0.86,1.06]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Hendriks 2010

Sharp 1996

Total (95% CI)

Psychological
therapies

n/N

SSRI

n/N

13/20

23/43

169

12/17

31/36

165

Total events: 87 (Psychological therapies), 122 (SSRI)

Heterogeneity: Tau2=0.17; Chi2=34.31, df=5(P<0.0001); I2=85.43%

Test for overall effect: Z=1.6(P=0.11)

Cochrane Database of Systematic Reviews

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

18.16%

20.63%

0.92[0.59,1.44]

0.62[0.46,0.85]

100%

0.72[0.49,1.08]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Study or subgroup

Azhar 2000

Bakker 1999

Black 1993

Hendriks 2010

Sharp 1996

Total (95% CI)

Analysis 15.2.   Comparison 15 Sensitivity analysis (worst case): All
psychological therapies versus SSRI, Outcome 2 Short-term response.

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

17/22

10/35

6/25

9/20

20/43

145

5/22

20/32

12/25

10/17

15/36

132

18.15%

21.06%

18.08%

20.54%

22.18%

3.4[1.52,7.59]

0.46[0.25,0.82]

0.5[0.22,1.12]

0.77[0.41,1.43]

1.12[0.68,1.84]

100%

0.91[0.48,1.69]

Total events: 62 (Psychological therapies), 62 (SSRI)

Heterogeneity: Tau2=0.39; Chi2=18.63, df=4(P=0); I2=78.53%

Test for overall effect: Z=0.31(P=0.76)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Comparison 16.   Sensitivity analysis (best case): All psychological therapies versus tricyclic antidepressants

Outcome or subgroup title

No. of studies

1 Short-term remission

2 Short-term response

3

4

No. of partici-
pants

229

270

Statistical method

Effect size

Risk Ratio (M-H, Random, 95% CI)

1.20 [0.94, 1.55]

Risk Ratio (M-H, Random, 95% CI)

0.78 [0.53, 1.15]

Analysis 16.1.   Comparison 16 Sensitivity analysis (best case): All psychological
therapies versus tricyclic antidepressants, Outcome 1 Short-term remission.

Study or subgroup

Psychological
treatments

Tricyclic anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Bakker 1999

Clark 1994

23/35

13/24

17/32

5/12

35.53%

10.63%

1.24[0.83,1.85]

1.3[0.61,2.79]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
treatments

Tricyclic anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Clark 1994

Shear 2000

Shear 2000

Total (95% CI)

7/24

33/36

19/30

149

6/12

7/12

7/12

80

Total events: 95 (Psychological treatments), 42 (Tricyclic antidepressants)

Heterogeneity: Tau2=0; Chi2=4.21, df=4(P=0.38); I2=4.88%

Test for overall effect: Z=1.44(P=0.15)

8.8%

25.05%

19.99%

0.58[0.25,1.35]

1.57[0.96,2.56]

1.09[0.63,1.88]

100%

1.2[0.94,1.55]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 16.2.   Comparison 16 Sensitivity analysis (best case): All psychological
therapies versus tricyclic antidepressants, Outcome 2 Short-term response.

Study or subgroup

Psychological
therapies

Tricyclic anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Bakker 1999

Clark 1994

Clark 1994

Shear 2000

Shear 2000

Tyrer 1988

Total (95% CI)

10/35

2/24

6/24

9/30

14/36

9/34

183

12/32

1/12

1/12

6/12

6/12

2/7

87

Total events: 50 (Psychological therapies), 28 (Tricyclic antidepressants)

Heterogeneity: Tau2=0; Chi2=2.4, df=5(P=0.79); I2=0%

Test for overall effect: Z=1.27(P=0.21)

30.97%

2.78%

3.67%

23.74%

30.12%

8.72%

0.76[0.38,1.52]

1[0.1,9.96]

3[0.41,22.18]

0.6[0.27,1.32]

0.78[0.39,1.56]

0.93[0.25,3.39]

100%

0.78[0.53,1.15]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Comparison 17.   Sensitivity analysis (worst case): All psychological therapies versus tricyclic antidepressants

Outcome or subgroup title

No. of studies

1 Short-term remission

2 Short-term response

3

4

No. of partici-
pants

229

270

Statistical method

Effect size

Risk Ratio (M-H, Random, 95% CI)

0.59 [0.45, 0.79]

Risk Ratio (M-H, Random, 95% CI)

0.75 [0.51, 1.10]

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.1.   Comparison 17 Sensitivity analysis (worst case): All psychological
therapies versus tricyclic antidepressants, Outcome 1 Short-term remission.

Study or subgroup

Psychological
treatments

Tricyclic anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Bakker 1999

Clark 1994

Clark 1994

Shear 2000

Shear 2000

Total (95% CI)

14/35

13/24

7/24

12/30

19/36

149

20/32

6/12

5/12

12/12

12/12

80

Total events: 65 (Psychological treatments), 55 (Tricyclic antidepressants)

Heterogeneity: Tau2=0.04; Chi2=6.22, df=4(P=0.18); I2=35.66%

Test for overall effect: Z=3.6(P=0)

21.37%

13.5%

8.23%

24.01%

32.89%

0.64[0.39,1.04]

1.08[0.55,2.13]

0.7[0.28,1.75]

0.42[0.27,0.65]

0.55[0.4,0.76]

100%

0.59[0.45,0.79]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 17.2.   Comparison 17 Sensitivity analysis (worst case): All psychological
therapies versus tricyclic antidepressants, Outcome 2 Short-term response.

Study or subgroup

Psychological
therapies

Tricyclic anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Bakker 1999

Clark 1994

Clark 1994

Shear 2000

Shear 2000

Tyrer 1988

Total (95% CI)

10/35

2/24

2/24

14/36

9/30

9/34

183

12/32

1/12

1/12

6/12

6/12

2/7

87

Total events: 46 (Psychological therapies), 28 (Tricyclic antidepressants)

Heterogeneity: Tau2=0; Chi2=0.55, df=5(P=0.99); I2=0%

Test for overall effect: Z=1.48(P=0.14)

31.25%

2.81%

2.81%

30.39%

23.95%

8.79%

0.76[0.38,1.52]

1[0.1,9.96]

1[0.1,9.96]

0.78[0.39,1.56]

0.6[0.27,1.32]

0.93[0.25,3.39]

100%

0.75[0.51,1.1]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Comparison 18.   Sensitivity analysis (best case): All psychological therapies versus other antidepressants

Outcome or subgroup title

No. of studies

1 Short-term remission

2 Short-term response

3

3

No. of partici-
pants

135

135

Statistical method

Effect size

Risk Ratio (M-H, Random, 95% CI)

0.90 [0.48, 1.67]

Risk Ratio (M-H, Random, 95% CI)

0.99 [0.72, 1.35]

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.1.   Comparison 18 Sensitivity analysis (best case): All psychological
therapies versus other antidepressants, Outcome 1 Short-term remission.

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Bressi 2010

Prasko 2004

van Apeldoorn 2008

Total (95% CI)

4/8

6/6

19/55

69

4/7

4/6

30/53

66

Total events: 29 (Psychological therapies), 38 (Other antidepressants)

Heterogeneity: Tau2=0.19; Chi2=5.9, df=2(P=0.05); I2=66.08%

Test for overall effect: Z=0.33(P=0.74)

23.48%

35.24%

41.28%

0.88[0.34,2.25]

1.44[0.8,2.6]

0.61[0.4,0.94]

100%

0.9[0.48,1.67]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 18.2.   Comparison 18 Sensitivity analysis (best case): All psychological
therapies versus other antidepressants, Outcome 2 Short-term response.

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Bressi 2010

Prasko 2004

van Apeldoorn 2008

Total (95% CI)

3/8

6/6

37/55

69

4/7

4/6

39/53

66

Total events: 46 (Psychological therapies), 47 (Other antidepressants)

Heterogeneity: Tau2=0.02; Chi2=2.5, df=2(P=0.29); I2=19.96%

Test for overall effect: Z=0.07(P=0.95)

7.52%

22.76%

69.72%

0.66[0.22,1.97]

1.44[0.8,2.6]

0.91[0.72,1.17]

100%

0.99[0.72,1.35]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Comparison 19.   Sensitivity analysis (worst case): All psychological therapies versus other antidepressants

Outcome or subgroup title

No. of studies

1 Short-term remission

2 Short-term response

3

3

No. of partici-
pants

135

135

Statistical method

Effect size

Risk Ratio (M-H, Random, 95% CI)

0.90 [0.48, 1.67]

Risk Ratio (M-H, Random, 95% CI)

0.99 [0.72, 1.35]

Analysis 19.1.   Comparison 19 Sensitivity analysis (worst case): All psychological
therapies versus other antidepressants, Outcome 1 Short-term remission.

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Bressi 2010

4/8

4/7

23.48%

0.88[0.34,2.25]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Prasko 2004

van Apeldoorn 2008

Total (95% CI)

6/6

19/55

69

4/6

30/53

66

Total events: 29 (Psychological therapies), 38 (Other antidepressants)

Heterogeneity: Tau2=0.19; Chi2=5.9, df=2(P=0.05); I2=66.08%

Test for overall effect: Z=0.33(P=0.74)

35.24%

41.28%

1.44[0.8,2.6]

0.61[0.4,0.94]

100%

0.9[0.48,1.67]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 19.2.   Comparison 19 Sensitivity analysis (worst case): All psychological
therapies versus other antidepressants, Outcome 2 Short-term response.

Study or subgroup

Psychological
therapies

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Bressi 2010

Prasko 2004

van Apeldoorn 2008

Total (95% CI)

3/8

6/6

37/55

69

4/7

4/6

39/53

66

Total events: 46 (Psychological therapies), 47 (Other antidepressants)

Heterogeneity: Tau2=0.02; Chi2=2.5, df=2(P=0.29); I2=19.96%

Test for overall effect: Z=0.07(P=0.95)

7.52%

22.76%

69.72%

0.66[0.22,1.97]

1.44[0.8,2.6]

0.91[0.72,1.17]

100%

0.99[0.72,1.35]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Comparison 20.   Sensitivity analysis (best case): All psychological therapies versus benzodiazepines

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

3

95

Risk Ratio (M-H, Random, 95% CI)

1.42 [0.99, 2.06]

Analysis 20.1.   Comparison 20 Sensitivity analysis (best case): All psychological
therapies versus benzodiazepines, Outcome 1 Short-term remission.

Study or subgroup

Ataoglu 2000

Klosko 1988

Taylor 1982

Total (95% CI)

Psychological
therapies

n/N

Benzodi-
azepines

n/N

14/20

14/18

0/10

48

11/20

8/17

0/10

47

Total events: 28 (Psychological therapies), 19 (Benzodiazepines)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

56.83%

43.17%

1.27[0.78,2.08]

1.65[0.94,2.9]

Not estimable

100%

1.42[0.99,2.06]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Psychological
therapies

n/N

Benzodi-
azepines

n/N

Heterogeneity: Tau2=0; Chi2=0.47, df=1(P=0.49); I2=0%

Test for overall effect: Z=1.88(P=0.06)

Cochrane Database of Systematic Reviews

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Comparison 21.   Sensitivity analysis (worst case): All psychological therapies versus benzodiazepines

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

3

95

Risk Ratio (M-H, Random, 95% CI)

0.93 [0.63, 1.38]

Analysis 21.1.   Comparison 21 Sensitivity analysis (worst case): All psychological
therapies versus benzodiazepines, Outcome 1 Short-term remission.

Study or subgroup

Ataoglu 2000

Klosko 1988

Taylor 1982

Total (95% CI)

Psychological
therapies

n/N

Benzodi-
azepines

n/N

10/20

11/18

0/10

48

13/20

9/17

0/10

47

Total events: 21 (Psychological therapies), 22 (Benzodiazepines)

Heterogeneity: Tau2=0; Chi2=1, df=1(P=0.32); I2=0.1%

Test for overall effect: Z=0.36(P=0.72)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

53.25%

46.75%

0.77[0.45,1.32]

1.15[0.65,2.06]

Not estimable

100%

0.93[0.63,1.38]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Comparison 22.   Sensitivity analysis (best case): All psychological therapies versus either antidepressants alone or
antidepressants and benzodiazepines

Outcome or subgroup title

No. of studies

1 Short-term remission

2 Short-term response

11

11

No. of partici-
pants

663

757

Statistical method

Effect size

Risk Ratio (M-H, Random, 95% CI)

1.12 [0.98, 1.27]

Risk Ratio (M-H, Random, 95% CI)

1.14 [0.89, 1.46]

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 22.1.   Comparison 22 Sensitivity analysis (best case): All psychological therapies versus either
antidepressants alone or antidepressants and benzodiazepines, Outcome 1 Short-term remission.

Study or subgroup

Psychological
treatments

n/N

Antide-
pressants

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Azhar 2000

Bakker 1999

Bakker 1999

Black 1993

Bressi 2010

Clark 1994

Clark 1994

Dannon 2004

Hendriks 2010

Prasko 2004

Sharp 1996

Shear 2000

Shear 2000

van Apeldoorn 2008

Total (95% CI)

7/22

12/18

11/17

21/25

4/8

7/24

13/24

24/24

15/20

6/6

36/43

19/36

12/30

40/55

352

0/22

21/32

17/32

18/25

4/7

6/12

7/12

24/33

15/17

4/6

24/36

7/12

7/12

30/53

311

0.22%

7.6%

6.02%

11.79%

1.82%

2.25%

4.09%

16.55%

11.39%

4.27%

13.47%

4.52%

3.61%

12.4%

15[0.91,247.6]

1.02[0.67,1.53]

1.22[0.75,1.97]

1.17[0.87,1.57]

0.88[0.34,2.25]

0.58[0.25,1.35]

0.93[0.51,1.7]

1.36[1.1,1.69]

0.85[0.63,1.16]

1.44[0.8,2.6]

1.26[0.96,1.64]

0.9[0.51,1.6]

0.69[0.36,1.31]

1.28[0.97,1.71]

100%

1.12[0.98,1.27]

Total events: 227 (Psychological treatments), 184 (Antidepressants)

Heterogeneity: Tau2=0.01; Chi2=17.67, df=13(P=0.17); I2=26.42%

Test for overall effect: Z=1.66(P=0.1)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 22.2.   Comparison 22 Sensitivity analysis (best case): All psychological therapies versus either
antidepressants alone or antidepressants and benzodiazepines, Outcome 2 Short-term response.

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Azhar 2000

Bakker 1999

Barlow 2000

Bressi 2010

Clark 1994

Clark 1994

Hendriks 2010

Prasko 2004

Sharp 1996

Shear 2000

Shear 2000

Tyrer 1988

van Apeldoorn 2008

Total (95% CI)

17/22

10/35

58/77

3/8

2/24

2/24

11/20

6/6

20/43

14/36

9/30

9/34

37/55

414

5/22

20/64

38/83

4/7

1/12

1/12

7/17

4/6

15/36

6/12

6/12

2/7

39/53

343

6.44%

8.6%

16.33%

4.03%

1.09%

1.09%

7.79%

9.39%

11%

7.72%

6.62%

3.07%

16.84%

3.4[1.52,7.59]

0.91[0.48,1.73]

1.65[1.26,2.15]

0.66[0.22,1.97]

1[0.1,9.96]

1[0.1,9.96]

1.34[0.67,2.67]

1.44[0.8,2.6]

1.12[0.68,1.84]

0.78[0.39,1.56]

0.6[0.27,1.32]

0.93[0.25,3.39]

0.91[0.72,1.17]

100%

1.14[0.89,1.46]

Total events: 198 (Psychological therapies), 148 (Antidepressants)

Heterogeneity: Tau2=0.08; Chi2=23.64, df=12(P=0.02); I2=49.24%

Test for overall effect: Z=1.06(P=0.29)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 23.   Sensitivity analysis (worst case): All psychological therapies versus either antidepressants alone or
antidepressants and benzodiazepines

Outcome or subgroup title

No. of studies

1 Short-term remission

2 Short-term response

11

11

No. of partici-
pants

663

757

Statistical method

Effect size

Risk Ratio (M-H, Random, 95% CI)

0.89 [0.72, 1.10]

Risk Ratio (M-H, Random, 95% CI)

0.99 [0.80, 1.23]

Analysis 23.1.   Comparison 23 Sensitivity analysis (worst case): All psychological therapies versus either
antidepressants alone or antidepressants and benzodiazepines, Outcome 1 Short-term remission.

Study or subgroup

Psychological
therapies

n/N

Antide-
pressants

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Azhar 2000

Bakker 1999

Bakker 1999

Black 1993

Bressi 2010

Clark 1994

Clark 1994

Dannon 2004

Hendriks 2010

Prasko 2004

Sharp 1996

Shear 2000

Shear 2000

van Apeldoorn 2008

Total (95% CI)

17/22

5/17

5/18

6/25

4/8

2/24

2/24

23/24

9/20

6/6

20/43

9/30

14/36

37/55

352

5/22

12/32

20/32

12/25

3/7

1/12

1/12

33/33

10/17

4/6

15/36

6/12

6/12

50/53

311

5.2%

4.67%

5.32%

5.15%

3.13%

0.81%

0.81%

20.17%

7.38%

7.99%

9.64%

5.37%

6.38%

17.98%

3.4[1.52,7.59]

0.78[0.33,1.86]

0.44[0.2,0.98]

0.5[0.22,1.12]

1.17[0.39,3.51]

1[0.1,9.96]

1[0.1,9.96]

0.95[0.86,1.06]

0.77[0.41,1.43]

1.44[0.8,2.6]

1.12[0.68,1.84]

0.6[0.27,1.32]

0.78[0.39,1.56]

0.71[0.59,0.87]

100%

0.89[0.72,1.1]

Total events: 159 (Psychological therapies), 178 (Antidepressants)

Heterogeneity: Tau2=0.05; Chi2=27.85, df=13(P=0.01); I2=53.33%

Test for overall effect: Z=1.07(P=0.28)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 23.2.   Comparison 23 Sensitivity analysis (worst case): All psychological therapies versus
either antidepressants alone or antidepressants and benzodiazepines, Outcome 2 Short-term response.

Study or subgroup

Azhar 2000

Bakker 1999

Barlow 2000

Bressi 2010

Clark 1994

Psychological
therapies

n/N

Antide-
pressants

n/N

17/22

10/35

37/77

3/8

2/24

5/22

32/64

38/83

4/7

1/12

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5.66%

9.26%

17.17%

3.32%

0.83%

3.4[1.52,7.59]

0.57[0.32,1.02]

1.05[0.75,1.46]

0.66[0.22,1.97]

1[0.1,9.96]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Clark 1994

Hendriks 2010

Prasko 2004

Sharp 1996

Shear 2000

Shear 2000

Tyrer 1988

van Apeldoorn 2008

Total (95% CI)

Psychological
therapies

n/N

Antide-
pressants

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2/24

9/20

6/6

20/43

14/36

9/30

9/34

37/55

414

1/12

7/17

4/6

15/36

6/12

6/12

2/7

39/53

343

0.83%

6.36%

9.02%

11.13%

7.05%

5.85%

2.46%

21.06%

1[0.1,9.96]

1.09[0.52,2.31]

1.44[0.8,2.6]

1.12[0.68,1.84]

0.78[0.39,1.56]

0.6[0.27,1.32]

0.93[0.25,3.39]

0.91[0.72,1.17]

100%

0.99[0.8,1.23]

Total events: 175 (Psychological therapies), 160 (Antidepressants)

Heterogeneity: Tau2=0.04; Chi2=17.48, df=12(P=0.13); I2=31.37%

Test for overall effect: Z=0.05(P=0.96)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Comparison 24.   Sensitivity analysis (without imputation): All psychological therapies versus SSRI

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

5

290

Risk Ratio (M-H, Random, 95% CI)

0.84 [0.60, 1.16]

Analysis 24.1.   Comparison 24 Sensitivity analysis (without imputation):
All psychological therapies versus SSRI, Outcome 1 Short-term remission.

Psychological
therapies

n/N

SSRI

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

14/35

12/25

23/24

13/20

23/43

147

21/32

18/25

27/33

12/17

24/36

143

17.52%

17.56%

25.69%

18.42%

20.8%

0.61[0.38,0.98]

0.67[0.41,1.07]

1.17[0.98,1.4]

0.92[0.59,1.44]

0.8[0.56,1.15]

100%

0.84[0.6,1.16]

Study or subgroup

Bakker 1999

Black 1993

Dannon 2004

Hendriks 2010

Sharp 1996

Total (95% CI)

Total events: 85 (Psychological therapies), 102 (SSRI)

Heterogeneity: Tau2=0.1; Chi2=16.22, df=4(P=0); I2=75.34%

Test for overall effect: Z=1.07(P=0.29)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 25.   Sensitivity analysis (without imputation): All psychological therapies versus other antidepressants

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

2

123

Risk Ratio (M-H, Random, 95% CI)

0.65 [0.44, 0.96]

Analysis 25.1.   Comparison 25 Sensitivity analysis (without imputation): All
psychological therapies versus other antidepressants, Outcome 1 Short-term remission.

Study or subgroup

Psychological
treatments

Other anti-
depressants

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

Bressi 2010

van Apeldoorn 2008

Total (95% CI)

4/8

19/55

63

4/7

30/53

60

Total events: 23 (Psychological treatments), 34 (Other antidepressants)

Heterogeneity: Tau2=0; Chi2=0.46, df=1(P=0.5); I2=0%

Test for overall effect: Z=2.14(P=0.03)

17.4%

82.6%

0.88[0.34,2.25]

0.61[0.4,0.94]

100%

0.65[0.44,0.96]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Comparison 26.   Sensitivity analysis (without imputation): All psychological therapies versus benzodiazepines

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Short-term remission

2

75

Risk Ratio (M-H, Random, 95% CI)

1.08 [0.70, 1.65]

Analysis 26.1.   Comparison 26 Sensitivity analysis (without imputation): All
psychological therapies versus benzodiazepines, Outcome 1 Short-term remission.

Study or subgroup

Ataoglu 2000

Klosko 1988

Total (95% CI)

Psychological
treatments

n/N

Benzodi-
azepines

n/N

10/20

11/18

38

11/20

8/17

37

Total events: 21 (Psychological treatments), 19 (Benzodiazepines)

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%

Test for overall effect: Z=0.33(P=0.74)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

52.76%

47.24%

0.91[0.5,1.64]

1.3[0.7,2.42]

100%

1.08[0.7,1.65]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 27.   Sensitivity analysis (without imputation): All psychological therapies versus either
antidepressants alone or antidepressants and benzodiazepines

Outcome or subgroup title

No. of studies

1 Short-term remission

2 Short-term response

9

3

No. of partici-
pants

652

305

Statistical method

Effect size

Risk Ratio (M-H, Random, 95% CI)

0.83 [0.67, 1.01]

Risk Ratio (M-H, Random, 95% CI)

0.97 [0.80, 1.17]

Analysis 27.1.   Comparison 27 Sensitivity analysis (without imputation): All psychological therapies versus
either antidepressants alone or antidepressants and benzodiazepines, Outcome 1 Short-term remission.

Study or subgroup

Bakker 1999

Bakker 1999

Black 1993

Bressi 2010

Clark 1994

Clark 1994

Dannon 2004

Hendriks 2010

Sharp 1996

Shear 2000

Shear 2000

van Apeldoorn 2008

Total (95% CI)

Psychological
therapies

n/N

Antide-
pressants

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/17

7/18

12/25

4/30

13/24

7/24

23/24

13/20

23/43

12/30

19/36

19/55

346

17/32

21/32

18/25

4/30

6/12

5/12

27/33

12/17

24/36

7/12

7/12

30/53

306

6.49%

6.82%

9.55%

2.19%

6.22%

3.94%

17.43%

10.24%

12.29%

6.57%

7.78%

10.49%

0.78[0.4,1.49]

0.59[0.32,1.11]

0.67[0.41,1.07]

1[0.28,3.63]

1.08[0.55,2.13]

0.7[0.28,1.75]

1.17[0.98,1.4]

0.92[0.59,1.44]

0.8[0.56,1.15]

0.69[0.36,1.31]

0.9[0.51,1.6]

0.61[0.4,0.94]

100%

0.83[0.67,1.01]

Total events: 159 (Psychological therapies), 178 (Antidepressants)

Heterogeneity: Tau2=0.05; Chi2=21.28, df=11(P=0.03); I2=48.31%

Test for overall effect: Z=1.86(P=0.06)

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Analysis 27.2.   Comparison 27 Sensitivity analysis (without imputation): All psychological therapies versus
either antidepressants alone or antidepressants and benzodiazepines, Outcome 2 Short-term response.

Study or subgroup

Barlow 2000

Hendriks 2010

van Apeldoorn 2008

Total (95% CI)

Psychological
therapies

n/N

Antide-
pressants

n/N

37/77

9/20

37/55

152

38/83

7/17

39/53

153

Total events: 83 (Psychological therapies), 84 (Antidepressants)

Heterogeneity: Tau2=0; Chi2=0.59, df=2(P=0.74); I2=0%

Test for overall effect: Z=0.33(P=0.74)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

33.25%

6.48%

60.26%

1.05[0.75,1.46]

1.09[0.52,2.31]

0.91[0.72,1.17]

100%

0.97[0.8,1.17]

Favour medication

0.01

0.1

1

10

100

Favour psychotherapy

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

A P P E N D I C E S

Appendix 1. CCMD’s core MEDLINE search strategy used to inform the Group’s specialised register

OVID Medline - weekly search alert (condition + RCT filter only)
1. [MeSH Headings]:
eating  disorders/  or  anorexia  nervosa/  or  binge-eating  disorder/  or  bulimia  nervosa/  or  female  athlete  triad  syndrome/  or  pica/
or  hyperphagia/  or  bulimia/  or  self-injurious  behavior/  or  self  mutilation/  or  suicide/  or  suicidal  ideation/  or  suicide,  attempted/  or
mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or depression,
postpartum/  or  depressive  disorder,  major/  or  depressive  disorder,  treatment-resistant/  or  dysthymic  disorder/  or  seasonal  affective
disorder/  or  neurotic  disorders/  or  depression/  or  adjustment  disorders/  or  exp  antidepressive  agents/  or  anxiety  disorders/  or
agoraphobia/  or  neurocirculatory  asthenia/  or  obsessive-compulsive  disorder/  or  obsessive  hoarding/  or  panic  disorder/  or  phobic
disorders/ or stress disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/
or anxiety/ or anxiety, castration/ or koro/ or anxiety, separation/ or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body
dysmorphic disorders/ or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ or munchausen syndrome by proxy/ or
munchausen syndrome/ or fatigue syndrome, chronic/ or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse
control disorders/ or firesetting behavior/ or gambling/ or trichotillomania/ or stress, psychological/ or burnout, professional/ or sexual
dysfunctions, psychological/ or vaginismus/ or Anhedonia/ or Affective Symptoms/ or *Mental Disorders/2. [Title/ Author Keywords]:
(eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid* or
mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or cyclothymic* or
depression or depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or agoraphobia
or obsess* or compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform or somati#ation or medical*
unexplained or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or munchausen or chronic fatigue*
or gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or mental disorder* or mental health).ti,kf.3. [RCT filter]:
(controlled clinical trial.pt. or randomized controlled trial.pt. or (randomi#ed or randomi#ation).ab,ti. or randomly.ab. or (random* adj3
(administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number* or place*
or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial* or study or
studies)).ab,ti. or ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. or clinical trial, phase ii/ or clinical trial, phase
iii/ or clinical trial, phase iv/ or randomized controlled trial/ or pragmatic clinical trial/ or (quasi adj (experimental or random*)).ti,ab. or
((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.)4. (1 and 2 and 3)

Records are de-duplicated and screened for reports of RCTs which fall within the scope of the Cochrane Common Mental Disorders Group.
Secondary reports of RCTs are tagged to the appropriate study record.

Similar weekly search alerts are also conducted on OVID EMBASE and PsycINFO, using relevant subject headings (controlled vocabularies)
and search syntax, appropriate to each resource.

Appendix 2. CCMDCTR-References search (psychotherapies and panic)

#1. (*therapy or *therapies or therapist*):ti,ab or psychotherapy:kw,ky,emt,mh

#2. (acceptance* or commitment* or adlerian or art or aversion or brief or “client cent*” or color or colour or “compassion* focus*” or
compassionate  or  conjoint  or  conversion  or  conversational  or  couples  or  dance  or  desensitization  or  desensitisation  or  dialectic*  or
diffusion or distraction or eclectic or (emotion NEAR focus*) or existential or experiential or exposure or expressive or family or “focus
oriented” or freudian or gestalt or "group" or humanistic or implosive or "insight oriented" or integrative or interpersonal or jungian or
kleinian or logo or marital or metacognitive or “meta cognitive” or milieu or morita or multimodal or “multi modal” or music or narrative
or  nondirective  or  “non  directive”  or  nonspecific  or  “non  specific”  or  “object  relations”  or  “personal  construct”  or  “person  cent*”  or
persuasion or play or primal or “problem focus*” or “problem sol*” or “process experiential” or “rational emotive” or reality or “reciprocal
inhibition” or relationship* or reminiscence or restructuring or rogerian or schema* or "short term" or sex or “social effectiveness” or “social
skill*” or “socio environment*” or “solution focus*” or “time limited” or transference or transdiagnostic or transtheoretical)

#3. (abreaction or “acting out” or “activity scheduling” or “age regression” or ((assertive* or attention or autogenic or mind or sensitivity)
and train*) or autosuggestion or “balint group” or ((behavior* or behaviour*) NEAR (activation or *therap* or treatment or contracting or
modification)) or bibliotherap* or biofeedback or "breathing retrain*" or catharsis or “brief *therap*” or *cognitive* or *CBT* or counsel*
or “contingency management” or countertransference or “covert sensitization” or “crisis intervention” or “dream analysis” or education*
or “emotional freedom” or “eye movement desensiti*” or EMDR or flooding or “free association” or “functional analys*” or griefwork or
“group *therap*” or "guided mastery" or hypno* or imagery or meditation* or “mental healing” or mindfulness* or "panic management" or
“panic program*” or "paradoxical intention" or ((pleasant or pleasing) NEAR event*) or psychoanaly* or psychodrama or psychodynamic
or psychoeducat* or “psycho educat*” or “psycho* support*” or "psychological therap*" or psychotherap* or relaxation or “role play*”
or “self analysis” or "self control" or “self esteem” or "self help" or "self master*" or "self monitor*" or “sensitivity training” or "stress

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

inoculation" or “stress management” or “support* group*” or “supportive *therap*“ or “therapeutic technique*” or therapist or “third
wave” or “transactional analysis” or “validation therap” or "virtual reality")

#4. ((1 and 2) or 3)

#5. (panic or agoraphobi*)

#6. (4 and 5)

Appendix 3. PubMed search strategy

(((((((((((trial[Title]))  OR  (randomly[Title/Abstract]))  OR  (clinical  trials  as  topic[MeSH  Terms]))  OR  (randomized[Title/Abstract]))  OR
(controlled  clinical  trial[Publication  Type]))  OR  (randomized  controlled  trial[Publication  Type])))  NOT  ((animals[MeSH  Terms])  NOT
humans[MeSH  Terms])))  AND  ((((((("Behavior  Therapy"[Mesh])  OR  "Bibliotherapy"[Mesh])  OR  "Feedback,  Psychological"[Mesh])  OR
"Nondirective  Therapy"[Mesh])  OR  "Psychoanalytic  Therapy"[Mesh])  OR  "Psychotherapy,  Brief"[Mesh])  OR  "Psychotherapy,  Rational-
Emotive"[Mesh])) AND (("Agoraphobia"[Mesh]) OR "Panic Disorder"[Mesh])

C O N T R I B U T I O N S   O F   A U T H O R S

TAF and HI devised the idea. TAF, HI, AT, PC, and AP worked on the first draft of the protocol. All authors reviewed and approved the final
version of the protocol.

D E C L A R A T I O N S   O F   I N T E R E S T

HI reports no competing interests.

AT has received honoraria for speaking at a meeting sponsored by Eli Lilly.

PC reports no competing interests.

AP reports no competing interests.

TAF has received honoraria for speaking at continuing medical education meetings sponsored by Asahi Kasei, Eli Lilly, GlaxoSmithKline,
Mochida, MSD, Otsuka, Pfizer, Shionogi, and Mitsubishi Tanabe. He is diplomate of the Academy of Cognitive Therapy. He has received
royalties from Igaku-Shoin, Seiwa Shoten, and Nihon Bunka Kagakusha. He is on the advisory board for Sekisui Chemical, and Takeda
Science Foundation. The Japanese Ministry of Education, Science and Technology, the Japanese Ministry of Health, Labor and Welfare,
and the Japan Foundation for Neuroscience and Mental Health have funded his research projects.

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

Our preplanned subgroup analysis for classes of antidepressants was deleted because this was performed in the main analysis.

We  added  the  following  subgroup  analyses  for  the  investigation  of  heterogeneity:  studies  excluding  group  psychological  therapies;
outcome using the same scales; and studies without extreme results.

We added the following sensitivity analyses to confirm the rigidity of the results: calculating primary outcomes using worst-case and best-
case scenarios, and limited to studies without imputed data.

We  assessed  researcher  and  therapist  allegiance  as  other  sources  of  potential  bias,  because  these  factors  could  bias  the  results
(Falkenstrom 2013; Munder 2011).

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Agoraphobia  [complications]  [*therapy];  Antidepressive Agents  [*therapeutic use];  Benzodiazepines  [*therapeutic use];  Panic
Disorder  [complications]  [*therapy];  Patient Dropouts  [statistics & numerical data];  Psychotherapy  [*methods];  Randomized
Controlled Trials as Topic;  Remission Induction;  Serotonin Uptake Inhibitors  [*therapeutic use]

MeSH check words

Adult; Humans

Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119
